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Background: People with psychotic disorders have reduced life expectancy largely because of physical
health problems, especially cardiovascular disease, that are complicated by the use of tobacco and cannabis.
Objectives: We set out to (1) chart lifestyle and substance use choices and the emergence of
cardiometabolic risk from the earliest presentation with psychosis, (2) develop a pragmatic health
promotion intervention integrated within the clinical teams to improve the lifestyle choices and health
outcomes of people with psychosis and (3) evaluate the clinical effectiveness and cost-effectiveness of
that health promotion intervention.
Design: We performed a longitudinal cohort study of people presenting with their first episode of
psychosis in three mental health trusts and followed up participants for 1 year [work package 1, physical
health and substance use measures in first episode of psychosis (PUMP)]. We used an iterative Delphi
methodology to develop and refine a modular health promotion intervention, improving physical health
and reducing substance use in psychosis (IMPaCT) therapy, which was to be delivered by the patient’s
usual care co-ordinator and used motivational interviewing techniques and cognitive–behavioural
therapy to improve health choices of people with psychosis (work package 2). We then conducted a
multicentre, two-arm, parallel-cluster, randomised controlled trial to determine the clinical effectiveness
and cost-effectiveness of using the intervention with people with established psychosis (work package
3: IMPaCT randomised controlled trial) in five UK mental health trusts. The work took place between
2008 and 2014.
Participants: All people aged between 16 and 65 years within 6 months of their first presentation
with a non-organic psychosis and who were proficient in English were eligible for inclusion in the
PUMP study. Participants in the work package 2 training development were staff selected from a
range of settings, working with psychosis. Participants in the phase 3 Delphi consensus and manual
development comprised three expert groups of (1) therapists/researchers recruited from the local and
national community, (2) clinicians and (3) service users, each of whom took part in two iterative review
and feedback sessions. For work package 3, IMPaCT randomised controlled trial, care co-ordinators in
participating community mental health teams who were permanently employed and had a minimum
of four eligible patients (i.e. aged between 18 and 65 years with a diagnosis of a psychotic disorder)
on their caseload were eligible to participate. In studies 1 and 3, patient participants were ineligible if
they were pregnant or had a major illness that would have had an impact on their metabolic status or
if they had a significant learning disability. All participants were included in the study only after giving
written confirmed consent.
Main outcome measures: Cardiometabolic risk markers, including rates of obesity and central obesity,
and levels of glycated haemoglobin (HbA1c) and lipids, were the main outcomes in work package 1
(PUMP), with descriptive data presented on substance use. Our primary outcome measure for the
IMPaCT randomised controlled trial was the physical or mental health component Short Form
questionnaire-36 items quality-of-life scores at 12 months.
Results: Obesity rates rose from 18% at first presentation with psychosis to 24% by 1 year, but
cardiometabolic risk was not associated with baseline lifestyle and substance use choices. Patterns
of increase in the levels of HbA1c over the year following first presentation showed variation by ethnic
group. We recruited 104 care co-ordinators, of whom 52 (with 213 patients) were randomised to deliver
IMPaCT therapy and 52 (with 193 patients) were randomised to deliver treatment as usual, in keeping
with our power calculations. Of these 406 participants with established psychosis, 318 (78%) and 301
(74%) participants, respectively, attended the 12- and 15-month follow-ups. We found no significant
effect of IMPaCT therapy compared with treatment as usual on the physical or mental health component
Short Form questionnaire-36 items scores at either time point in an intention-to-treat analysis [physical
health score (‘d’) –0.17 at 12 months and –0.09 at 15 months; mental health score (‘d’) 0.03 at 12 months
and –0.05 at 15 months] or on costs. Nor did we find an effect on other cardiovascular risk indicators,
including diabetes, except in the case of high-density lipoprotein cholesterol, which showed a trend
for greater benefit with IMPaCT therapy than with treatment as usual (treatment effect 0.085,
95% confidence interval 0.007 to 0.16; p = 0.034).
ABSTRACT
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Limitations: Follow-up in work package 1 was challenging, with 127 out of 293 participants attending;
however, there was no difference in cardiometabolic measures or demographic factors at baseline
between those who attended for follow-up and those who did not. In work package 3, the IMPaCT
randomised controlled trial, care co-ordinators struggled to provide additional time to their patients
that was devoted to the health promotion intervention on top of their usual clinical care contact
with them.
Conclusions: Cardiometabolic risk is prominent even soon after first presentation with psychosis and
increases over time. Lifestyle choices and substance use habits at first presentation do not predict
those who will be most cardiometabolically compromised 1 year later. Training and supervising care
co-ordinators to deliver a health promotion intervention to their own patients on top of routine care
is not effective in the NHS for improving quality of life or reducing cardiometabolic risk.
Future work: Further work is needed to develop and evaluate effective, cost-effective and affordable
ways of preventing the emergence of and reversing existing cardiometabolic risk indicators in people
with psychosis.
Trial registration: Current Controlled Trials ISRCTN58667926.
Funding: This project was funded by the National Institute for Health Research (NIHR) Programme
Grants for Applied Research programme and will be published in full in Programme Grants for Applied
Research; Vol. 8, No. 1. See the NIHR Journals Library website for further project information.
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Plain English summary
Background
People with psychosis have poor physical health and reduced life expectancy, with cardiovascular
disease causing about 60% of early deaths in this population.
Aims
We aimed to record the physical health risks and lifestyle choices of those with early psychosis, devise
a way to help people make healthier choices and test whether or not this improved their quality of life.
Methods
First, we followed people for the year after they first presented with psychosis, documenting their mental
and physical health and their lifestyle choices. Second, we then worked with carers and service users to
develop a health promotion intervention, IMPaCT therapy, to address exercise, diet, smoking, alcohol and
substance use, plus diabetes management where relevant. Finally, we ran a trial to see whether or not
IMPaCT therapy helped and if it was good value. The work took place between 2008 and 2014.
Results
Patients with their first episode of psychosis had many risk factors for heart disease, such as obesity,
diabetes, high levels of cholesterol, poor diet and little exercise.
In the IMPaCT therapy trial, we recruited over 100 care co-ordinators and split them into two groups
randomly; half were trained in IMPaCT therapy and offered supervision of their practice, and the
other half provided standard care. We reassessed the patients 1 year later to see whether or not there
was any difference in quality of life and physical or mental health. We found no extra benefit for the
patients allocated to IMPaCT therapy compared with those receiving standard care, although if at
least 3 hours of IMPaCT therapy was received on top of standard care, waist circumference reduced.
Costs of the intervention were low.
These findings signify the difficulty in reducing risk factors for physical health problems once these are
established.
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Scientific summary
Background
Physical health and severe mental illness
The physical health of people with severe mental illness is very poor, resulting in a markedly increased
premature mortality rate. Much of the excess mortality is caused by diseases that affect the ageing
population (e.g. cardiovascular and respiratory diseases and neoplasms) but affect patients with a
diagnosis of severe mental illness earlier. Although intrinsic risk factors, such as age, genetics and
ethnicity, may increase vulnerability to physical ill health, people with severe mental illness are more
likely to have lifestyles that add to the risk of non-communicable disease, such as tobacco smoking,
obesity, poor diet, lack of exercise and poor oral hygiene. Furthermore, amotivation and difficulties in
executive function reduce the likelihood of people with severe mental illness engaging in the lifestyle
changes needed to avoid diabetic complications, while episodes of acute illness often destabilise
glucose control. The development of modifiable cardiovascular risk factors can be prevented and,
as the name suggests, reversed; however, there are challenges in achieving this in practice.
Severe mental illness and substance use
Cannabis use is highly prevalent in the UK and results in a vulnerability to severe mental illness, with
one-third of new cases of first episode of psychosis in south London now attributable to high-potency
cannabis. Regular cannabis use increases the risk of schizophrenia two- to fourfold, and there is a
dose–response relationship between the level of use and the risk of psychosis. Ongoing cannabis use by
people with severe mental illness leads to increased relapse and hospitalisation, reduced adherence to
treatment and longer illness. Early work suggested that cannabis users had higher blood glucose levels
than non-cannabis users. A few recent studies note that cannabis use among the general population is
not associated with serious physical health problems. A better understanding of the relative effect of
cannabis on physical and mental health outcomes in people with severe mental illness is needed to
inform the development of focused interventions.
The use of alcohol and other substances adds further complexity. A recent nationwide Danish register
study has shown a clear effect on mortality; all types of substances were significantly associated with
excess mortality in schizophrenia, especially alcohol and hard drugs. At a practical level, alcohol, itself
a high-calorie substance, has well-described properties as an appetite stimulant, quite aside from its
disinhibiting effect, which makes choosing the healthy option more difficult. However, the use of any
psychoactive substance will affect one’s ability to achieve consistency of physical and mental health
management.
First episode of psychosis, physical health and substance use
Prior to coming into contact with mental health services, people experiencing their first episode
of psychosis have physical health similar to that of the general population. A rapid emergence of
cardiometabolic risk is seen on treatment initiation. It is clear that medication has a significant and
rapid effect on this risk, but many other factors, including the wider determinants of health, lifestyle
choices, substance use and access to preventative interventions, are also relevant. Identifying those
most at risk of developing cardiometabolic risk would allow the development and, if appropriate,
the targeting of prevention strategies.
Rates of tobacco smoking are very high among people with severe mental illness. This increases the risk
of early death. It has long been assumed that people with severe mental illness may take up smoking
because of illness-related factors, either to help with symptoms or as a result of custom and practice in
inpatient units, such as smoking breaks. However, more recent analyses suggest that tobacco smoking
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may predate and itself be a risk factor for schizophrenia, as pre-morbid tobacco use is associated with
increased risk of psychosis and an earlier age of psychotic illness onset.
There is, overall, a pressing need to identify the factors most associated with emergent cardiometabolic
risk in people with psychosis, as targeting at-risk groups and lifestyle choices may help to reduce the
cardiovascular burden responsible for much early mortality.
Established psychosis, physical health and substance use
Effecting behaviour change in the general population is a challenge and likely to be even more so for
people with severe mental illness. For those with enduring psychosis, no established and practical
treatment programmes target both reducing substance use and improving physical health. Even
interventions to improve cardiovascular risk alone encounter hurdles when applied outside selected
settings. A recent meta-analysis showed that lifestyle interventions can help prevent and reduce weight
gain and cardiometabolic risk in people with psychosis, but most of the interventions trialled were
‘added on’ to standard care or focused on an individual risk factor, such as weight or body mass index,
and had few longer-term follow-ups. Recent European trials have found no effect of a multifactorial
lifestyle intervention delivered in the patient’s usual health-care setting on cardiovascular risk profiles.
A recent trial in UK primary care also failed to show an effect. Furthermore, the patients most at risk
of early death may not be those who readily sign up for extra sessions with their health teams. It is,
therefore, vital to identify effective and cost-effective ways of reducing cardiovascular risk that are
accessible to all people using psychosis services.
Objectives
The overall aims of the improving physical health and reducing substance use in psychosis (IMPaCT)
programme were to determine the extent of physical health and lifestyle risks for people with psychosis
and to develop and evaluate a culturally appropriate, innovative, practical, effective and cost-effective
programme for achieving better physical and mental health in people with severe mental illness by
improving lifestyle choices and decreasing substance use.
The specific objectives were to:
l Determine the prevalence of cardiovascular risk factors and substance use in people with psychosis,
both at first presentation [work package 1: physical health and substance use in first episode of
psychosis (PUMP)] and in those with established psychosis (work package 3: IMPaCT randomised
controlled trial).
l Develop a better understanding of the roles cannabis plays in the pathophysiology and health
outcomes of psychosis (see work package 1: PUMP).
l Define the development of cardiovascular risk after first presentation with psychosis
(work package 1: PUMP).
l Develop guidelines for screening for the emergence of cardiometabolic risk.
l Use this information for training and screening guidelines for cardiovascular risk factors in
early psychosis.
l Develop a manualised modular health promotion programme to improve health choices of people
with psychosis (work package 2).
l Evaluate the effectiveness of this manualised health promotion programme on the quality of life of
people with psychosis (work package 3: IMPaCT randomised controlled trial).
l Examine the costs associated with these patient groups and evaluate the cost-effectiveness of the
health promotion intervention from health/social care and societal perspectives (work package 3:
IMPaCT randomised controlled trial).
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Methods
We divided the study into three phases, which took place between 2008 and 2014.
Work package 1: PUMP
We conducted a prospective cohort study examining physical health and substance use in people
with a first episode of psychosis, aged 16–65 years. Patients were assessed at first presentation with
psychosis and again 12 months later. A proportion was also assessed at 3 months. Cardiometabolic
markers (including vitamin D and inflammatory markers), substance use, lifestyle choices and psychiatric
symptomatology were recorded at each time point. Psychotropic medications and resource utilisation
were recorded, with permission, from the electronic health records and a full economic evaluation
performed.
Work package 2: development of the health promotion intervention (IMPaCT therapy)
We used the emerging knowledge base to design a manualised, modular health promotion intervention.
The health promotion intervention principles and techniques were based on an adapted version of the
physical health intervention used in the ‘Well-being Support Programme’ and a substance use intervention
model, ‘Managing Mental Health and Drug Use’. The intervention was integrated to cover physical health,
mental health and substance use, using motivational interviewing and cognitive–behavioural therapy
approaches, and aimed to be pragmatic enough to be deliverable within the NHS. We employed a Delphi
technique to refine and co-produce the intervention with people with lived experience. To support the
intervention, we published in book form a manual, reference guide and Better Health Handbook for
service users.
We also developed a 4-day training programme for practitioners, encompassing skills and knowledge
about physical health, substance use, cognitive–behavioural therapy and motivational interviewing.
Work package 3: IMPaCT randomised controlled trial
We undertook a Phase III randomised controlled trial comparing the clinical effectiveness and
cost-effectiveness of combining treatment as usual with a 1-year IMPaCT health promotion intervention
with that of treatment-as-usual alone for improving health at 1-year follow-up. The randomised controlled
trial had a multicentre, two-arm, parallel-cluster design and was conducted across five mental health
NHS trusts in the south of England. Eligible participants were aged 18–65 years and had a diagnosis of a
psychotic disorder. The cluster was at the level of the community care co-ordinators who were randomly
assigned to deliver the health promotion intervention IMPaCT therapy or treatment as usual to their own
patients. The primary outcome was the physical and mental health component scores of the quality-of-life
measure, the Short Form-36 questionnaire. A mixed-effects model was used to analyse the data. The
trial included a comprehensive economic evaluation from two perspectives: (1) health and social care and
(2) societal. Resource use data were collected by self-report using a specifically adapted interview schedule at
baseline and at 12 months and 15 months; the data from 12 and 15 months were the focus for the economic
evaluation. Costs estimated for each perspective were linked with outcome measures at 15 months.
Results
Work package 1: PUMP
Overall, 293 people experiencing their first episode of psychosis consented to the study [mean age
30.6 years (standard deviation 10.5 years), 65% male, 22% antipsychotic naive]. At baseline, half of the
participants were overweight and 18% were obese. There were higher rates of central obesity among
women (62.7%) than among men [35.3%, χ2(1) = 11.34; p = 0.001]. Tobacco was smoked by 76.8% of
participants, and a similar proportion (77.0%) did < 150 minutes of moderate or vigorous exercise
per week. One-quarter of participants had a high-fat diet and nearly half had hazardous patterns of
alcohol consumption. Almost half (102/206) of the participants were current users of cannabis and
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12.6% used other recreational drugs. Dietary fat scores, sedentary behaviour, alcohol use and
pre-baseline olanzapine use were not significantly associated with any of the baseline cardiometabolic
outcomes or change in cardiometabolic outcomes over the year, taking into account potential confounders.
Patients from black and minority ethnic groups were more likely to develop glucose dysregulation over
the first year, with a mean rise in HbA1c levels of 3.3 mmol/mol over the year, than patients of white
ethnicity, whose HbA1c levels showed no change, suggesting a differential pattern of emergence of
glucose dysregulation. By contrast, white men showed a marked increase in waist circumference, gaining
a mean of 4.9 cm over the year, whereas men from black and minority ethnic groups gained 1.6 cm.
Obesity at baseline was associated with higher subsequent admission costs, low levels of high-density
lipoprotein cholesterol at baseline were associated with lower subsequent admission costs and higher
levels of high-density lipoprotein cholesterol at baseline was associated with a greater subsequent
quality-of-life gain.
Together with our colleagues in the Biomedical Research Council-funded Genetics and Psychosis
study, we demonstrated that one-quarter of first presentations of psychosis to the South London and
Maudsley NHS Foundation Trust are attributable to the use of high-potency cannabis. This has since
risen to one-third.
Substance use also had an effect on medication adherence over the first year of psychosis, thereby
affecting outcomes.
Work package 2: development of the health promotion intervention (IMPaCT therapy)
Five expert therapists took part in two rounds of Delphi consultation on the therapy manual, reference
book, and service user handbook, informing the redrafting after each round and providing additional
qualitative feedback. Two clinicians provided quantitative feedback when they each used the therapy
manual with a service user, and all four provided qualitative feedback, which informed the final version.
The mean ratings for user-friendliness, spirit of motivational interviewing, integration with cognitive–
behavioural therapy, usability in the NHS, length and complexity increased with development.
Work package 3: IMPaCT randomised controlled trial
We recruited 104 care co-ordinators in random order; 52 (with 213 patients overall, mean age
43.8 years, 54.9% male) were randomised to receive training and supervision in IMPaCT therapy, and
the other 52 (with 193 patients, mean age 44.7 years, 60.6% male) were randomised to administer
treatment as usual. Of the 406 patients randomised, 318 (78%) attended 12-month and 301 (74%)
attended the 15-month follow-up assessments. There was no significant effect of IMPaCT therapy on
the physical or mental health component Short Form questionnaire-36 items scores versus treatment as
usual at either 12 or 15 months [physical health score (‘d’): –0.17 at 12 months and – 0.09 at 15 months;
mental health score (‘d’): 0.03 at 12 months and –0.05 at 15 months]. No statistical difference was
observed for the secondary outcomes, including cardiometabolic risk, substance use or mental health
measures, compared with treatment as usual alone, except for high-density lipoprotein cholesterol,
which improved more with IMPaCT therapy than with treatment as usual (treatment effect 0.085,
95% confidence interval 0.007 to –0.16; p = 0.034). There were challenges in delivering additional time
for the intervention with just 19 (9%) out of 219 IMPaCT patients receiving six or more sessions of
≥ 30 minutes from their care co-ordinator in addition to their routine care. When participants received
> 180 minutes of IMPaCT therapy in addition to usual care, they achieved a greater reduction in waist
circumference than those in the treatment-as-usual group, and this was clinically significant.
The economic evaluation suggested no difference between the trial arms in costs from either perspective
or for any of the four outcomes. Data suggested that the health promotion intervention was unlikely to be
cost-effective from a health and social care perspective, with probabilities of cost-effectiveness ranging
between 29% and 38% at willingness-to-pay thresholds of £0–50,000 per quality-of-life gain. Probabilities
of cost-effectiveness were even lower from a societal perspective.
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Conclusions
Work package 1: PUMP
Even within the first month of treatment, people experiencing their first episode of psychosis have high
levels of cardiometabolic risk factors, which worsen over the following year, with a differential effect of
ethnicity on glucose dysregulation. In addition, the use of tobacco and high-potency cannabis is common
in this population, and this reduced medication adherence and the likelihood of remission in the first year.
Work package 2: development of the health promotion intervention (IMPaCT therapy)
Three books (a reference guide, a manual and a Better Health Handbook) to support IMPaCT therapy were
written and a Delphi process was used to co-produce IMPaCT therapy with patients, staff and carers.
IMPaCT therapy training significantly improved knowledge of physical health and substance use.
Work package 3: IMPaCT randomised controlled trial
Training and supervision in IMPaCT therapy was insufficient to produce significant improvements in
physical or mental health quality of life or to meaningfully improve cardiovascular risk. Only a minority
of patients received the intervention in six or more sessions of ≥ 30 minutes in addition to routine
care. There was some dose effect, with patients who received the intervention for > 180 minutes
having greater reductions in waist circumference.
Recommendations for future research
People with psychosis in the UK have extremely high levels of cardiovascular risk, which are compounded
by high tobacco use; and this is evident soon after first presentation. We have demonstrated that simply
enhancing care provided by the local care team is insufficient to reverse cardiovascular risks in people
with established psychosis. Identifying effective, affordable interventions to improve health outcomes in
psychosis remains a priority of health services internationally. Evidence-based approaches to prevent
emergent cardiometabolic risk in people first presenting with psychosis are also needed.
Trial registration
The IMPaCT randomised controlled trial is registered as ISRCTN58667926.
Funding
This project was funded by the National Institute for Health Research (NIHR) Programme Grants for
Applied Research programme and will be published in full in Programme Grants for Applied Research;
Vol. 8, No. 1. See the NIHR Journals Library website for further project information.
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SYNOPSIS
Background
The physical health of people with severe mental illness (SMI) is very poor overall and the rates of
premature death in this population are markedly increased, mainly attributable to natural causes,1 similar
to those in the ageing general population. Mortality rates from cardiovascular disease (CVD) in SMI
are nearly threefold higher than in the general population.2 The World Health Organization’s (WHO’s)
definition of a ‘healthy life’ makes it clear that this encompasses physical, mental and social health, and,
indeed, at the WHOWorld Mental Health Day in 2014, ‘living a healthy life with schizophrenia’ was
highlighted (reproduced with permission from WHO3). Therefore, we should treat the physical health of
people with psychosis alongside their mental health. TheWHO’s Comprehensive Mental Health Action Plan,4
adopted in 2013 by the World Health Assembly,4 advises the development of policy to improve the
physical and mental health of people with SMI with a particular focus on improving access to good-quality
physical health-care services.
Although intrinsic risk factors such as age, familial traits and ethnicity may increase vulnerability
to physical illness, people with SMI are also more likely to have lifestyles that increase the risk of
preventable physical disease, such as smoking, obesity, poor diet and lack of exercise; in addition,
they are more likely to live in poverty.5–8 Although the wider determinants of health are challenging to
change in a research setting, the above knowledge brings with it the hope that lifestyle choices could
be modified, leading to better outcomes.
But which outcome to choose? There is evidence that the mortality rate is highest in people with psychosis
who are not on antipsychotic medication;9,10 however, we also know that starting antipsychotic medication
accelerates weight gain and diabetes risk.11,12 Although it is important to minimise the side-effect burden of
medication, to do so by inadequately treating the psychosis may well be counterproductive in terms of both
short-term quality of life (QoL) and longer-term life expectancy. Taking a cardiovascular measure as one’s
only outcome measure runs the risk of neglecting the whole person, just as much as concentrating only on a
mental health measure. It seems that QoL may be the most important measure for assessing overall health,
in addition to reporting cardiovascular risk factors and measures of psychopathology and substance use.
We also need to gather evidence of the costs of the cardiovascular risk states and of the cost-effectiveness
of interventions to address them.
Cardiovascular risk factors include weight, blood pressure (BP) and markers of lipid and glucose
metabolism, as well as smoking rates. One way of conceptualising cardiovascular risk is the metabolic
syndrome (MetS). MetS is a constellation of CVD risk factors (abdominal obesity, insulin resistance/
glucose intolerance, hypertension and dyslipidaemia)13 that predict the chance of a person developing
or dying from a cardiac event. Each risk factor alone almost doubles the risk of a CVD event occurring
in the next decade. MetS is highly prevalent among people with psychosis,14 at a rate of 52%;15 in
addition, the prevalence of obesity and dyslipidaemia is 50%, with diabetes at 14% and hypertension at
49.5%.16–18 A rapid emergence of components of MetS is seen on treatment initiation.19 Despite this,
screening for cardiovascular risk factors remains poor.20–24
Likewise, the US CATIE17 study found high rates of diabetes, obesity, hypertension and high cholesterol
in people with SMI; this has since been confirmed in meta-analysis.14 The emergence of cardiovascular
risk and full-blown MetS can be prevented and reversed. At the time of applying for the programme,
the CATIE study17 had suggested that smoking cessation, nutrition counselling and supervised exercise
programmes could help to reduce cardiovascular mortality in this population.17 However, practice changes
had yet to consolidate. Despite government initiatives to improve better physical health monitoring for UK
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patients with SMI, a survey of 209 general practitioners (GPs) at that time revealed that only half provided
lifestyle advice and fewer than one-third referred patients with SMI to specialist physical health support
programmes.25 Since then, Commissioning for Quality and Innovation (CQUIN) incentivisation targets have
greatly improved physical health screening and intervening in mental health inpatient settings, but this
has been more challenging to achieve in community settings. The recent National Audit of Schizophrenia26
audited whether or not clinicians assess five factors [smoking, elevated body mass index (BMI), blood
glucose control, blood lipids and BP] annually and found that in only 33% of people with schizophrenia
were all of these factors monitored.
To add to the burden, there is a clear excess of diabetes in schizophrenia. A recent meta-analysis27
from our wider group showed a prevalence of type 2 diabetes mellitus among 438,245 people with
SMI of 11.3% [95% confidence interval (CI) 10.0% to 12.6%]. Notably, the corresponding figure in
antipsychotic-naive patients was only 2.9% (95% CI 1.7% to 4.8%). We also reported27 that people who
have experienced multiple episodes of psychosis (n = 133,470) were more likely in our comparative
meta-analysis to have type 2 diabetes mellitus than were matched controls [n = 5,622,664, relative risk
(RR) 1.85, 95% CI 1.45 to 2.37; p < 0.001] and women were more at risk than men (RR 1.43, 95% CI
1.20 to 1.69; p < 0.001).
The management of diabetes and CVD risk is particularly difficult in people with SMI, and carries massive
projected long- and short-term cost implications. Worryingly, patients with diabetes and SMI are
treated less aggressively for CVD risk than those without mental disorders.28 Rates of non-treatment
for conditions such as diabetes, hypertension and dyslipidaemia in psychosis are high, with the
discrepancy most marked in non-white women.29 The effectiveness of cardiovascular risk management
in people with SMI who have diabetes is also poor.30 These patients are less likely to be prescribed
cholesterol-lowering statin medications, angiotensin-converting enzyme inhibitors and angiotensin
receptor blocking agents than diabetes patients without SMI.28 A recent study of Danish population
registers found significantly fewer prescriptions for cardiovascular medications for patients with
schizophrenia or bipolar disorder than for the general population.When the authors examined the
records of people without previous myocardial infarction or cerebrovascular disease, those with
schizophrenia or bipolar disorder had up to 6- and 15-fold increased mortality from all causes or
unnatural causes, respectively, compared with the general population; this was most pronounced
among those without CVD treatment (16-fold increase). This concurs with previous work suggesting
that the treatment of CVD risk factors is relatively neglected in these patients, although the excess
of unnatural deaths in the untreated group also suggests that the link between CVD treatment and
mortality may be confounded by illness severity.31
Unfortunately, evidence on optimal management of people with SMI and comorbid diabetes is lacking
and there are many obstacles in practice. Poor motivation makes it difficult for people to make the
lifestyle changes needed to avoid diabetic complications and episodes of acute illness can interrupt
diabetic control. This cohort will put significant strain on NHS resources unless effective, evidence-
based measures are developed to improve outcomes.
Those from black and ethnic minority (BME) communities face particular inequalities concerning both
their physical and their mental health, and large-scale epidemiological work is under way in our wider
group to specifically investigate CVD in BME groups with SMI.32 BME groups have higher rates of not
only SMI33 but also diabetes.34 Our study was largely based at the South London and Maudsley (SLaM)
NHS Trust, where BME groups are over-represented among those attending services. The improving
physical health and reducing substance use in psychosis (IMPaCT) study population contains a high
proportion of BME participants to ensure that the results will be relevant to the health needs of a
multiethnic society.
As well as the poor diet and sedendary lifestyles common in so much of our society, and especially in
those with psychosis, health outcomes are compromised still further by concomitant substance use.
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Tobacco-smoking, a major prognostic factor for health, is decreasing in the general population,35 but
remains common among people using mental health services, adding to their longer-term cardiovascular
risk. Alcohol has a deleterious effect on both physical and mental health and complicates the management
of psychotic conditions. Use of illicit substances also introduces complexity and unpredictability into the
lives of people with psychosis.
Cannabis use
Over the last two decades, there has been a justified interest in comorbid substance use by those with
a psychotic illness because of its high prevalence and significant impact on clinical and social problems,
as well as the heavy burden laid on the health services. According to the Health and Social Care
Information Centre’s 2014 report36 on statistics in drug misuse in England, primary diagnoses of a
drug-related mental health and behavioural disorder increased by 8.5% from 2012/13 to 2013/14.36
The size of the problem becomes even more important when those with a psychotic illness use
substances significantly more than the general population.
The interaction between a psychotic illness and substance use is complex and can have major
detrimental effects on the course of the illness, including a patient’s risk of experiencing violence and
being hospitalised, their ability to comply with treatment and even possibly the aetiology.37,38 Such
patients may also be at particular risk of deterioration in their mental health. A recent systematic
meta-analysis of the outcomes associated with psychosis and comorbid substance use showed that
current substance users with psychosis may have more severe positive symptoms than patients who
have never used substances.39
Aetiological links between cannabis and psychosis
Interestingly, cannabis was used 150 years ago to treat ‘insanity’, while also being recognised as
increasing the risk of ‘madness’, especially among young persons at the Maudsley Hospital.40 Apart
from some experimental studies examining the effects of cannabis during the 1960s, no interest
was shown in cannabis studies. In 1987, Andréasson et al.41 published a longitudinal study involving
> 50,000 Swedish conscripts and reported that those who used cannabis by the age of 18 years were
twice as likely to develop schizophrenia as non-users. The risk increased to sixfold in heavy cannabis
users. This study was criticised and ignored until the early 2000s, when Zammit et al.42 reanalysed
the Swedish data, coming up with similar findings. The subject of cannabis and psychosis once more
attracted empirical interest and the subsequent publications indicated a causal link.43–45 Other studies,
including systematic reviews, concluded that using cannabis increased the risk of developing a
psychotic illness by two to six times, particularly in those with a predisposition to the condition
and in a dose-dependent manner.37,46,47
Furthermore, experimental studies carried out on healthy volunteers have shown that cannabis can
induce transient psychosis in some individuals, but not all.48–50 At the same time, biochemical, imaging
and genetic studies were carried out to examine the links between cannabis and psychosis, which have
all added to the existing knowledge. For instance, we now know that the main psychoactive ingredient
of cannabis, delta-9-tetrahydrocannabinol (THC), binds to CB1 receptors within the endocannabinoid
system, and the very same brain regions are also implicated in psychoses, particularly in
schizophrenia.51–53
Cannabis use in first episode of psychosis patients, prevalence and increased risks
Cannabis is the most frequently used illicit substance in the world, with nearly half of 15- to 34-year-olds
reported to be lifetime users in the USA, Australia and Canada.54 According to the 2015 European
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) report,55 lifetime use of cannabis among the
same age group in the UK is reported to be 29.9%, whereas the last 12-month use was 11.2%. Cannabis
is also the most commonly used substance after tobacco, according to epidemiological surveys of people
with psychosis.56–59 Perhaps unsurprisingly, we found that the use of substances other than cannabis
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among first episode of psychosis (FEP) patients was minimal. Given the changing attitudes towards
cannabis use, reflected by its ever-increasing medicinal use or decriminalisation in some countries, its
more widespread use by new users is expected.60 It is, therefore, important that the health risks of
cannabis use are sufficiently researched.
At the time of the original National Institute for Health Research (NIHR) Programme Grants for Applied
Research application, we wrote that a higher percentage of people with psychosis used cannabis and
other drugs than the general population61 and regular cannabis use increased the risk of schizophrenia
two- to threefold.44 We also highlighted that ongoing cannabis use in those with psychosis led to
increased relapse and hospitalisation, lack of compliance with treatment and longer illness.39
Indeed, a considerable number of studies since have further emphasised the impact of cannabis use on
people with psychosis. First, the higher prevalence of cannabis use among people with FEP has been
validated in numerous studies.62,63 A recent meta-analysis64 on the prevalence of cannabis use in people
with FEP pooled the data from 37 studies and concluded that cannabis use is highly prevalent in this
group. The same study64 also reported that the pooled estimate from 10 studies showed that regular
use of cannabis begins 6.3 years before the onset of psychosis. In fact, the same research group has
previously shown in another meta-analysis65 that the age at the onset of psychosis among cannabis
users was nearly 3 years earlier.
Additionally, prospective epidemiological studies and meta-analyses of such studies have concluded
that using cannabis can indeed increase the risk of developing a psychotic illness and that there is a
dose-related risk.37,66–68 It should be noted that the main psychoactive compound of cannabis (i.e. THC)
is nearly three times as concentrated in the cannabis used today as that used in earlier decades.
In a study in South East London, using ‘skunk-like’ cannabis was shown to triple the risk of psychosis
and, when the results were extrapolated across the population, the use of high-potency cannabis was
found to be associated with a 24% increase in new cases of psychosis.67 It was also shown that both
the frequency of use and the strength of the variety of cannabis used were associated with the
increased risk. In another recent study with FEP patients carried out across Europe and Brazil in 11
sites, daily cannabis use with high-potency varieties increased the odds of psychotic disorder nearly
five times in comparison with never users, and population attributable fractions calculations indicated
that, if such high-THC cannabis had not been available, 12.2% of cases of FEP could have been
prevented across these sites.69
Why do first episode of psychosis patients use cannabis?
The questions of why people with FEP use cannabis significantly more than others and why some
continue to use it despite its deleterious effects remain important and have been explored using
various theories. One of the first proposed theories was ‘self-medication’ hypothesis or ‘reverse
causality’, suggesting that psychiatric symptoms are alleviated by cannabis or that cannabis is used to
counter the side effects of psychotropic medication. However, this theory has since been disputed by
several studies.46,47,70 The recent meta-analysis64 finding of a 6.3-year gap between the initiation of
cannabis use and the onset of FEP is further evidence against this proposal.
However, some studies support the self-medication or reverse causality theory, as it is possible that
some early dysphoric symptoms or anxiety make it more likely that some people will use cannabis.
One such study carried out a comprehensive examination of experiences of cannabis use and reasons
for using cannabis among people with psychosis and found that the primary reason given was not related
to positive or negative symptoms or side effects of medication,71 as only 10% reported using it for
these reasons. Instead, the most frequently cited motivations were to reduce boredom, to improve
socialisation and to alleviate some symptoms, such as agitation (47%) and difficulty sleeping (43%).
Participants also reported that cannabis reduced feelings of depression.
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The increased use of cannabis among people with psychosis has also been attributed to certain
personality traits/disorders. There is mounting evidence that high-scoring schizotypal people who use
cannabis are more likely to experience psychotic symptoms.72–74 Another study has shown that conduct
disorder symptoms are significantly associated with use of cannabis, particularly if it is used by the age
of 14 years, among people with FEP; conduct disorder symptoms have been suggested to independently
increase the possibility of cannabis use, which then increases the risk of psychosis.75
Finally, genetic studies have gained particular significance because most cannabis users do not develop
psychosis; therefore, genetic factors need to be examined to find out what determines sensitivity to
the psychosis-inducing effects of cannabis.76 One of the earlier theories was genetic confounding:
in other words, that cannabis use and psychosis risk shared genetic origins. However, more recently
gene–environment interaction studies have gained more recognition; these refer to an environmental
factor, such as the use of cannabis, being influenced by genetic factors. For instance, when there was
a familial risk, taken as the measure of genetic loading, the non-psychotic siblings of people with
psychosis were found to be significantly more vulnerable to mental health disturbances than the
control participants.77 Further support was provided by another study that showed increased
sensitivity to the psychotogenic effects of cannabis to be associated with familial risk of psychosis.78
In addition to familial risk factors, there have been a number of candidate gene studies. The first of
these was carried out by Caspi et al.,79 who focused on a functional polymorphism of the valine allele
of catechol-O-amyltransferase (COMT) gene in the New Zealand birth cohort study in examining the
interaction between cannabis use and risk of psychosis. Later, a number of studies concentrated on
this gene, leading to mixed results when further replication and validation studies were carried out.80,81
However, one promising gene candidate is thought to be alpha serine/threonine-protein kinase (AKT1) as
a variant of this gene displayed a twofold increased risk of a psychotic disorder after use of cannabis.82
This finding was later independently replicated.83 However, further studies need to be carried out
because of the small evidence base.
In conclusion, the available evidence suggests that the interaction between the increased use of
cannabis and the development of a psychotic illness is complex and may have both environmental and
genetic causes.
What are the physical health effects of cannabis on first episode of psychosis patients?
Although the mental health risks of cannabis have been well studied, there is paucity of research on its
possible health-care risks not only in psychiatric but also in general populations.
The question of why cannabis could affect physical health is linked to the knowledge that the
endocannabinoid system where THC binds exists not only in the brain but also in most other organs, such
as the heart, lungs, liver, kidneys, thyroid, bones and reproductive organs, as well as the immune system.84–86
Although knowledge about the multiple functions of this widespread neurotransmitter system is evolving,
the available evidence implies that the endocannabinoid system has varied roles ranging from regulating
the metabolism, circulatory system, reproduction, sleep and pain to ocular pressure.87–90 It would therefore
be possible to assume that the interference of THC, by interrupting the normal functioning of this
widespread system, may lead to physical health problems. Only during the last few years has there been
an interest in studying the physical health-care effects of cannabis among non-psychiatric populations.
One possible risk is to the functioning of the respiratory system as a result of the fact that cannabis is
usually inhaled. The use of both cannabis and tobacco is common,91 which also creates confounding
effect problems in research. Findings so far show that there may be a dose-related risk, in that low
levels of cannabis use (three to five joints per month) may increase respiratory function, whereas
higher levels of use have the opposite effect.59,92 So far, a conclusive association has not been
established between cannabis use and lung cancer.93
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The endocannabinoid system plays an important role in the regulation of food intake and reduces
energy expenditure.94,95 Based on this knowledge, some cannabis compounds are used to stimulate
appetite and encourage weight gain in some patients with HIV (human immunodeficiency virus),
AIDS (acquired immunodeficiency syndrome) or cancer. Interestingly, however, some recent studies
have shown that in the general population cannabis use is associated with lower body mass than
in non-users.96 This paradoxical finding may be due to various factors. For instance, there may be a
difference between long-term use, as found in general population studies, and short-term use, as found
in appetite stimulation studies. The other explanation would be the possibility of poly-drug use or food
and drugs competing for the same reward sites in the brain. It is also suggested that cannabis may
act as a regulatory compound, increasing weight in those with low weight but not in those who are
already overweight.97 Interestingly, however, most recent studies carried out not only on the general
population98–100 but also on people with SMI101 report that cannabis use is associated with lower BMI,
smaller waist circumference, lower diastolic BP and more severe psychotic symptoms.
Unfortunately, no established and practical treatment programmes target both improving physical
health and reducing substance use among people with psychosis, and attending parallel treatment
programmes is often impractical. Treatment programmes, such as MIDAS, for people with both psychosis
and substance misuse appeared promising,102,103 but these are lengthy, complex and expensive.
The huge implications of these health gaps in terms of morbidity, mortality, QoL and projected future
cost make addressing physical health in SMI a national priority. The National Service Framework
and the National Institute for Health and Care Excellence (NICE) have emphasised the importance
of good physical health in people with SMI and encourage primary and secondary care services
to collaborate to improve physical outcomes in this population.104,105 In 2004, the UK government
emphased physical health promotion as a means of reducing CVD burden and endorsed the aims of
programmes addressing physical health in people with SMI.106 None of these programmes, however,
was adequately tested in the UK to ensure that it could accurately quantify the problem in those with
SMI, could identify those most at risk, could reduce physical health risk factors and was reliable and
reproducible enough to be disseminated across the NHS.
This is a matter of equity. A decade ago, the UK Disability Rights Commission investigation stated
overtly that people with mental health problems were more likely than others to experience major
illness and develop serious health conditions earlier to and die earlier as a result.107 Yet this group
were less likely to receive some important treatments/health checks and faced real barriers to
accessing services. The report called for a clear shift in approach to eliminate inequitable treatment
and to target high-risk groups. The idea was that this would prevent the extra costs of serious ill health
being passed on to other parts of the NHS and enable people with SMI to be healthier and participate
fully in society.107 Similar concerns were reflected in the Choosing Health: Making Healthy Choices Easier
White Paper.106 Since then, this topic has gathered momentum; there have been a number of high-
profile policy documents, including No Health Without Mental Health,108 the Department of Health and
Social Care report Closing The Gap: Priorities For Essential Change in Mental Health,109 Whole-person Care:
from Rhetoric to Reality,110 the BMA report Recognising the Importance of Physical Health in Mental Health
and Intellectual Disability,111 the Annual Report of the Chief Medical Officer 2013112 and the London Health
Commission report Better Health for London.113 Indeed, the London Health Commission’s ambition to
reduce the gap in life expectancy between adults living with SMI and the rest of the population has led
to the creation of a working group, ‘Stolen Years’, to work across health systems to make this a reality.
The challenge remains the evidence base. Most studies of health promotion in SMI to date have
focused on selected groups of patients and achieved only modest outcomes. None has addressed
comorbid substance misuse. Importantly, none has evaluated the cost-effectiveness of a combined
lifestyle intervention across a service, work needed to inform health commissioning. The next logical
step was to develop a more practical alternative to separate programmes, and so we set out to develop
and evaluate the benefits of a well-defined, standardised, person-centred intervention, using modules,
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as appropriate, to target both lifestyle and substance use to maximise physical and mental health. We
also undertook an evaluation of the costs of the cardiovascular burden and the cost-effectiveness of
the intervention to reduce it.
Healthy living interventions should be an integral part of the care provided to people with SMI. This
must become a priority for both primary and secondary care services, although it will require a cultural
shift in terms of how care is provided to those with SMI, with a greater emphasis on a holistic approach.
There is an urgent need for (1) a reliable way of identifying those most at risk, (2) guidelines on how
best to screen for the emergence of MetS and (3) an effective intervention to reduce modifiable
cardiovascular risk factors in this group.
Aims and objectives
The aim of IMPaCTwas to use the available evidence to develop culturally appropriate, innovative and
cost-effective programmes to achieve better physical and mental health in people with SMI by improving
lifestyle choices and decreasing illicit drug use.
Programme plan (Figure 1)
Work package 1: PUMP
The Physical health and substance Use Measures in first episode of Psychosis (PUMP) study was a
prospective observational cohort of patients presenting with their FEP. The participants were recruited
from the four boroughs of the SLaM NHS Foundation Trust, two boroughs of the Oxleas NHS Foundation
Trust and two boroughs of the Sussex Partnership NHS Foundation Trust. Patients from both inpatient
and outpatient services were followed up for 12 months to observe health and service utilisation
markers over time and to test the association between lifestyle (diet, exercise and substance use) and
antipsychotic medication factors and the emergence of components of MetS.
In the first part of the IMPaCT programme, we also wanted to examine the extent of cannabis use
among our group of FEP patients, as well as finding out the mental and physical health-care effects of
this use at baseline and at 12 months’ follow-up, compared with non-users.
Work package 1: PUMP
Prospective multisite recruitment and follow-up
of people experiencing a FEP
Work package 2
Development, piloting, publishing
of intervention and manuals
Work package 3: IMPaCT RCT
RCT of health promotion intervention.
Multisite recruitment, randomisation, 15 months’
follow-up, data analysis and dissemination
of findings
Work packages 1–3
Appointments,
research ethics,
governance
permissions and
registration
Data
cleaning,
analysis and
dissemination
FIGURE 1 Research design pathway.
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Work package 2: development of the health promotion intervention (IMPaCT therapy)
The available evidence was used to inform the development, validation and manualisation of a health
promotion intervention (HPI) tailored to the needs of the individual, addressing a number of lifestyle
choices, including substance use. The purpose of the development of the manual was to create a
culturally appropriate, innovative and effective programme for use in routine care systems to achieve
better physical and mental health in people with SMI by improving lifestyle choices and decreasing
substance use. This intensive HPI (IMPaCT therapy) was designed to cover physical health, mental
health and substance use using motivational interviewing (MI) and cognitive–behavioural therapy (CBT)
and was designed to be sufficiently pragmatic to be deliverable within the NHS.
Work package 3: IMPaCT randomised controlled trial
A randomised controlled trial (RCT) assessing whether or not the addition of an intensive HPI (IMPaCT
therapy) to usual mental health care delivered by care co-ordinators is more effective and more cost-
effective than usual mental health care in improving metabolic outcomes and reducing substance use
among people with SMI on completion of the intervention at 12 months and 15 months after baseline.
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Work package 1: physical health and
substance use in first episode of
psychosis (PUMP)
Background
People with SMI experience a significant reduction in life expectancy of approximately 10 years.1
There are a number of possible contributors to this premature death rate; for example, at the service
level, risk factors such as unequal access to care followed by substandard treatment influence outcomes.
At the individual level, a greater prevalence of CVD, and unhealthy lifestyle choices or substance use,
may also increase risk. Some of these factors may interact; for example, lifestyle choices may have an
impact on cardiometabolic status, thus reducing life expectancy. Although there is evidence surrounding
the impact of unhealthy lifestyle choices, little is known about whether lifestyle choice or substance
use predicts changes in cardiometabolic status. Investigating these factors among patients presenting
with their FEP thus offers the opportunity to map the course and impact of lifestyle choices on
cardiometabolic risk in people with psychosis. This section reports a longitudinal study that sought to
observe health behaviours and the progression of cardiometabolic disease among patients with FEP
and to investigate links between these factors over time.
Setting and method
A total of 293 patients with first-onset psychosis were recruited from inpatient units and community
mental health teams (CMHTs) across eight boroughs in the south of England. Participants meeting
the following inclusion criteria were consented to the study: (1) aged between 16 and 65 years,
(2) experiencing a FEP [according to International Statistical Classification of Diseases and Related Health
Problems, Tenth Revision (ICD-10),114 codes F20–29 and F30–33], (3) proficient in English with no
requirement for an interpreter and (4) no diagnosis of severe learning difficulties.
A total of 118 participants completed the 3-month follow-up and 127 participants completed the
12-month follow-up.
Patients who were pregnant or had an organic cause of their psychosis, those with a major medical
illness or neurological disease, and those with history of previous contact with health (GP or psychiatric)
services for the presence of psychosis were excluded from participating in the study.
Measures
A range of measures were collected over three time points (baseline and 3 and 12 months), including
the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression Severity scale, Global
Assessment of Functioning (GAF), Young Mania Rating Scale, Calgary Depression Scale and operational
criteria checklist for psychotic and affective illness (OPCRIT) diagnostic scale, as well as anthropometric
measures and blood sampling for cardiometabolic and inflammatory markers and measures of nicotine,
alcohol and substance use, including the Nicotine Dependence questionnaire (Fagerström scale), the
Alcohol Use Disorders Identification Test (AUDIT) and a modified Cannabis Experience Questionnaire
(CEQ-4), along with the International Physical Activity Questionnaire (IPAQ).72,115–121 All measures in the
study were administered face to face by a trained researcher, except the OPCRIT, which was rated by a
clinician based on the clinical notes.
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Follow-up contacts
Clinical, sociodemographic and substance use data were also collected using the Follow-up Psychiatric
and Personal History Schedule (FUPPHS). This records information about the patient’s mental state,
general behaviour, substance use, events and personal history over a defined period using information
obtained from patients, informants, case notes and other records.122 Researchers rating the Psychiatric
and Personal History Schedule (PPHS) at follow-up achieved an intraclass correlation of 0.90 on
all PPHS items when duplicate ratings were compared. Information on medication adherence and
remission during the 1-year follow-up was also extracted from the PPHS, where poor adherence
is defined as 1 = lapses of ≥ 3 days more than once, and 2 = not taking any prescribed medication.
Remission was operationally defined as the absence of positive, negative or disorganised symptoms
for at least 30 days. In our study122 examining the effect of substance use and medication adherence
on outcomes, the 1-year follow-up period was taken as the date of first contact with mental health
services of the SLaM NHS Foundation Trust for psychosis to the date exactly 1 year later using the
clinical records held on the SLaM electronic Patient Journey System (ePJS), with all of the PPHS
measures completed by a researcher retrospectively using the electronic mental health records
system (i.e. the SLaM electronic Patient Journey System).
Linear regression models were used to examine for the associations between baseline diet, alcohol use,
sedentary behaviour and prescriptions of olanzapine with cardiometabolic risk both at baseline and at
12 months’ follow-up. Baseline cross-sectional associations between continuous scores for lifestyle and
cardiometabolic factors were investigated using unadjusted and adjusted linear regression models,
as was the relationship between baseline lifestyle choices and change in cardiometabolic factors at
12 months, investigating associations between use of dibenzodiazepine medications between baseline
and 12 months (yes/no) and cardiometabolic factors in the same way. We used the mi impute chained
command in Stata® version 15.1 (StataCorp LP, College Station, TX, USA) with 50 imputed data sets for
each MI model to account for different patterns of missingness. To account for multiple testing, a stricter
alpha of 0.01 was prespecified as the significance level. The assumptions of the regression analyses of
constant variance and normal distribution were assessed with a visual inspection of residual plots.
We used univariate and multivariate analyses to determine the relationship between measures of
cardiometabolic risk at baseline and admission, and home treatment costs in the following year
(see Appendix 1).
Patient and public involvement
Service user and carer experts were part of the core planning and management throughout the project
(see Programme patient and public involvement).
Results
Metabolic characteristics and changes over 12 months
There were significant levels of cardiometabolic risk at first presentation, with rates of obesity, raised
levels of glycated haemoglobin (HbA1c), levels of C-reactive protein (CRP) and low levels of high-density
lipoprotein (HDL) cholesterol increasing over the following 12 months. In the overall group, central
obesity rates at baseline were higher in women (62.7%; n = 37/59; waist circumference ≥ 80 cm)
than in men (35.3%; n = 36/102; waist circumference ≥ 94 cm; χ2 = 11.34; p = 0.001). The mean waist
circumference in white men increased by 4.9 cm over the year, such that by 12 months white men
had a waist measurement 7.3 cm greater than their counterparts of other ethnicities, despite having
comparable measures at baseline. The average waist circumference of white women at baseline was
9.6 cm smaller than of women of other ethnicities.
WORK PACKAGE 1: PHYSICAL HEALTH AND SUBSTANCE USE IN FIRST EPISODE OF PSYCHOSIS (PUMP)
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The mean total cholesterol levels among those participants of white ethnicity (4.9 mmol/l) and those
of other ethnicities (4.7 mmol/l) were comparable at baseline, but white patients had higher levels at
12 months (5.1 vs. 4.6 mmol/l; p = 0.04) (see Gaughran et al.123).
Baseline antipsychotic use and associated metabolic impact
The median duration of treatment with antipsychotics at baseline was 21 days (interquartile range
9–55.5 days) (mean 33.7 days, SD 50.3 days), with 95% of the sample prescribed second-generation
antipsychotics. The most frequently prescribed antipsychotic was olanzapine.
Patients who had been prescribed antipsychotic medication for ≥ 2 weeks had an average total
cholesterol higher (0.5 mmol/l, 95% CI 0.1 to 0.8 mmol/l; p = 0.007) than those who had been prescribed
antipsychotics for less than a fortnight. Participants medicated prior to baseline had a higher baseline
average waist circumference (7.7 cm, 95% CI 2.0 to 13.4 cm; p = 0.009) than antipsychotic-naive patients.
Lifestyle choices and baseline cardiometabolic outcomes and changes over time
There was no association between any of the baseline or 12-month cardiometabolic outcomes and
Dietary Instrument for Nutrition Education (DINE) fat scores, sedentary behaviour, AUDIT scores and
pre-baseline olanzapine. The lack of association remained when adjusting for potential confounders
(age, gender, ethnicity or pre-baseline days on medication) and in sensitivity analyses using all
non-missing data from the full data set.
Subgroup analyses were run comparing those participants who took olanzapine between baseline and
12 months and those who did not. No differences were found between the two groups in the magnitude
of associations between changes in cardiometabolic outcomes at 12 months’ follow-up and baseline
lifestyle factors, nor were there any such associations within either of the two groups. No associations
emerged from sensitivity analyses using the full data set (both unadjusted and adjusted for the same
potential confounders) (see Gaughran et al.123).
Obesity at baseline was associated with higher subsequent admission costs, low HDL cholesterol at
baseline was associated with lower subsequent admission costs and higher HDL cholesterol at baseline
was associated with a greater subsequent quality-adjusted life-year (QALY) gain (see Appendix 1).
Cannabis use in PUMP first episode of psychosis patients
Of 206 patients with FEP, 102 used cannabis at baseline (49.5%), with 23 out of 183 (12.6%) reporting
current use of other recreational drugs. Current users at baseline were more likely to be men [59.4%,
degrees of freedom (df) 1; p < 0.05] and most were younger, belonging to the 18–33 years age group
(df 1; p < 0.05), than the non-users. They were also more likely to be single (df 4; p < 0.05). In terms of
ethnicity, occupation, having close confidants, ICD-10 diagnoses from OPCRIT, drug naivety and seeing
GP or health specialists, there were no significant differences between cannabis users and non-users.
Cannabis users also differed from non-users in terms of using cigarettes (df 1; p < 0.0001) and other
stimulants (df 3; p < 0.01). At 12 months’ follow-up, we had data on 105 patients and the number of
current users dropped to 40 (38.1%). The corresponding figure at 12 months for those reporting use
of other substances was 12 out of 102 (11.8%). From first data collection to 12 months, 12 (11.3%)
participants started using cannabis, whereas 16 people (15.5%) stopped.
Effects of cannabis on outcomes in first episode of psychosis patients
In terms of physical health outcomes, non-cannabis users had higher cholesterol levels at 12 months’
follow-up than non-users (df 1; p <.045). Female users were thinner at baseline (df 1; p < 0.036) but
male users were heavier at 12 months (df 1; p < 0.003) than non-users. Female users had smaller
waistlines at baseline (df 1; p < 0.008) than female non-users and male users had larger waistlines at
12 months (df 1; p < 0.01) than male non-users.
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There has been much speculation about why people with a diagnosis of psychosis may use cannabis;
some suggest a self-medication hypothesis, whereas other evidence suggests that it is used to alleviate
dysphoria. Kolliakou et al.124 conducted a study nested within the PUMP study, which investigated the
reasons for use reported by those participants who used cannabis and how these varied over time.
Participants rated their motives at baseline (n = 69), at 3 months (n = 29) and at 12 months (n = 36)
on the Reasons for Use Scale, which has five subscales (enhancement, social motive, coping with
unpleasant affect, conformity and acceptance, and relief of positive symptoms and side effects). At all of
the time points, ‘enhancement’ received most endorsement, followed by ‘coping with unpleasant affect’
and ‘social motive’. ‘Conformity and acceptance’ followed closely. The least endorsed motive was ‘relief
of positive symptoms and side effects’. When participants continued to use cannabis at 3 months and
12 months, they endorsed these reasons less strongly than at baseline. We found little support for the
theory that people were using cannabis for self-medication or to alleviate dysphoria. Rather, in keeping
with the general population, the most common reason that people with their FEP gave for their use of
cannabis was ‘enhancement’.
Colizzi et al.122 demonstrated that substance use and poor medication adherence contribute to poor
outcomes in the year following the FEP. Colizzi et al.’s work detailed the relative contributions of
medication adherence and substance use to outcome over the year after the FEP. We had data on 205
patients on use of tobacco, alcohol, cannabis and stimulants at psychosis onset and at 1 year, along
with data on medication adherence and symptom remission. Rates of overall substance use were high
both before (37–65%) and after psychosis onset (45–66%). Nicotine dependence was reported in
53.2% of patients at baseline, whereas 40.5% reported premorbid problem drinking, 65.4% reported
premorbid cannabis use and 36.6% reported premorbid stimulant use. A total of 44% of patients had
poor medication adherence and 55% failed to reach remission from psychosis.
Both nicotine dependence and cannabis use after the onset of psychosis predicted poor medication
adherence and non-remission significantly. Poor medication adherence occurred in 43.9% of patients
at some point in the first year and also significantly predicted remission during the 1-year follow-up,
with patients with poor medication adherence having a sixfold increased likelihood of psychosis
non-remission when compared with those with good adherence. This association between medication
adherence and remission was still significant when substance use in the 1-year follow-up period was
added into this model. Sobel tests for mediation showed that medication adherence was a significant
mediator of the relationship between nicotine dependence and remission (z = 2.02; p = 0.04) and of
that between cannabis use and remission (z = 2.12; p = 0.03).122
Discussion
Cardiovascular disease risk emerges very soon after presentation, consistent with recent US work.125
These findings confirm previous literature that demonstrates people with FEP lead unhealthy lifestyles
marked by poor diet, lack of physical activity and high rates of nicotine, alcohol and drug use. Our
sample also presented with impaired metabolic status on first contact with services as indicated by
glycose dysregulation and hypertension. They also had metabolic features consistent with the emergence
of type 2 diabetes mellitus. Throughout the study, there was significant weight gain in both men and
women. Interestingly, despite national stop-smoking campaigns that were running alongside our study,
we did not find a significant reduction in smoking rates. Indeed, a high proportion of the sample smoked
at baseline (76.8%), which had changed little at 12 months.
Strengths of this study include the diverse population recruited from both inpatient and community
settings in the south of England. A limitation is that there were missing data at both time points. Although
booklets were produced to ensure the consistent order of the administration of questionnaires, this order
was not always followed for pragmatic reasons. However, we have no reason to believe that data were
not missing at random. Another limitation is the level of follow-up, with only 125 of the 293 eligible
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participants completing 12 months’ follow-up and 140 dropping out after baseline. The largest group of
non-completers were those who declined an individual assessment point, although a smaller number
withdrew from the study. The reasons for this are likely to be manifold, and the main recruitment site,
south London, has a very mobile population. There was recompense for time, but no overt financial
incentivisation. Where we had missing measures of key variables, these were imputed using a commonly
used statistical approach and sensitivity analyses was undertaken to demonstrate the robustness of the
imputation process. We have no reason to believe that attrition was not random, with no differences
between demographic or baseline clinical attributes between completers and non-completers, although
they may have differed on other factors.
Despite concerns regarding the use of olanzapine as a first-line antipsychotic, over half of participants
had been prescribed olanzapine by the time of the baseline assessment. Not all of these participants
continued to be prescribed olanzapine over the 12 months of the study, and, although we controlled
for days prescribed olanzapine at baseline, we would not have been able to identify whether or not
cardiometabolic risk reduced once olanzapine had been discontinued.
These high and rising levels of CVD risk are worrying outcomes and it is hugely clinically important
that both nicotine dependence and cannabis use after the onset of psychosis predicted both poor
medication adherence and non-remission significantly. Poor medication adherence mediated the effects
of substance use on non-remission, demonstrating that medication adherence is on the causal pathway
between cannabis use and nicotine dependence and a non-remission outcome.122
Planned future work
We plan to look further at the relationship between inflammatory markers and cardiovascular risk in this
population. Preliminary work by our wider team126 has suggested that greater increases in inflammatory
markers soon after first presentation with psychosis are associated with a greater risk of short-term
metabolic abnormalities, in particular dyslipidaemia, which are independent of gains in weight. We are,
therefore, interested in whether or not early evidence of inflammation may predict those most likely to
develop cardiometabolic disease.
Mapping health promotion programmes
As part of work package 1, we also mapped local health promotion programmes (HPPs). Below is a
summary of work published in O’Brien et al.127
Background
The increased risk of physical health comorbidities combined with low socioeconomic status means
that patients with SMI require higher levels of physical health care and in particular greater attention
to cardiovascular risk factors. However, in practice, reports indicate that medical treatment rates for
those factors are low among those with SMI and, if SMI patients receive medications, the choice of
medication may be outdated.29,31 The physical health of people with mental health problems has been
set as a priority for improvement by the Department of Health and Social Care (DHSC).128 The NHS
and local authorities have been encouraged to develop HPPs, with particular emphasis on HPPs
addressing modifiable health issues pertinent to SMI patients: diet, exercise and substance use.
However, prior to our work, it was not clear what the distribution of such HPPs was or whether
or not there were barriers to access for people with psychosis.
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Aims and hypotheses
Because a systematic exploration of the provision of HPP available for SMI patients was lacking, the
study objective was to assess the magnitude and type of HPPs that were available for or inclusive of
people with SMI in four socially deprived boroughs in south London, UK.
Methods
The study looked at the four boroughs served by the SLaM NHS Foundation Trust: Southwark,
Lewisham, Croydon and Lambeth. These boroughs (especially Lambeth, Lewisham and Southwark)
have lower health-related sociodemographics than London and the national average.
The study design was a cross-sectional mapping of HPPs available to people with SMI across these
four boroughs of London in 2008–9. These programmes covered a range of health promotion areas:
sexual health, carer support, diabetes and nutrition, drug and alcohol use, physical activity and smoking
cessation. The programmes were based in drop-in centres, outpatient services and day centres.
Mapping was stratified by local authority, the voluntary sector and the NHS. It was performed using
standard scoping methodologies using internet searches of websites of the local authority, mental
health charities, mental health trusts and primary care trusts. After this, confirmation was sought
of the HPP identified, and further details (the costs, the access methods and the extent to which
people with SMI were included in the programme) were requested from the programme convener or
administrator.
Health sociodemographic details for each borough were obtained from GP registers.
The service user and carer experts in the IMPaCT Programme Management Group had input on the
development of this work.
Results
The prevalence of people with SMI was 1.1% in Croydon and Southwark, 1.2% in Lewisham and 1.5%
in Lambeth. A total of 145 HPPs available to people with SMI were identified: 38 in Lewisham (1 : 82
people with SMI), 50 in Southwark (1 : 60 people with SMI), 27 in Lambeth (1 : 149 people with SMI)
and 30 in Croydon (1 : 121 people with SMI).
As for availability, 61 HPPs [15 in Lewisham (40%), 14 in Southwark (28%), 14 in Lambeth (52%) and
18 in Croydon (60%)] were targeted specifically at people with SMI and the rest were inclusive of
people with SMI. No publicly funded local authority leisure centre across the four boroughs stated in
response to direct questioning that they had the facility to perform risk assessments or had staff
trained to run HPPs inclusive of this population.
A small proportion of HPPs stipulated eligibility criteria for people with SMI, which, if not satisfied,
would preclude. These access to the service the programme’s included the patient being required
concordance with prescribed medications or to attend with their care co-ordinator.
Looking at the focus of HPPs across boroughs, physical activity was most common (51 HPPs) and
sexual health was least common (10 HPPs), with only two specifically provided for or inclusive of
SMI patients.
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Discussion
The number of HPPs accessible to people with SMI varied across the four boroughs; for example,
Lambeth had the largest number of people with SMI but provided the fewest accessible HPPs (rate of
1 : 149), in contrast to Southwark, which had fewer people with SMI but more HPPs available to them
(1 : 60).
Stipulating inclusion and exclusion criteria may impede access to HPPs and cause unnecessary stress
and distress, as well as adding to the stigma surrounding SMI. This is likely to act as a deterrent to this
population, who are in great need of health promotion services.
The mapping was time-consuming, which may account for the difficulties that clinicians and service
users themselves experience when trying to identify available HPPs. These details should ideally
be readily accessible from a single source to patients and staff alike. This action would have three
foreseeable benefits. First, it would facilitate the integration of physical and mental health care.
Second, it would be easier for health-care professionals to recommend certain programmes to service
users. Third, it would support people with SMI and their carers who may have difficulty in navigating
information from multiple resources to access HPPs themselves. However, such a resource would
require to be updated regularly, which has cost implications.
Conclusion
This was the first attempt to map HPPs available for patients with SMI across these South London
boroughs and demonstrated that the distribution of these was inequitable. This may not reflect
demand, as some HPPs set exclusion criteria and provide inadequate support to staff. Accurate and
readily available information on local HPPs would benefit the population with SMI who are in dire
need of such services.127
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Work package 2: the IMPaCT therapy –
development of a comprehensive,
integrative manualised psychological
intervention for physical health and
substance use in severe mental illness
Introduction
People with psychosis experience significant and broad-ranging physical health problems, including
CVD and diabetes, leading to lower QoL and a 10- to 25-year reduction in life expectancy compared
with the general population.129–131 Those with psychosis in the adult age group are 5.7 times more likely
than the general population to be treated for diabetes.132 Contributing factors include medication
treatment regimes, lifestyle choices, inequities in health service access and substance use.133–135
Despite the size of the problem, effective intervention models, tailored to the person’s needs, are few
and are not used in clinical settings in a standardised manner. Studies examining the topic reinforce
recommendations that people with co-occurring disorders require more intensive and integrated
interventions.136
Psychological interventions for physical health in psychosis have largely focused on a single aspect of
health, such as smoking,137 diet and weight gain,138 exercise139–141 and substance use.142,143 Yet clinical
presentation and research evidence suggests that these health risks often co-exist, are inter-related
and contribute exponentially to morbidity and mortality. In fact, a recently published 10-year follow-up
of the ÆSOP frst-episode cohort study144 demonstrates the significant impact of substance use on
both natural and unnatural causes of mortality. The authors conclude that early intervention and
dual-diagnosis services may play a key role in achieving more rapid remission and carer involvement
in addressing substance use problems to reduce excess mortality in psychosis. Indeed, there is a long
overdue need for the development of comprehensive, person-centred intervention models tailored to
individual needs to improve health and QoL and reduce the economic burden on services and society.145
Psychological interventions have traditionally been denied to people with psychosis not only because
of a lack of resources but also because of a belief that people with psychosis cannot benefit from these
because of their illness, lack of insight and cognitive deficits.
The theory behind the cognitive model of psychopathology can be defined as how thoughts and
perceptions or inner interpretations of specific situations can influence one’s behaviour and emotions
and can even lead to physiological reactions. Cognitive–behavioural therapy is a well-researched and
validated intervention model that aims to modify a person’s negative thoughts and interpretations. The
evidence on the effect of CBT for psychosis has accumulated over only the last 15 years.146 Meta-analyses
studying the efficacy of CBT on positive symptoms of schizophrenia,147–149 as well as secondary outcome
measures such as functioning levels, mood and social anxiety,148,150 have revealed medium beneficial
effects. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study151 examined the
decision-making capacity of patients with schizophrenia and found that negative symptoms had very
little effect and positive symptoms had no effect on this. These studies have emphasised the need to
develop and adapt for psychological interventions in patients with psychosis.
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As a result of this renewed interest in psychological interventions in psychosis, models of psychological
intervention used in non-psychotic populations, such as those with substance misuse, have been proposed
for a psychosis population. One such model is MI, which is a ‘directive, client-centred counselling style
for eliciting behaviour change by helping people to explore and resolve ambivalence’ in relation to health
behaviour.152 MI aims to build a person’s motivation for change by increasing their awareness of the
impact of problem behaviour, while maintaining an empathic approach to encourage responsibility as
part of an open, non-judgemental therapist–client interaction and with realistic expectations about
what can be achieved. There is a robust evidence base for this type of intervention in alcohol, substance
use and smoking, and emerging evidence also in diet, exercise and diabetes, in non-psychotic
populations.153,154
In a large population of university students who had been using substances, a 3-month follow-up
revealed that a single session of MI had reduced their use of cigarettes, alcohol and cannabis, mainly
through moderation rather than complete cessation.155 However, it is unlikely that a single MI session
would be sufficient for patients with psychosis. Indeed, a study156 involving patients who use
substances suggests that modifications be made to standard MI, particularly taking into account
possible cognitive deficits by simplifying open-ended questions, refining reflective thinking skills,
heightening emphasis on affirmations and integrating psychiatric issues into personalised feedback.
A number of studies have examined the effectiveness of integrative models combining different
interventions, particularly comorbid psychosis and substance use studies that have used a combination
of MI and cognitive approaches, as well as family therapy,102,103,137,142 and most have found modest
improvements, particularly in the medium term. This integrated approach is consistent with theoretical
and aetiological models that link substance use with psychosis onset and maintenance,157 psychosis onset
with deterioration in self-beliefs, motivation and insight,158–160 and psychosis treatments with physical
health complications. However, interventions in psychosis that focus on only physical health or
substance use have suffered from high attrition rates in addition to poor outcomes.161 It is recommended
that future research would need to take into account methodological standardisation, longitudinal
perspectives, interventions of subgroups and stages, sequenced interventions and the changing realities
of treatment systems.162 Integrating of MI with CBT approaches provides more opportunities to address
the complex mental and physical health presentations that are common in psychosis.162
Previous group-based interventions for substance use in psychosis and brief CBT interventions that focus
on aspects of mental health such as worry, sleep and self-esteem have comprised 6–8 sessions.142,163
Furthermore, previous ‘integrated’ therapies for specific behaviours, such as substance use, in the context
of psychosis extended interventions to 9 months.161 Pre-clinical modelling demonstrates that HPIs
are particularly crucial for people with psychosis and should be integrated within CMHTs, ideally in a
cost-effective manner.
Although there has been some interest in promoting better physical health among patients with psychosis
over the last few decades, only a small number of trials have sound methodologies and a limited range of
treatment models tested, as shown by a recent systematic review on the topic.164 Different groups have
tried different approaches and have concentrated on pharmacological interventions and/or behavioural
interventions.164 For instance, some studies have targeted weight gain by promoting healthy diets and
physical exercises. In another systematic meta-analysis, individual or group interventions, CBT and
nutritional counselling were found to be effective in reducing antipsychotic-induced weight gain.165 More
recently, however, a number of studies have taken a holistic approach by targeting patients with psychosis
and their multiple health behaviours in terms of their lifestyles. For instance, Baker et al.166 in their RCT
compared a 90-minute face-to-face ‘healthy lifestyles’ intervention for smoking and cardiovascular risk
behaviours with a telephone-based intervention, in addition to providing both groups with nicotine
replacement therapy. Both types of interventions resulted in improvement in 12 months, with no
differences between conditions.
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As part of the IMPaCT programme, we thought that by integrating the two well-established
intervention methods, namely CBT for psychosis and MI, we would theoretically be focusing on
increasing personal awareness of the impact of one’s thought processes on emotions and behaviour
while applying MI principles, which would positively enhance the person’s autonomy in making choices.
We thought that this approach would be beneficial to patients with psychosis, as well as meeting their
individual needs, whether or not the person had physical health problems and/or used substances.
To validate this intervention, we had to prepare manuals that described the actual intervention, as
well as providing it in a modular format, so that the therapist could use the required modules with a
particular person who needed to make certain lifestyle changes towards an improved healthier life.
We adapted the actual intervention, which included a combination of MI and CBT, similar to the one
used by James et al.,142 although applied in individual face-to-face contact.
Aims
The study was designed to develop, validate and manualise IMPaCT therapy, a HPI tailored to the
needs of the individual, addressing unhealthy lifestyle factors including substance use and inter-related
comorbid cognitive and mental health difficulties in psychosis. The aim of the intervention was to
modify lifestyle factors that have a negative impact on health in SMI (i.e. substance use, cigarette
smoking, weight gain, poor nutrition and lack of exercise). IMPaCT therapy followed a staged model of
behavioural therapies development.167–169
Method
Design
Initially, a consultation among experts in therapeutic interventions for mental and physical health,
substance use and diabetes generated the key features and focus of the intervention. After this,
IMPaCT therapy was developed through three stages of design and analysis: (1) therapy and training
development, and manual writing; (2) piloting, evaluation and refining the training package with
clinicians; and (3) a Delphi process to reach consensus on the therapy model and manual through initial
consultation followed by two rounds of follow-up questionnaire feedback. The feedback was from each
of three expert groups: (1) therapists, (2) clinician providers within CMHTs and (3) psychosis service
users. The emphasis was on an iterative process leading to a therapy model and manual that would be
well grounded both in theory and in feedback from experts in behavioural change therapies, clinician
providers within CMHTs and psychosis service users.
The intervention was based on the transtheoretical behaviour change model.170 The training and
reference guide introduced this model of behaviour change and its link with the intervention approach.
The intervention manual was then framed around this model. The manual was divided into separate
sections for the distinct stages of behaviour change: (1) precontemplation, (2) contemplation,
(3) preparation and contingency planning, (4) action and (5) maintenance and relapse prevention.
At the start of each section was an overview that defined the stage and how to identify whether or
not a client was in this stage. This was followed in each section by aims, objectives and between 3 and
12 specifically behaviour change ‘interventions’ that were consistent with the behaviour change
taxonomy171,172 and applicable to that stage.
Participants
Participants in the phase 2 training development were eight staff selected from a range of in- and
outpatient settings and backgrounds, working in the area of psychosis within the SLaM NHS
Foundation Trust, but not eligible to participate in the subsequent IMPaCT RCT. Participants in the
phase 3 Delphi consensus and manual development comprised three expert groups of (1) therapist/
researchers, (2) clinicians and (3) service users, each of whom took part in two iterative review and
feedback sessions. Therapist/researcher experts were recruited from the local and national community
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and were involved in the development, implementation or research evaluation of CBT and MI
approaches in psychosis. Clinicians were staff who took part in the phase 3 training, and service users
were people who were receiving a service from the relevant clinicians at the time and had provided
informed consent to participate in the study.
Pilot training
All participants completed a 5-day pilot training, which comprised 10 sessions: (1) introduction to
IMPaCT and the manual/basic CBT skills, (2) introduction to MI, (3) practical MI, (4) intermediate MI
skills in psychosis I, (5) intermediate MI skills in psychosis II, (6) physical health awareness and
monitoring, (7) physical health awareness and diabetes monitoring, (8) substance use awareness,
(9) group work skills and (10) healthy living groups. The training was delivered by members of the
research team (KG, SS, ZA and Manyara Mushore), as well as an expert in healthy living groups and
an expert in MI for psychosis. All participants in the training self-rated of their knowledge and skills
before and after the training, and their confidence in therapy delivery after training.
Delphi consultation
The Delphi process comprised three iterative stages of consultation revolving around an adapted
questionnaire that incorporated feedback from each preceding stage, consistent with recommended Delphi
methodology. The Delphi consultation on the model and manuals was collected in semistructured e-mail
questionnaires for therapist/researchers and clinicians, and in face-to-face interviews with service users,
in accordance with the algorithm presented by Jones and Hunter173 (see Appendix 2, Figure 2). The Delphi
process allowed us to access the acceptability and face validity of the model, manuals and training package,
using expert consensus. The Delphi process was an in-depth consultation requiring the expert clinician and
patient consultants to undertake a selected practice intervention session in pairs, using the intervention,
reference guide, manual and handbook, and provide iterative feedback. Feedback was obtained in the form
of qualitative comments and Likert scale ratings. For each feedback session, each participant read specified
sections of the manuals. Therapists/researchers read all sections of all manuals (the reference guide, the
manual and the Better Health Handbook), whereas clinicians focused preferentially on the therapy manual
and handbook sections. The service users took part in two selected intervention sessions with their trained
clinician and reviewed preferentially the service user resource handbook. Questions considered user-
friendliness, spirit of MI, integration with CBT, usefulness in routine NHS practice, length and complexity,
and whether anything was missing or should be added. Feedback was obtained from numerical ratings on
a Likert scale (0–10), where 0 was least positive and 10 was most positive, as well as qualitatively. After
each round of feedback, changes were made to the content and structure of the manual before the next
round of feedback. In follow-up consultations, the previous individual ratings and group rating were also
fed back, and participants were encouraged to revise their ratings towards or away from the group mean
to determine consensus within each group. Consensus across the group as a whole was based on threshold
ratings for the acceptability and user-friendliness of key elements of the manual on Likert scales of ≥ 7 in
the final stage.
Alongside the Delphi process, an informal presentation and consultation were conducted with a carers
group for people with SMI. The perspectives gained from this presentation were used in the
development of a brief carers’ section to support the therapy.
Results
Initial consultation to form key features and components of the intervention and to consider
mechanisms of change
A consultation among experts in the field of MI and psychosocial interventions for physical health, substance
use and diabetes and CBT for psychosis (KG, SS, ZA, KI and Gill Todd) yielded a set of broad features and
foci of the intervention for consideration in subsequent stages of development. The initial therapy built on
an adapted version of the physical health intervention used in theWell-Being Support Programme,140,174
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incorporating a substance use intervention based on ‘Managing Mental Health and Drug Use’.142 Key features
of the therapy were that it had to be comprehensive, integrative, flexible and pragmatic, deliverable by
mental health clinicians from a range of backgrounds, and able to be readily implemented in NHS
settings. The focus of the components incorporated (1) mental health and psychosis, (2) alcohol use,
(3) cannabis use, (4) smoking, (5) other drug use, (6) diabetes, (7) exercise and (8) healthy eating. It was
initially proposed that, based on previous research, the intervention should be delivered in a group format.
Phase 1: initial therapy training development and manual writing
Extensive review of the Well-Being Support Programme and substance use intervention, as well as of
relevant literature about mental health, physical health and substance use interventions incorporating
CBT and/or MI in psychosis and non-psychosis populations, led to the development of a preliminary
outline of the intervention and of the training package.
Phase 2: piloting, evaluation and refining the training package
The pilot training was delivered to clinicians (n = 8; 50% male) from CMHTs (n = 2), to specialist
inpatient (n = 3) and psychiatric intensive care units (n = 3), and to individuals from a range of
disciplines [psychiatric nurses (n = 5), occupational therapists (n = 2) and social workers (n = 1)].
The knowledge/skills ratings pre and post training are presented in Appendix 2, Figure 3. The mean
self-rated knowledge scores increased from pre to post training on all core areas of training (physical
health, substance use, running groups and using MI).
In addition, the mean post-training confidence ratings were all high for core components (physical
health 81.3%, substance use 79.4%, running groups 86.3%, MI 83.8%) and the mean ratings of the
importance of these aspects of support for psychosis were also all high (physical health, 86.9%;
substance use, 86.9%; running groups, 87.5%; MI, 92.5%).
Clinicians rated the core training modules on various dimensions, including training quality, resources,
level, value, applicability and impact on confidence, as well as on specific skills learnt. Ratings were on
a scale from 1 (poor/strongly disagree) to 5 (excellent/strongly agree). The mean ratings and ranges for
physical health, substance use, healthy living groups and MI training were 4.4 (4.0–4.9), 4.7 (4.09–5.0),
4.4 (4.0–5.0) and 4.3 (4.0–4.9), respectively.
Qualitatively, clinicians recommended that the primary mode for intervention delivery be individual
sessions because of the difficulty in co-ordinating and engaging service users in groups. They also
requested that basic CBT be included in the training programme and the manual. They reported that the
physical health training was empowering, unleashing potential, and should be more available and that
the substance use training should be longer, mandatory and focused more on individual substances. The
training on healthy living groups seemed to fine-tune and enhance existing skills, whereas the MI training
challenged preconceived ideas and a ‘nursing’ model, and was well shaped for community populations.
It gave a structured approach to the intervention, had good links to theory, and provided an opportunity
to try things out, but it should be more focused specifically on MI in mental health as opposed to general
health.
Phase 3: the Delphi consultation
A total of five expert therapist/researchers from a range of backgrounds (two psychologists, two
psychiatrists and one nurse) took part in two rounds of Delphi consultation on the reference book, the
therapy manual and the service user handbook. All manuals were redrafted after each round of the
process, based on numerical and qualitative feedback, and re-rated such that each underwent three
iterations, involving substantial modification of content, format and language. Owing to time pressures
in development, no Delphi rating was obtained for the final version. One expert service user/researcher
also provided qualitative feedback in both rounds. [See www.amazon.co.uk/Impact-Reference-Improving-
Physical-Substance/dp/095688850X (accessed 6 December 2019) for the final versions of the reference
guide, the manual and the Better Health Handbook.]
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Among those expert therapist/researchers who completed both rounds of the Delphi process, the
mean ratings of the therapy manual for user-friendliness, spirit of MI, integration with CBT, usability in
the NHS, length and complexity increased over time from 7.3 to 7.6 out of 10, with a rating of 7.4 out
of 10 from four participants for the second rating. Similarly, ratings for the reference book increased
over time from 6.8 to 7.1 out of 10, with a rating of 7.4 from four participants for the second rating.
Finally, ratings for the handbook increased over time from 7.3 to 7.7 but with a lower second rating
from four participants in the second iteration of 6.4. This lower rating was as a result of a low mean
score from one expert, who also provided extensive feedback that was incorporated in the final
handbook.
Two clinicians (one nurse and one occupational therapist) reviewed the therapy manual quantitatively
and qualitatively while using it to deliver a ‘test’ session each with a service user (one male and one
female). These service users in turn provided qualitative feedback on their experiences of the session.
For the therapist who completed both rounds of the Delphi process, the mean rating for the therapy
manual increased from 7.3 to 8.2. This related to its usability for day-to-day standard NHS work,
including length, complexity and confidence provided.
The expert therapists/researchers generated a large amount of qualitative feedback. The therapy
manual was seen as too long, and all manuals needed more simplified language. Specific core
recommendations for change included developing the therapy into modules, including practice
examples and case studies, providing greater clarity on how to manage interactions with mental health
and issues with medication, having built-in guidelines on training and having supervised practice to
support manualised therapy delivery. In terms of therapy content and structure, recommendations
were made to include a clear definition of each stage of change, what a client might say or do in this
stage, and the sessions associated with this stage; that a structure should be followed for each session
to include a session number and why and when to do the session, followed by clear aims and
objectives and then session content; and that therapists should be advised that they can dip into
the sessions and materials relevant to their client and should not be expected to cover everything.
This would allow flexibility and avoid overprescription. Explicit links were recommended to be made
between the sessions and linked handbook resources. Greater CBT for Psychosis coverage was
requested; some concern was raised about offering too brief a CBT for Psychosis section without a
preliminary formulation. Another recommendation was to include the application of CBT to enable
goals to be reached at the action stage in MI. The various flow charts were often viewed as rather complex.
The general point was made that outside IMPaCT therapy in the NHS there would need to be some form
of physical health assessment or other means to lead to a health target.
One therapist/researcher rightly suggested that the relatives session may be too short to reduce
expressed emotion at home. The relatives session did not aim to be a therapy. At the suggestion of carers
who were presented with the IMPaCT study and asked for comments, the session aimed to address
some of the misconceptions about and heightened expectations for change that might be held by
relatives following the offer of therapy. The session therefore aimed to present only the basic tenets of
behaviour change and the notion that most change occurs at a cognitive level before any behavioural
change occurs. It aimed to clarify that developing intrinsic motivation will lead to more long-lasting
change, as opposed to a forced change that may be short lived.
Clinicians fed back qualitatively that the theory should be clearly separated from the therapy sessions
as a separate reference book. The sessions themselves needed to be simplified and clearer in their
aims, and more stand-alone as individual session guides, with less ‘jargon’. There was a need to ensure
better cross-referencing between the therapy manual sessions and the handbook resources. The MI
section was viewed very positively. Overall, echoing the view of the expert therapists/researchers,
the consensus was that the initial therapy manual was too long.
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The two service users provided only qualitative feedback over the two time points. They confirmed that
they found the focus on health to be beneficial, leading to an increase in knowledge, motivation and
ideas for improving health, and one reported a significant change in alcohol use (from heavy drinking to
2-week abstinence) following the session. Materials in the handbook were viewed positively. One expert
service user/researcher provided specific and detailed feedback on the handbook. Key points included,
again, using simpler language; giving greater explanation of how to use and complete the various
resources, and what they are; including colour and pictures to liven up the handbook; and including
positive language and hopeful messages about change. Consistent with expert therapists, a suggestion
was made that terms such as ‘heavy’ or ‘light’ smoking/substance use needed to be defined; in addition,
benchmarks and thresholds, for example for problematic waist circumference, should be provided for
mainstream NHS use. In the research therapy, this will be provided as part of the IMPaCT assessment.
Discussion
The production of the training and manuals for the IMPaCT therapy followed multiple iterative phases
of piloting, consultation and refinement. The process culminated in a 5-day training programme and a
set of three manuals to support training and intervention delivery: the reference guide, the manual and
the Better Health Handbook.
The final training retained all of the pilot training sections but extended the substance use training.
The MI section was delivered with a greater focus on application for service users with comorbid physical
and mental health difficulties. The training included sessions on basic skills in CBT for (1) mental health and
(2) achieving goals in physical health during the action stage of behavioural change. Finally, it commenced
with a specific session on how to use the reference guide, the manual and the Better Health Handbook
as part of a therapeutic process.
The set of three manuals was designed to provide all of the basic information required to deliver
IMPaCT therapy within routine NHS practice. The manuals were necessarily lengthy but significant
effort was made to ensure that these were concise and used plain language.
The reference guide contained three sections:
1. An introduction to the IMPaCT study and the guiding ethos, including an overview and key
information on the primary approaches of MI and CBT.
2. A section comprising the primary interventions. This encompassed an overview of the eight
individual module plans for CBT in mental health, alcohol, cannabis, smoking, other drugs, diabetes,
exercise and healthy eating; a chapter on working with carers in the IMPaCT approach; and a
chapter on running groups. A specific emphasis here was on how to adapt the basic session and
group plans for working with different target health issues, how to integrate MI and CBT for
these issues, and how these issues might overlap with mental health. Outcome measurement
and module-specific resources were introduced.
3. A section on setting up a service. This section contained information about how to run the training
and to set up and deliver supervision as part of an IMPaCT therapy service. It also included
information on how to map local community health provisions, to which service users could then be
directed as part of the intervention.127
Finally, a set of appendices included guidance on aspects of therapy delivery, such as flow charts to
determine the starting module, for transition between modules and for the evaluation of module
progress. Outcome measures and psychoeducation materials were also included.
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The final manual comprised introductory materials on how to use the manual and the Better Health
Handbook, followed by information on getting started and the introductory session. In response to
feedback from the Delphi process, 37 individual intervention sessions followed, grouped into:
l introductory sessions (1–3)
l supplementary session (4–7) if initial sessions did not lead to a health goal
l sessions for pre-contemplation (3, 4, 8–12)
l sessions for contemplation (13–21)
l sessions for preparation and contingency planning (22–29)
l sessions for action (30–32)
l sessions for maintenance and relapse (33–37).
This last section also included an extensive CBT session (36), which was itself broken down into eight
subcomponents. Based on feedback from the Delphi process, each section commenced with a definition of
the particular stage of change, what the client might say or do in this stage, and key aims and objectives for
this stage, with a contents list. Then followed each individual session plan, which commenced with reasons
to offer this session, when to offer this session and a guide to session content. The sessions were designed
so that therapists could select the relevant sections based on the client’s individual needs and stage of
change. Each session included links to appendices that provided example dialogues, derived from real-case
examples, to show how to implement the intervention. Each session also provided a reference to all
relevant resources in the Better Health Handbook.
Finally, the manual also included group session plans for (1) beginner’s exercise (six sessions),
(2) maintaining exercise (six sessions), (3) healthy eating (nine sessions), and (4) social activities
(10 sessions).
The Better Health Handbook comprised a set of useful resources that could be photocopied, separated
according to stages of change and numbered according to the intervention session. They included
diaries, worksheets, physical health summary sheets, questionnaires, and lists of coping strategies and
alternative behaviours. The resources were colourful and included images, where appropriate, and
could be used to develop a tailored therapy pack for each service user.
The intervention for any particular health issue was the delivery of a module of up to approximately
eight sessions, lasting approximately 1 hour. Sessions were designed to be tailored to the individual’s
needs, to be positively framed, and to encourage opportunities to replace unhealthy with alternative
health and social behaviours. Mental health support was incorporated alongside support for physical
health, and modules were designed so that individuals could work flexibly alone or in groups at their
own pace and level.
We designed and developed the manualised approach and training package to provide registered
mental health nurses and other care co-ordinators in routine clinical care with knowledge and skills
so that they would feel more confident monitoring and supporting their clients with their physical
health. Resources associated with the development and implementation of the HPI will be measured
to estimate its costs and inform service providers. The implementation, fidelity to protocol and efficacy
of the intervention was assessed in a large-scale RCT in SMI: the IMPaCT trial (see Work package 3:
IMPaCT randomised controlled trial).175
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Work package 3: randomised controlled
trial of the effectiveness of an
integrated psychosocial health promotion
intervention aimed at improving health and
reducing substance use in established
psychosis (IMPaCT)
This section provides a summary of work published in Gaughran et al.175,176 and Heslin et al.177
Parts of this text have been reproduced from Gaughran et al.176 This is an Open Access article
distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license,
which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided
the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below
includes minor additions and formatting changes to the original text.
Parts of this text have been reproduced from Heslin et al.177 This is an Open Access article distributed
in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use, provided the original
work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below includes minor
additions and formatting changes to the original text.
Background
Living with a diagnosis of psychosis is associated with a reduced life expectancy of 10–20 years, largely
because of CVD. As detailed in work package 2, we developed a HPI to help people to make healthier
choices. We aimed to determine the effect of the HPI on improving health and reducing cardiovascular
risk in people with psychosis compared with treatment as usual (TAU). Additionally, given the demands
on health services, we planned to examine the costs associated with these patient groups and to
evaluate the economic impact of the proposed interventions (see Work package 3: IMPaCT randomised
controlled trial, Health economics). Therefore, this trial aimed to determine the clinical effectiveness and
cost-effectiveness of a modular HPI in psychosis when compared with the established normal treatment.
Aims and hypothesis
The primary objective was to test the clinical effectiveness and cost-effectiveness (see Work package 3:
IMPaCT randomised controlled trial, Health economics) of adding IMPaCT therapy, an intensive HPI
designed to improve physical health and reduce substance use, to TAU delivered by care co-ordinators
to people with psychosis.
Our primary hypothesis was that the addition of IMPaCT therapy to the normal mental health care
delivered by care co-ordinators over 9 months would be more effective than TAU alone in improving
patients’ QoL, as measured with the Short Form questionnaire-36 items (SF-36) mental health and physical
health subscales178 at 12 months from baseline, and that this advantage would be maintained at a follow-up
assessment 15 months from baseline. The 12-month post-randomisation period included an initial 3 months
in which the care co-ordinators were trained to provide the HPI over the subsequent 9 months.
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Our secondary hypothesis was that the HPI group would see a greater improvement in metabolic
outcomes and substance use than the TAU group at both time points; specifically, (1) TAU plus IMPaCT
therapy would result in a greater reduction of waist circumference by at least 1 cm at 12 months than
TAU alone, (2) TAU plus IMPaCT therapy would be more effective in reducing weight at 12 months
compared with TAU alone, (3) TAU plus IMPaCT therapy would result in a 50% reduction in the
proportion of people using cannabis compared with TAU alone and (4) TAU plus IMPaCT therapy
would be more effective in reducing the symptoms of psychosis than TAU alone.
Methods
A multicentre, two-arm, parallel-cluster RCT was conducted across five mental health UK NHS trusts.
Care co-ordinators were randomly assigned to either receiving training, and ongoing supervision, in
delivering IMPaCT therapy or delivering TAU to their current patients with psychosis (cluster).
A more detailed explanation of all methods can be found in the published study protocol, available
open access;175 the methods are briefly described in the following sections.
Study design and setting
A pragmatic, multicentre, two-arm, parallel-cluster, RCT design was used and the HPI was integrated
into routine services across five mental health trusts in South London, Kent, Sussex, Somerset and
Staffordshire, including both urban and rural populations. The Consolidated Standards of Reporting
Trials (CONSORT) cluster trial extension standards guided the planning and implementation of this
study. Ethics approval was obtained from the joint South London and Maudsley and the Institute of
Psychiatry NHS Ethics Committee (REC reference number 09/HO80/41). Colleagues with lived
experience, including both service users and carers, were involved throughout the research, from
contributing to funding applications, to managing steering groups, to coauthoring the papers arising
from the work.
Participants
Recruitment took place between 1 March 2010 and 1 July 2014. Eligible participants were aged
between 18 and 65 years and had an established diagnosis of a psychotic disorder (ICD-10114 diagnosis
F20–29, F31.2 or F31.5). Patients were excluded if they (1) had a primary diagnosis of learning
disability, (2) had a pre-existing physical health problem that would independently affect the metabolic
measures (as judged by medical investigators), (3) were pregnant or < 6 months post partum or (4) had
a life-threatening or terminal medical condition. We did not recruit from FEP services. Recruitment
started on 1 March 2010, with first randomisation on 9 August 2010.
Study procedure
There were two waves of participant recruitment. First, all permanently employed community care
co-ordinators with a minimum of four psychosis patients on their caseload in participating CMHTs were
approached in random order (using a random number generator) and invited to participate. Following
informed consent from individual care co-ordinators, patients from their caseload who met the inclusion
criteria were identified. These patients were then approached and invited to participate, also in a random
order, until either four participants consented or all eligible patients had been approached. Baseline
measures were then taken from the consenting patients. After baseline assessments of all consenting
patients on a care co-ordinator’s caseload were completed, care co-ordinators were randomised and
stratified by borough using randomisation blocks of random sizes to deliver IMPaCT therapy or TAU
alone to their own current patients (cluster). Both researchers and the statistician remained blind to
treatment allocation for the duration of data collection.
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In the treatment arm, the intervention (IMPaCT therapy) was provided by a patient’s usual community
care co-ordinator. In the first 3 months following a patient’s randomisation, their community care
co-ordinator received a 4-day IMPaCT training course. This covered physical health and substance
misuse, MI, CBT techniques for running group sessions, and how to deliver IMPaCT therapy and
health promotion, and it was given by trainers in MI and in CBT. An evaluation of this is reported in
Appendix 3. Throughout the subsequent 9-month intervention, participating care co-ordinators were
offered fortnightly supervision in IMPaCT therapy and all care co-ordinators were offered a 1-hour
training session in best practice for physical health awareness to ensure more standardised TAU.
The intervention was rolled out into routine care by holding discussions with management, which
confirmed their strong support, and then approaching local team management about the practicalities,
and then informing the community teams about the RCT and offering the 1-hour education session as
above. Further practicalities were addressed at the 4-day training sessions in the intervention group,
including advice on planning group sessions if needed. Day-to-day practical issues that arose were
dealt with in the fortnightly supervision sessions or, if these were at the team, borough or trust level,
the relevant layer of management was involved.
Outcome measures
A change in outcome was defined as a difference from baseline and (1) on completion of the
supervised intervention, at 12 months, and (2) 3 months after the end of treatment, at 15 months.
Baseline and follow-up assessments were conducted during face-to-face interviews by researchers
within established time windows (–6 weeks/+4 weeks at 12 months’ follow-up and ± 4 weeks for
15 months’ follow-up). Data collected outside these times were recorded but used only for sensitivity
analyses and not for the main analysis.
Primary outcome
The primary outcomes were the physical and mental health component scores of the SF-36,178
measured at 12 and 15 months. We originally proposed the SF-36 as an integrated score but revised
the protocol so that each of the two components was a primary outcome.
Secondary outcomes
Secondary outcome measures were (1) physical health measures (levels of total HDL and low-density
lipoprotein cholesterol, triglycerides, HbA1c and CRP; anthropometric measurements, including waist
circumference, BMI, BP; MetS defined according to the International Diabetes Federation criteria);13
(2) substance use measures [alcohol use recorded using the AUDIT,121 smoking prevalence and cigarettes
per day using the Nicotine Dependence Questionnaire,120 use of cannabis and other illegal substances
(e.g. opiates, methamphetamine, cocaine) using the Time Line Follow Back];72 (3) lifestyle measures
(dietary patterns quantified using the DINE179 and physical activity using the short-form International
Physical Activity Questionnaire);116,180 and (4) mental health status (using PANSS,115 GAF,117 SF-36 and
Montgomery–Åsberg Depression Rating Scales).181
Sample size
Power analyses were performed for the two subscales measures: physical and mental health components
of the SF-36 QoL scale.178 To detect a clinically significant reduction of 5 points (using 80% power,
a 5% alpha level and two-tailed assumption), and to allow for a 20% loss of care co-ordinators and an
additional 30% loss of patients to follow-up, a total sample size of 70 care co-ordinators, yielding
280 participants, was needed for the physical scale (d = 0.5), and 98 care co-ordinators, yielding
392 participants, were needed for the mental health scale (d = 0.42).
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Statistical analysis
Primary statistical analyses was based on the intention-to-treat principle and aimed to estimate the
difference in mean outcomes between participants randomised to HPI and those randomised to TAU at
12 and 15 months using mixed-effects models. Bias as a result of missing follow-up data was assessed by
comparing the baseline characteristics of those with and those without complete data. In two linear
mixed-effects models, the physical and mental health component scores at 12 months and 15 months
constituted the dependent variable. ‘Treatment randomisation group’, ‘time’ (with two levels, i.e. 12 and
15 months post randomisation), and the interaction between ‘treatment group and time’, ‘centre’ and
the ‘baseline values of physical and mental health component scores’ constitute the fixed part of the
model. An unstructured covariance pattern model was used to model the dependency of the repeated
observations of the same subject and to account for the dependency of the subjects within a cluster,
and the care co-ordinator was included as a random factor. Model assumptions were assessed by visual
inspection of the residuals. Standardised effect sizes, using pre-randomisation variability for
standardisation, were also reported.
Secondary outcomes were analysed using the same methods as for the primary outcome. For all
models, the interaction between treatment group and time was not significant and was removed from
the final analyses. Treatment effects are, therefore, estimates for both time points. Logistic mixed
models were used for binary outcomes (e.g. smoking) and Poisson mixed models were used for count
data (e.g. number of cigarettes per day). Because of the large number of tests, significant results need
to be treated as explorative.
Sensitivity analyses
Approximately 15% of the observations were collected outside the time window, so analyses using all
available data were repeated as sensitivity analyses.
Handling of missing data
Models were rerun with predictors related to outcome missingness included as further covariates
in the model. For the main outcomes, a second sensitivity analysis of missing outcome data, using
multiple imputations by chained regression equations, was performed using all available clinical and
demographic scores. This was done separately for each treatment group. A further sensitivity analysis
was carried out to explore the impact of not missing at random patterns by adding positive or negative
values to the imputed data sets.
Complier average effect analyses
In addition to the standard intention-to-treat (efficiency) analysis, we estimate the measure of the
treatment impact for compliers only (treatment efficacy) using an instrumental variable approach
with randomisation indicator as an instrumental variable.182 Analyses were carried out using Stata’s®
(StataCorp LP, College Station, TX, USA) ivregress package, with centre, treatment arm and baseline
values of the outcome constituting the fixed part of the model and with cluster robust standard errors
(SEs) to control for clustering effects of care co-ordinator.
Results
Key findings
A total of 104 care co-ordinators were recruited; 52 (with 213 patients) were randomised to deliver
IMPaCT therapy and 52 (with 193 patients) were randomised to TAU. Of the 406 patients, 318 (78%)
and 301 (74%) attended the 12- and 15-month follow-ups, respectively. The total sample size was
reduced to 263 (64.8%) for 12 months (TAU, n = 132; HPI, n = 131) and to 238 (58.6%) for 15 months
(TAU, n = 114; HPI, n = 124) because some of the patients who attended follow-up assessments were
not seen within the required time frame. The required sample size based on the power analyses was
achieved at both time points.
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IMPaCT therapy showed no significant effect on the physical or mental health components of the
SF-36 scores compared with TAU at 12 or 15 months.176 Sensitivity analyses, including missing data
analyses, did not alter any conclusion176 (see Appendix 5). A complier average casual effect analysis
did not provide evidence of the efficacy of the intervention at 12 months for the physical health
component (PHC) (mean difference –2.01, 95% CI –4.18 to 0.16; p = 0.07) or mental health component
(MHC) (mean difference 0.02, 95% CI –2.79 to 2.83; p = 0.99).
No effect was observed for cardiovascular risk indicators, except for HDL cholesterol, which showed
greater improvement following IMPaCT therapy than following TAU (treatment effect 0.09, 95% CI
0.007 to 0.16; p = 0.034). The 22% of patients who received > 180 minutes of IMPaCT therapy in
addition to usual care achieved a greater reduction in waist circumference (–4.2 cm, 95% CI –7.2 to
–1.2 cm; p = 0.006) than did control patients. This reduction is clinically significant. There was no
difference in the rates of serious adverse events between the groups. The fidelity assessment is
detailed in Appendix 3.
Discussion
Strengths of the trial
The main strength of this trial is that it was a pragmatic study: the design of the HPI was centred on
creating an intervention accessible to the greatest possible number of people with psychosis receiving
care in CMHTs. This is a traditionally hard-to-reach group; many people are unable or unwilling to
attend standard group interventions, which is particularly problematic because of the high levels of
cardiometabolic risk.183
This study’s integrated personalised approach sought to maximise representativeness of the population
studied. It addressed both lifestyle choices and substance use and avoided a piecemeal approach to
behavioural change. By integrating IMPaCT therapy into established mental health care and by
providing the care through a patient’s usual therapist, care could be adapted to the patient’s individual
needs. To date, few large-scale, long-term RCTs have attempted to improve health in its widest sense
in people with psychosis, instead focusing on a single target and often introducing new therapists to
run the trial intervention.
The study recruited to target and was sufficiently powered to detect a difference between the two
groups of at least 5 points in physical and mental health component scores (Cohen’s d = 0.42), had
good follow-up rates and recruited a diverse, multiethnic sample of people with psychosis.
Limitations of the trial
Continuity of care was affected by multiple reorganisations of staff among the hospital trusts. Staff
turnover sometimes delayed recruitment to the trial, as an inclusion criterion was that the staff
members expected to be in post for the forthcoming year. Despite this, although not statistically
different, staff turnover was slightly greater in the treatment arm than in the control group. However,
when patients remained with the same trained care co-ordinator throughout the trial, there were
indications that the intervention may result in significantly lower cholesterol levels and more exercise
in the treatment group than in the control group. It is known that diminished continuity of care is
associated with worse clinical outcomes.184
Care co-ordinators struggled to deliver six or more 30-minute sessions of the HPI in addition to
routine care, despite the training and ongoing supervision, and had limited fidelity to the MI model.
This is in keeping with the recognised challenges of delivering targeted psychosocial interventions to
people with psychosis that are faced by care co-ordinators in a busy secondary care environment.185
It is also consistent with the findings of the Health Improvement Profile (HIP) RCT, which trained community
mental health nurses to administer health checks to their patients and found that the volunteer nurses
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administered health checks to only a minority of participating patients.186 However, given that the
subset who received > 180 minutes of additional time devoted to IMPaCT therapy had a clinically
significant reduction of –4.2 cm (95% CI –7.2 to –1.2 cm) in their waist circumference, a focus on
implementation strategies in future work may be important.
A pilot trial was not conducted because the intervention was built on two pre-existing, successful,
published interventions in this population, used a recognised behaviour change theory and
incorporated additional recommendations for improving the preceding interventions. However, the
longer combined intervention and the delivery model using non-expert care co-ordinators in a UK
setting were not tested previously and raised logistical issues, which perhaps could have been
identified and addressed more effectively in a large-scale pilot trial, although it is doubtful that they
would have been identified in a small pilot.
The HPI was broad and participants self-selected, the target behaviours to focus on. It is conceivable
that a more structured intervention targeting specific health behaviours, such as those described
elsewhere,187,188 could be more successful in demonstrating statistically significant improvements in
circumscribed aspects of the physical health of this population. Nonetheless, a longer-term, sustainable
and integrated approach to overall health behaviours and health outcomes is urgently needed to allow
successful and accessible routine care in the NHS.
Conclusions
Training and supervising community care co-ordinators to administer IMPaCT therapy to patients
with psychosis was seen to be insufficient for significantly improving physical or mental health QoL.
Front-line clinical staff, although willing to take part in training and supervision, struggled to
consolidate training as part of applied MI therapy. However, the data suggest that continuity of care
staff and protected time to deliver HPI work may potentially enhance outcomes.
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Work package 3: economic evaluation section
Introduction
To address the key question of value for money in a resource-constrained health-care system, we
conducted a comprehensive within-trial economic evaluation of the IMPaCT HPI to inform future
decisions about its adoption into the NHS. This section summarises the work published in Heslin et al.,177
with further unpublished data presented in Appendix 4.
Economic evaluation methods
Data collection
An adapted version of the Client Service Receipt Inventory (CSRI)189 was used to measure individual-level
resource use. It covered the use of (all-cause) secondary and community-based health and social care
services, prescription medication, time off work, and social security benefits received by participants and
carers. It was administered as a retrospective, self-report, questionnaire-based interview conducted by
assessors who were blind to treatment allocation. It covered the previous 6-month period at baseline and
at the 12-month follow-up, and the previous 3-month period at the 15-month follow-up.
Health-related QoL was assessed with self-report questionnaires at baseline and at 12 and 15 months,
and the SF-36 and EuroQol-5 Dimensions, three-level version (EQ-5D-3L),190 were used to estimate
QALY gains.
Costs
Unit costs were applied to individual-level resource use data to calculate the total costs per participant
from two cost perspectives: health and social care, and societal. All-cause health and social care costs
included the trial interventions (HPI for the intervention group and standard information session for
the control group), specialist accommodation, inpatient services, outpatient services, community-based
services, community-based professionals and prescription medications. Societal costs included the same
health and social care costs plus third-sector (charity) costs, lost productivity costs due to absence from
work (if in employment during the assessment period), participant out-of-pocket expenditure on
community-based day services and selected social security benefits. Lost productivity costs were
capped at 5 days per week (maximum of 130 days for 6-month data and 65 days for 3-month data).
Unit costs are detailed for reference in Appendix 4, Table 9. In brief, the unit costs for most hospital
and primary care services were obtained from the NHS Reference Costs 2010–11191 (inflated to
2011–12 prices using the Hospital and Community Health Services Pay and Prices Index or retail price
index as appropriate) and the Unit Costs of Health and Social Care 2012 compilation.192 Medication unit
costs, taken from the British National Formulary,193 were converted into cost per milligram based on the
most cost-efficient pack size, choosing maintenance doses over initial treatment doses and generic
formulations over branded ones to obtain conservative estimates.
All costs are reported in Great British pounds (GBP) at 2011–12 prices. Discounting was applied to
cost and outcome data related to the 12- to 15-month assessment period. Intervention costs were not
discounted before being added to the 12- to 15-month costs because they were incurred in the first
year. Discounting was applied at a rate of 3.5%.194
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Cost of the health promotion intervention
We included the following resource components to estimate the costs associated with the intervention:
l the production of manuals (excluding the development work)
l the training of care co-ordinators
l the ongoing supervision of care co-ordinators
l the implementation of the intervention by care co-ordinators with trial participants.
The resources and costs associated with each of these components are available for reference in
Appendix 4, Table 9. The costliest of the four components was the implementation with patients, at a
mean cost of £92.31 per case. To estimate the total participant-level intervention costs, we first
averaged out general costs using a ‘top-down’ approach (i.e. we summed the costs of the manual,
training and supervision, and divided this by the recommended number of patients under the care of
each care co-ordinator). To this average we added the individual-level implementation costs.
Health promotion intervention manual costs
Care co-ordinators randomised to the intervention arm were provided with a copy of the IMPaCT
manual, the IMPaCT reference guide and the Better Health Handbook. The time inputs to the
intellectual development of these documents were considered a sunk cost and were, therefore,
excluded. However, we included the reproduction costs.
Health promotion intervention training costs
Costs related to training care co-ordinators included the following components: the cost of trainer time
(contact and non-contact), the cost of care co-ordinator attendance time and the cost of materials
necessary to deliver the training courses. The training programme was delivered over 4 days by
members of the research team in a standardised manner, with specific staff dedicated to implementing
certain parts of the programme. The total number of hours and the number of sessions for each staff
type were calculated as detailed in Appendix 4, Table 10. Preparation time was estimated by multiplying
the number of training sessions by an assumed preparation time per session of 10 minutes. Costs were
calculated by multiplying the appropriate unit costs by the number of minutes for each staff type.
Each of the care co-ordinator attendees was an NHS band 6 nurse. Each training programme took
32 hours including breaks (09.00 to 17.00 for 4 days). Costs were calculated by multiplying the
appropriate unit costs by this time.
Materials were broken down into one-off costs and repeat costs. One-off costs included BP machine,
weighing scales, tape measure, flip-chart stand and memory stick. Repeat costs included flip-chart
paper, flip-chart pens, paper and pens.
Health promotion intervention supervision costs
At the outset of the study, it was envisaged that ongoing supervision of care co-ordinators would take
place in a combination of individual and group sessions, led by a band 6 nurse trainer and a band
8 nurse trainer, for 9 months after attendance at the training programme. However, because of
practical limitations, group supervision was unable to be provided, so all supervision took place at the
individual level in 90-minute sessions. Costs were calculated by multiplying appropriate unit costs by
the number of minutes spent in supervision by both the supervisors and the supervisees.
Health promotion intervention participant implementation costs
Similarly, it was originally envisaged that the intervention would be delivered in a combination of
individual and group sessions led by care co-ordinators. However, group intervention sessions were not
provided, largely because of practical limitations, so all implementation occurred in individual sessions.
To estimate the costs of the intervention at the level of individual patient participants, we multiplied
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the cost of each individual therapy session by the care co-ordinator estimates of the proportion of time
in each session spent delivering an aspect of the HPI.
Cost of the control intervention
Care co-ordinators in the control group of the trial were given a one-off information-giving session on
mental and physical health issues. This involved a consultant psychiatrist delivering the session over a
1.5-hour period. The appropriate unit costs were applied and the cost per care co-ordinator was then
divided by the recommended number of patients under the care of each care co-ordinator.
Outcome measures
Cost-effectiveness analyses were based on the joint primary outcome measures: the SF-36 MCS score
and SF-36 PCS score. Cost–utility analyses were based on QALYs derived from the EQ-5D-3L and the
SF-36 (US version 1) via the Short Form questionnaire-6 Dimensions (SF-6D). Appropriate utility
weights were attached to health states for each measure at baseline and at 12 and 15 months.178,190
QALY gains between 12 months and 15 months were then calculated using the total area under the
curve approach with linear interpolation between assessment points.195
Analyses, missing data and sensitivity analyses
For the economic evaluation analysis, see Appendix 4.
Key findings
The economic evaluation showed no evidence of a clear difference in health and social care costs
between the two trial groups. Societal costs may be higher in the intervention group. Alongside a lack
of additional benefit, there is no evidence that the intervention is cost-effective. The integrated mental
and physical health-care intervention itself involved no significant additional resource use or associated
costs. However, it is unclear to what extent this finding reflects a true lack of impact on costs and
outcomes, or whether or not it reflects the fact that, because very few participants in the intervention
group received the intervention as planned, both groups ultimately received similar care.
Discussion
Limitations
The economic evaluation had some limitations. Data on resource use and, therefore, on costs were
collected using the self-reported CSRI. This makes the data subject to participant recall bias. However,
there is evidence for the reliability of self-reported resource use data in similar populations196,197 and
we considered the approach necessary given the multisite and multiperspective nature of this study;
the lack of integration of all relevant health and social care sector client records necessitated such an
approach to avoid restriction to a narrow definition of health and social care. Furthermore, at least
some resource use would still have been needed to be collected via self-report (i.e. welfare benefits
and employment losses) to enable a societal perspective to be considered, which we considered of
particular relevance for a patient group whose health and care needs can have economic impacts on
multiple sectors of society. Additionally, there is no reason to believe that any biases related to data
collection would be unbalanced between the two trial groups, particularly because the CSRI was
administered by blinded assessors.
A further limitation is that we may have double counted resource use associated with the HPI. We
collected this information separately from care co-ordinators rather than from patient participants to
avoid unblinding the assessors conducting the participant interviews. However, this carried the risk of
participants reporting resource use related to the intervention in response to questions about their
service use. Although this may skew absolute estimates of costs for the intervention arm, any bias in
the calculation of treatment effects would work against the intervention group by overestimating the
intervention cost.
DOI: 10.3310/pgfar08010 Programme Grants for Applied Research 2020 Vol. 8 No. 1
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Gaughran et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
33
There has been some discussion around the validity of using the SF-36 and EQ-5D-3L with study
participants who have mental health problems, especially those with schizophrenia and other
psychoses.198 Brazier et al.198 suggest that neither scale performs particularly well in terms of
quantitative testing against psychometric criteria and that both have a limited coverage of domains
identified as relevant by people with mental health problems. Thus, it is unclear whether or not the
lack of QALY difference between the two trial groups reflects a lack of intervention effect or
limitations associated with the measurement properties of these two health-related QoL measures.
However, given the lack of effect based on the SF-36 MCS and PCS, and all other outcome measures,
it is unlikely that there was a difference in QALYs that we have been unable to detect.
Finally, the time horizon of the evaluation is likely to have been insufficient to identify all relevant
outcomes for this patient group, particularly given the longer-term impacts of physical health problems.
However, it is unlikely that any effects of the intervention would transpire in the longer term if absent
in the short term.
Conclusions
There was no evidence of a difference in costs or outcomes from a health and social care perspective.
From a societal perspective, the intervention may incur higher costs for no associated benefit.
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Programme discussion
People with SMI are at increased risk of poor health outcomes and have a marked premature mortalityrate. The aim of the IMPaCT project was to develop culturally appropriate, innovative, practical and
effective programmes to achieve better physical and mental health in patients with SMI by improving
lifestyle choices and reducing illicit drug use. Three separate studies were conducted.Work package 1
(‘the PUMP study’) aimed to observe health behaviours, the progression of cardiometabolic disease
among patients with their FEP, and the links between these factors over the course of 1 year. Consistent
with previous studies, we found high rates of cardiometabolic risk at presentation, which increased over
the 12-month period. No relationship was found between antipsychotic choice and emergence of
cardiometabolic risk.Work package 2 saw the successful development of a HPI, IMPaCT therapy, based
on MI and CBT techniques aimed at effecting behaviour change in people with established psychosis.
Work package 3 was a large RCT of IMPaCT therapy among patients with established psychosis that was
carried out in five NHS trusts throughout the UK. The intervention was integrated into NHS secondary
care as care co-ordinators delivered it to their own patients. IMPaCT therapy was not found to affect QoL
any more than did TAU, nor was it cost-effective. There was limited evidence of efficacy on secondary
outcomes such as cardiovascular risk indicators, substance use or mental health measure compared with
TAU alone.
Work package 1, PUMP, demonstrated that the use of substances such as tobacco and alcohol and
less healthy dietary and exercise choices among people with FEP are common on presentation to clinical
services and that cardiometabolic risk continues to increase over the course of the year, with rates of
obesity rising from 17.8% to 23.7% in this relatively young population. These health profiles may also
have an impact on service costs, with obesity at baseline showing an association with higher subsequent
admission costs, low HDL cholesterol at baseline being associated with lower subsequent admission
costs and higher HDL cholesterol at baseline being associated with a greater subsequent QALY gain.
In the IMPaCT study group, who were older, half were obese; furthermore, 20% of our population with
established psychosis had diabetes, and a further 30% had glucose dysregulation.183 These findings both
testify to the importance of preventing diabetes in the first instance and highlight the challenge in
preventing diabetes among people with SMI. Management of diabetes is also difficult in this population;
for example, people with diabetes and SMI have fewer routine eye checks and poorer glycaemic and
lipid control,199 and perhaps ultimately have a 50% poorer survival rate, than those with a diagnosis of
diabetes alone.200
In both PUMP and the RCT study, we found high rates of physical inactivity alongside an unhealthy
dietary intake typified by high saturated fat and low dietary fibre, which is consistent with previous
literature. It is acknowledged that sedentary behaviour and unhealthy eating further increase
vulnerability to ill health and early death.201 Furthermore, we conducted a systematic review and
meta-analysis of sedentary behaviour in people with psychosis, which showed that people with
psychosis engage in very high levels of sedentary behaviour while awake.202 We related sedentary
behaviour in the IMPaCT population to an inflammatory marker of CVD, CRP.203 We found that those
with higher levels of sedentary behaviour have elevated CRP levels. Yet, despite the IMPaCT HPI
addressing the above lifestyle behaviours, there were no significant improvements in physical activity
or dietary consumption over the course of the study. The HPI exercise module aimed to increase the
level of exercise and, specifically, the number of minutes patients engaged in physical activity but was
unsuccessful. This is in keeping with the findings from our recent meta-analysis that people with
schizophrenia engage in significantly less moderate and vigorous physical activity than do control
participants.204 The above finding suggests that although the overall aim is to make people more
physically active, attention needs also to be directed at making people less sedentary. As a result of
our findings, we are now running a trial of an intervention specifically to increase activity and reduce
sedentary behaviour, Walk this Way.202
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We found that 62% of our patients with established psychosis smoke tobacco, and the rates were even
higher among people presenting with their FEP. Although tobacco-smoking rates are known to be high
in people with psychosis, our figures are thrown into sharp relief when compared with the current
18% prevalence rate among the general UK population.We are currently investigating in our sample
of people with established psychosis the effect of cigarette smoking on both depressive and psychotic
symptoms over time. The very high rates of tobacco-smoking in the first episode group changed little
over the following year, especially so among those from black and minority ethnic groups. A potential
explanation for this may be that national smoking campaigns and incentives for health-care practitioners
to address smoking behaviours are not well targeted towards this population. The potential adverse
effects of nicotine dependence among our sample highlight the need for effective smoking cessation
strategies in psychosis. The findings may also help both patients and clinicians to view smoking cessation
more positively by understanding the detrimental effects smoking can have both on physical health and
on mental health symptoms.
We failed to identify differences in cardiometabolic risk in people with established psychosis who were
prescribed antipsychotic medication of different types or in emergent cardiometabolic risk in FEP
patients.176 Despite the side effects, antipsychotic medication is important in optimising one’s mental health
so that one is well enough to take charge of one’s physical health. In a large study of 66,881 patients with
schizophrenia over a 10-year period, long-term treatment with antipsychotic medication was associated
with lower mortality than receiving no antipsychotic medication.9 Additionally, the longer people were
prescribed antipsychotics, the smaller the mortality gap became. Furthermore, those prescribed with
clozapine, the gold-standard treatment for refractory schizophrenia that is known to have a risk of rapid
weight gain and glucose dysregulation,12 had the lowest mortality rate of all patients with schizophrenia.
Therefore, antipsychotics, used thoughtfully at the lowest effective dose, should be seen as integral to
mortality reduction strategies.
A relatively small proportion of our IMPaCT patients were prescribed cardiovascular medication,
although further work is needed to determine the proportion of our sample for whom medications
such as statins were indicated under current NICE guidelines, which are not based on blood test results
alone. Nevertheless, it is an important area for attention. A Danish study31 has shown that people with
schizophrenia with concomitant CVD are prescribed most cardiovascular drug classes less often than
the general population, in particular lipid-lowering and antihypertensive medication. Additionally, in that
study, patients with SMI were less likely to be prescribed more potent medications (such as angiotensin-
converting enzyme inhibitors or beta-blockers), suggesting inadequate treatment of CVD.
It is not immediately clear why the IMPaCT therapy intervention conferred no advantage on recipients,
relative to control treatment under intention-to-treat conditions. It is possible that potential efficacy
was suppressed because of factors affecting consistent implementation of the intervention in an
increasingly busy NHS setting, despite ongoing supervision. A key strength of the IMPaCT RCT was
its pragmatic design; the trial was integrated into the existing workforce and conducted across several
NHS foundation trusts, thus widening its generalisability. Significant practical challenges were overcome
during implementation; for example, as services were reconfigured or contracted, there was some
emergent resistance among team leaders to allowing care co-ordinators to fully participate in the study
as planned. Once care co-ordinators were randomised to the IMPaCT therapy arm of the trial, they were
required to attend a mandatory 4-day training course on how to deliver IMPaCT therapy, but difficulties
were experienced in encouraging care co-ordinators to attend the planned course. For example, despite
initial buy-in to the IMPaCT study from team leaders, there was a degree of resistance at team level to
freeing the care co-ordinator from clinical duties to attend the training. Resistance may have arisen
because, within each participating centre, several care co-ordinators could be recruited from one team.
Given care co-ordinators’ already heavy workload, team leaders were understandably reluctant to allow
to be absent from their regular duties for the full 4-day period. In anticipation of these concerns, the
study team offered care co-ordinators the opportunity to attend 2-day training in any given week and to
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complete the remaining 2 days at the following training session. Feedback from participating care
co-ordinators indicated that the training was well received. Although a reduction in training duration
appeared to have improved the acceptability of the intervention among team managers, the shortened
training session may have been less immersive and, thus, less effective than the planned 4-day session,
which may have had an impact on the results.
Indeed, it is questionable whether or not intensive training courses are sufficient to equip care
co-ordinators with the skills needed to deliver a given psychosocial intervention. Motivational
interviewing requires that therapists reframe the way in which they approach discussions with their
clients. Shifting from a didactic to a more client-centred approach probably requires that care
co-ordinators reconsider their ingrained practices. The care co-ordinators recruited to the study had
many years’ experience in their role, over which time they were likely to have formed habitual clinical
practices. Indeed, no care co-ordinator ran group sessions with patients, despite receiving training in
this and supervision to support group work; we noted that running groups had not been standard
practice for any of the care co-ordinators before joining the study. Not only may care co-ordinators
have lacked the time to organise and facilitate these sessions, but changing practice may have required
them to break habits. Care co-ordinators may require support from team leaders to deliver new
models of care and, although trust management and team leaders were supportive, future work may
need to include an element addressing organisational barriers.
Care co-ordinators can be from a number of professions, but in the participating trusts they were
predominantly from either nursing or social work backgrounds. We did not want to limit the
evaluation to nurses only as the cardiometabolic risk was universal. Social workers would not have
received training in physical health management as part of their professional training; additionally,
in recent decades, mental health nurses will have received only limited training in physical health
when completing their undergraduate course. The intervention was designed with this in mind and to
address the gaps between physical and mental health care. Interventions such as the HIP RCT have
also highlighted challenges in incorporating physical health management into mental health care.186
There has also been recent consideration of other service models. The research evidence suggests
that high-intensity interventions incorporating specialists in diet and exercise are most effective,187,205
although, in the UK, service providers may be hesitant owing to the cost of such initiatives.
Additional challenges were posed by shifts in the political landscape during the study period, specifically
the implementation of the Health and Social Care Act 2012,206 accompanied by significant economic
pressure and a large-scale restructuring of the NHS. The IMPaCT RCT study relied on the recruitment of
CMHTs, which are embedded in mental health trusts. The main recruiting mental health trust experienced
major restructuring and changes in remit during the study period, which in turn led to delays, as care
co-ordinators could not commit to participation until this reorganisation was complete. The reorganisation
was associated with a degree of uncertainty among staff about their job continuity, which had an impact
on their ability to participate in the IMPaCT therapy training; specifically, many were unsure, because
of restructuring, whether or not they would be with the team for the duration of the trial (15 months).
Additionally, there may have been tensions within teams regarding care co-ordinators’ involvement in
the study; although training staff members is perceived as beneficial to the team, freeing staff for training
purposes inevitably means distributing their workload among other staff members. However, it is
important that these challenges are recognised; this intervention was designed to be easily incorporated
within standard care teams and the practicalities of doing so are part of the evaluation. This context
should be considered when interpreting the costs associated with IMPaCT therapy. The evaluation
suggested that the intervention itself involved no significant additional resource use or associated costs,
nor an impact on broader overall costs, but it is unclear to what extent this reflects a true lack of impact
on costs or merely low levels of implementation and, thus, limited potential to have an impact on
resource use.
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Additional methodological limitations must be acknowledged. Study procedures may have been
conducive to selection biases. Studies of non-participation have typically found that those who decline
to participate in psychosis research studies tend to be male, have severe symptoms, substance abuse
problems, low educational attainment and socioeconomic status, and be unmarried and unemployed.
Additionally, patients were required to provide informed consent to participate, which presupposes
sufficient cognitive ability to read, interpret and deliberate over the information presented in a patient
information sheet and to make decisions regarding whether or not to consent to all aspects of the
research, while acknowledging the potential risk of doing so. Obtaining informed consent risks
excluding the most impaired patients from a study.
Work package 1, PUMP, was designed so that all people presenting with their FEP were potentially
eligible for inclusion, whereas the RCTwas carefully designed to be as representative as possible, so that
all patients with a primary diagnosis of a psychotic disorder allocated to the care of a participating care
co-ordinator were potentially eligible for inclusion. To further explore representativeness of psychosocial
research models, we decided to test the hypothesis that, even with such an inclusive RCT design, those
who consented to participate in the trial would be less ill than those who did not. We did this by
comparing the Health of the Nation Outcomes Scales (HoNOS) scores at baseline among the SLaM
IMPaCT RCT participants (n = 293) with similarly timed HoNOS scores recorded as part of clinical care
in the eligible population of patients (i.e. those eligible patients of the participating care co-ordinators,
n = 774) using an anonymised case register. The mean total HoNOS score of the eligible comparator
population was indeed significantly higher than that of the IMPaCT RCT participants (t = 3.810;
p = 0.006), as was the degree of overall illness severity and functional impairment, as measured with
HoNOS.We concluded that the patients who participated in the RCT had better mental health at entry
to the trial than the total eligible population, although we found no difference in physical health needs.207
This is important to bear in mind when interpreting the findings of RCTs of lifestyle interventions for use
in service planning.We would further speculate that the greater the effort needed to participate in an
intervention and evaluation thereof, the more selective recruitment and the less generalisable the results
to the overall SMI population in need.
Furthermore, in the PUMP study, the mean duration of treatment was 35 days prior to consent to the
study. This time lag was the product of waiting for participants to be well enough to provide informed
consent to the study. Thus, our measure of baseline symptom severity is necessarily more representative
of a less ill population. This highlights the difficulties that researchers face in recruiting participants at the
time of presentation to psychosis services, while also illustrating the potential for results not to generalise
to people with more severe psychosis at the point of presentation. Because of these problems, it is possible
that our sample under-represents the severity of illness often witnessed in people with psychosis. Indeed,
the relatively low total PANSS scores in the PUMP study suggest mild to moderate symptom severity.
However, it is likely that we were examining a cohort of patients representative of FEP. For example, our
study208 examining the longer-term follow-up of the same sample found that 34% of the sample were
treatment resistant at 5 years, with 70% of those never achieving symptomatic remission from the time of
first presentation.
Missing data also posed a challenge in the PUMP study. Partly, this may have been a result of attrition;
one of the key difficulties of conducting both prospective cohort studies and RCTs is the time lag between
study recruitment and follow-up, which can lead to attrition bias.209 PUMP included a large number of
assessments and so participants may have felt fatigued and unable to complete all of the tests. To minimise
repetition, the PUMP study joined with the Genetics and Psychosis (GAP) study210 that was recruiting FEP
patients concurrently; although this limited the number of repeat assessments, the overall assessment
battery remained intensive. Additionally, participants living in inner-city areas are highly mobile, making it
harder to locate them at follow-up. This, combined with the social deprivation faced by this population,
may also increase the mobility of this sample, with many participants being frequently rehoused, which
may result in limited traceability.211 However, measures were employed to limit attrition. Contact details of
the participant and their relatives/friends (e.g. e-mail and postal address, mobile and home phone numbers)
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were collected at the start of the study and contact was pursued using participants’ preferred contact
mode.We also sought to maintain interest and remind participants of the study aims by sending
newsletters to participants between baseline and follow-up assessments. Additionally, a courtesy call was
made midway between the assessments to remind participants of their upcoming follow-up appointments.
These communications also alerted the research team to barriers to contacting the participant (e.g.
newsletter returned as undelivered), and other means of contact were used to maximise the likelihood of
booking follow-up assessments. Nonetheless, in the PUMP study, only 125 of 293 participants completed
the 12-month face-to-face assessment measures. However, we retrieved follow-up data from a number of
sources including case notes and other records, thereby, not solely relying on face-to-face measures, which
resulted in high completeness rates.122 Thus, the potential impact of attrition was mitigated.
To minimise the impact of missing data on our research findings in the PUMP study, we utilised, with
consent, data from a number of sources; these included anthropometric, metabolic and biochemistry
data recorded in the patients’ electronic case records. However, we found low levels of documentation
of physical health measures. This is in keeping with a series of national audits of schizophrenia, which
have retrospectively examined the quality of physical health monitoring, including whether or not
weight, BMI, BP, tobacco use, alcohol use, substance misuse, blood glucose, blood lipids and family
history of CVD, diabetes, hypertension or dyslipidaemia were documented. Documented evidence
in the case notes fell below agreed standards, with < 25% of patients having all nine parameters
documented.212 This highlights the need to regularly monitor and record these data systematically.
However, it should be noted that this finding was before the introduction of CQUIN targets, which
have since enhanced physical health data documentation substantially, particularly for those patients
who have had an inpatient stay.
Finally, both studies relied heavily on self-report measures. Although these are validated for use with
participants with psychosis, potential problems are associated with the accuracy of such measures,
which must be acknowledged. Of note is that many participants chose not to self-administer the
measures, largely because of the nature of the illness (which can result in lack of motivation, low mood,
cognitive impairment), and low literacy levels. Instead, researchers were often required to read aloud
each item and present the corresponding scale on which participants would indicate their response.
Although researchers sought to read aloud questionnaire items in a non-biased manner, it is known
that the way in which data collection is conducted, or by whom it is conducted, can have unintended
potential consequences on study findings.
Recommendations for research
At the individual level, having schizophrenia makes it more difficult to engage in healthy behaviours.
For example, social withdrawal reduces opportunities to participate in physical activity,213 and negative
and cognitive symptoms make it even more difficult for people with schizophrenia to organise
themselves to prepare healthy meals. We have not yet had the opportunity to fully explore the effect
of negative and cognitive symptoms on outcomes in our study populations, but this is work we plan to
do in the future.
At a biological level, genetic factors may also influence cardiometabolic risk. An identified locus is
associated with both increased CVD risk factors and schizophrenia,214 while polymorphisms in a type 2
diabetes gene may increase susceptibility to schizophrenia.215 We are examining the IMPaCT population
to look for genetic predictors of metabolic status both in people with FEP and those with established
psychosis. We have created a genetic risk score and are performing statistical analyses to establish the
relationship between this score and MetS in psychosis.
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Inflammatory mechanisms have been suggested as a possible driver of CVD in schizophrenia.216
We examined the relationship between inflammation as measured by levels of CRP and metabolic risk
factors in people with their FEP. We found that triglyceride dysregulation is associated with elevation
of CRP levels early in the disease course of people with psychotic disorders.126 This suggests that
inflammation should be investigated as a therapeutic target in the future.
Sexual dysfunction is common in people with schizophrenia, with a reported prevalence of up to
80%.217,218 In our service user focus group this was highlighted as a priority topic. Although sexual
dysfunction is often attributed to the side effects of psychotropic medication, we have found that it
exists even before the FEP in people not treated with antipsychotic medication.219 Nevertheless, the
development of sexual side effects contributes to non-adherence to psychotropic medication. This is a
frequently overlooked aspect of general well-being in people with schizophrenia; it is important to
QoL and should be actively enquired about by treating clinicians. Future clinical research is needed
to determine how best to systematically identify and manage sexual dysfunction in people with a
diagnosis of SMI, bearing in mind its multiple causes, many of which, such as medication choice,
obesity, smoking and sedentary behaviour, are also relevant to cardiovascular health.
The search for effective evidence-based approaches to reduce the excess cardiometabolic risk experienced
by people with SMI is proving a challenge for many research groups, following the negative results
in all recent large European RCTs on the topic, namely IMPaCT, STEPWISE, PRIMROSE, HIP and
CHANGE.176,186,220–222 Although the interventions in all these studies were intuitively sensible and it was
reasonable to believe that they should have been helpful, researchers are struggling to demonstrate
evidence of additional effectiveness in the context of structured health-care systems. It may be that
the effectiveness of more individualised long-term approaches to reverse cardiometabolic risk in this
population needs to be evaluated, bearing in mind that reversing established cardiometabolic risk in the
general population is also a challenge.
Conclusion
The IMPaCT programme has highlighted the high rates of cardiometabolic risk soon after first
presentation with psychosis and the early emergence of additional risk. We did not find that baseline
lifestyle choices and addiction behaviours identified those people most likely to increase their
cardiometabolic risk in the first year, but we did note a differential pattern of emergence of
cardiometabolic risk in relation to ethnicity.
We developed, in an iterative process, a modular HPI to be used in routine clinical care and
implemented by the patient’s usual care co-ordinator and evaluated it in what is to our knowledge the
first randomised trial of such an intervention. The RCT confirmed the challenges in targeting lifestyle
and substance use to modify cardiometabolic risk and highlighted the difficulties of adding specific
psychosocial interventions to the workloads of increasingly stretched clinical teams.
Our work also demonstrated that, even in the early stages of psychosis, there are high rates of vitamin D
deficiency, which was associated with cardiometabolic risk markers in people with established psychosis.
As a result of this, we have now started a RCT of vitamin D supplementation in FEP (URL: www.
clinicaltrialsregister.eu/ctr-search/trial/2014-002639-32/GB; accessed 2 December 2019).
A better understanding of the role and interplay of exercise, nutrition, substance use and medication
will allow for the development, delivery and evaluation of better and more efficient interventions, for
example targeting the overall individual’s fitness instead of simple measure of their body shape.223
Importantly, at a wider level, factors hindering access to care should also be addressed to improve
the knowledge of service planners and to plan reasonable adjustments. The low efficacy of HPI
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interventions such as IMPaCT RCT in reversing established unhealthy behaviours is consistent with
other emerging work.220 In this context, our results underlined the importance of preventing the
formation of (unhealthy) habits around physical exercise, alimentation, substance use and lifestyle
choices rather than modifying them later.
The IMPaCT study provides important information to health service planners, suggesting that they need
to be aware that training and supervising staff to work on lifestyle choices and substance use with their
patients as part of routine care is not sufficient to reduce cardiometabolic risk or improve mental and
physical QoL.
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Programme patient and public involvement
This whole programme was, from the outset, co-produced with experts by experience. Ms Bee Harrieswas a co-applicant on the original grant application. Ms Harries was involved in the planning and
development of IMPaCT and facilitated our patient and public consultation, starting in the borough of
Lewisham. She led the focus groups held there, which informed our study design and emphasis; for
example, the inclusion of work on sexual dysfunction derived from that focus group (Reis-Marques et al.219).
She helped generate solutions to enhance recruitment to the study and presented the work with us to
collaborating services. Sadly, Ms Harries died during the course of the study. She contributed immensely
to the development and accessibility of the intervention, which is dedicated to her memory.
A stakeholder engagement event was held in the Civic Suite in Lewisham on 20 March 2008 entitled
‘Our Bodies are Important Too . . . as well as our mental health’ (Box 1). The event included information,
small-group work (up to six people in a group) and, at lunchtime, a well women’s group, hand massage,
BOX 1 Stakeholder engagement event timetable
‘Our Bodies are Important Too . . . as well as our mental health’
10.00–10.30 Sign-in and registration
Delegates can leave their addresses if they want information from the day.
11.00 Introduction of the day
Miriam
11.15 Interview of Fiona Gaughran about the IMPaCT Project
Bee and Kristine
11.45 Group exercise – what one thing would you say about your health to your support worker, doctor, etc.
Collated and used in theatre after lunch
12.00 Small groups and consultation exercise around IMPaCT questions
13.00 Lunch – hot and cold food
14.00 Playback theatre around Bee’s poem – I am a person 1, 2 and 3, and group exercise results
14.15 Where do we go from here – next steps
Kristine/Miriam/Bee
Questions/areas for the group work included:
l What has worked already for you within SLaM services for your health care?
l Why did this work?
l What would you like to see more of/different?
l Talk about the health module – what is important to have on the health module (e.g. exercise, diet, etc.)?
l Any interest in getting involved in the health modules, training on the health module?
l Any interest in joining the advisory group for the IMPaCT Project?
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activity from Network Arts, information on physical activity and expert patients’ group. The aim of
the day was to find out from people using mental health services what is important to them in their
treatment around physical health care. We wanted to find out what people would like to see more of or
change and whether or not people would like to get involved in planning or advising on health promotion
services. The day was co-ordinated by Ms Miriam Mica, Mental Health Promotion Co-ordinator at SLaM
NHS Foundation Trust, and the sessions were led by Bee Harries. The day was co-hosted with Family
Health Isis, a local African and Caribbean mental health organisation.
On the untimely death of Bee Harries, Thomas Kabir from the Mental Health Research Network
helped us with the essential patient and public involvement input to the programme and then put us
in touch with Maurice Arbuthnott, who also has expertise by experience. Maurice Arbuthnott has
contributed hugely as an equal partner to the running of all aspects of the programme.
We set up a partnership with carers through the Mental Health Research Network body FACTOR,
co-ordinated by Dr Geraldine Mason. We set up a carers’ consultation group; this consisted of six
to eight carers who met regularly with two IMPaCT team members to discuss the project. Two
carer members of that group, Philippa Lowe and Diana Orr, started to attend the monthly IMPaCT
management meetings and are important partners in the team, advising on recruitment and follow-up
strategies as well as engagement and dissemination.
All our experts through lived experience have not just contributed to the development and
implementation of the research, but also brought their own knowledge and expertise to enrich the
quality and applicability of the work. Our carer involvement structures are described in detail in a case
report by an anthropologist in Devon Partnership NHS Trust (see Report Supplementary Material 1;
reproduced with permission from Dr Sarah Robens, Devon Partnership NHS Trust).
Expert service user input
My name is Maurice and I live in Central London. I have been using mental health services for just over
20 years. I became involved in IMPaCT through the Mental Health Research Network and I am pleased
to help with representing service user interests in the IMPaCT research project. My main role is as a
participant and observer at the monthly IMPaCT steering group meetings. I consider my participation at
these meeting in three ways: 1. Offering advice where appropriate e.g. on how to encourage service users to
get involved in the project. 2. Enquiring about the progress and methodology of the project for the sake of
clarification. 3. Making constructive comments for general consideration. My perspective of the research in
question comes not only as a service user experienced in psychosis and treatment but also as a lay person
e.g. the proverbial man in the street so I aim to keep this perspective as wide as possible.
On occasion I have also talked to researchers about my own experiences of how my physical health needs
have been met and my relationship with medical professionals, especially my community mental health
team. I am very interested in being a source of reference to researchers and for them to enquire about my
experiences as a service user. I also compiled a questionnaire for the service users to complete after their
involvement in IMPaCT. This aimed to find out what service users found was important to them in
participating in research and what they found interesting, useful or otherwise. We are soon to analyse
these results.
I am particularly interested in how this project will benefit the maximum number of service users through
helping them achieve the best possible physical health and I am looking forward to assisting with the
dissemination of the eventual results and findings not only to the medical profession but also to my fellow
service users and the lay person. I feel very positive about IMPaCT goals to empower people into better
health especially as it is a well-documented observation that people with a mental illness also endure poor
physical health.
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Expert carer input
Written by Philippa Lowe:
There are many ways of coping as a carer for someone with mental illness and one of them is to get
thoroughly involved in the subject and to take an interest in related research developments. This is the
path I chose, so I was very pleased to be invited to be a carer adviser for the IMPaCT project.
The subject of the research was of particular interest to me as my son, who has had schizophrenia for
nearly 20 years, is now very much better in respect of the more dramatic symptoms of the illness but has
experienced considerable weight gain which puts him at risk of developing severe physical illnesses which
may shorten his life. I was grateful for the opportunity to help shed light on the problem both for the sake
of my own family and for others facing similar issues.
I found it a pleasure to work with a team of people from different relevant disciplines who were clearly
dedicated to their subject and welcomed the various contributions with respect and interest. I found that
I could make a useful input, for example, by suggesting ways of helping the research subjects cope with
the various procedures which were required of them, by proposing the best ways of setting out clear
information in guidance notes and newsletters and by urging the involvement of carers, where available,
as the people who can offer support and encouragement for ongoing participation. Colleagues involved
with the project gave a clear indication that this sort of input was of value to the project, which was very
good to hear.
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Appendix 1 Work package 1: PUMP – health
economics
Background
Although there is clear evidence of the increased cardiometabolic risk among people with SMI14 and
its likely consequences for long-term morbidity (diabetes, heart disease, stroke, amputation, renal
failure, blindness) and care costs later in life, it is unclear whether or not there are more immediate
impacts on service costs and QoL following first presentation to mental health services.
Aims and hypotheses
We aimed to investigate the relationship between metabolic factors/syndrome at first presentation to
mental health services and (1) mental health hospital admission costs in the subsequent 1-year period
and (2) QALYs in the subsequent 1-year period.
Method
Measures
At baseline, after giving informed, written consent, each participant was asked to complete a battery
of measures. This included sociodemographics, clinical measures and health-related QoL, measured
using the EQ-5D-3L.190 Clinical measures relevant to these analyses were clinical indicators of
MetS/cardiometabolic risk (obesity, triglycerides, HDL cholesterol, BP and fasting plasma glucose).13
The EQ-5D-3L was again administered at the 12-month follow-up to enable the calculation of 1-year
QALY gains.
Data on mental health care hospital admissions for the 12 months prior and 12 months following
presentation for FEP were manually extracted from electronic patient record systems in each of the
relevant NHS trusts using a pro forma specifically designed for the task to standardise the methodology
and information that was collected. Core data included admission and discharge dates of each admission
to enable the calculation of length of stay per admission, and ward type to enable more accurate
estimation of costs.
Unit costs
Unit costs were applied to individual-level inpatient days according to ward type to calculate total
mental health hospital admission costs per participant over 1 year. Unit costs were obtained from
NHS Reference Costs for the year 2010–11 and inflated to 2011–12 prices using the Hospital and
Community Health Services Pay and Prices Index.192 We used the Reference Costs 2010–11191 because
they offered more detailed cost data according to the type of mental health service, which is not
offered in the 2011–12 Reference Costs. Unit costs are detailed in Table 1. All costs are reported in
GBP at 2011–12 prices. Discounting was not necessary as all costs related to a 1-year period.
Analyses
For the purpose of univariate associations with costs and QALYs, individual metabolic factors were
examined in both binary (present or not) and continuous form. Furthermore, the total number of
metabolic factors present was investigated.
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To estimate QALYs, we applied general population utility weights to EQ-5D-3L health state
measurements at baseline and at 12 months.124 QALY gains between baseline and 12 months were
then calculated using the total area under the curve approach with linear interpolation between
assessment points.195
Data were analysed using Stata 11. Despite the skewed nature of the cost data, the mean and SDs for
cost data are reported as recommended.224 Associations with costs and QALYs were explored using the
stepped approach.225 Univariate associations of metabolic and sociodemographic variables with costs
were examined using non-parametric bootstrap regressions (ordinary least squares); we conducted
each regression both with and without a covariate for baseline costs. All independent variables that
were associated (p < 0.1) with costs in these univariate analyses were then carried forward for
inclusion in a multivariate non-parametric bootstrap regression. We examined the results of the
multivariate regression to identify any variables that no longer remained significantly associated with
costs (p > 0.1) and then reran the multivariate regression without those variables. Variables that did
not appear significantly associated with costs in the univariate regressions were then added into the
model and retained if they significantly improved the model or rejected if they did not. The same
process was repeated for the analysis of associations with QALYs.
Results
Of 321 people initially consented, 28 were subsequently deemed ineligible, leaving 293 eligible
participants recruited to the study.
Sample characteristics
Of the 293 participants, 190 (65%) were male and 136 (46.4%) were of white ethnic origin. The mean
age was 30.6 years (SD 10.5 years). Seventy-six (31.8%) lived alone and 155 (66.2%) were unemployed.
TABLE 1 Unit costs of PUMP
Service Unit
Unit cost
(2010–11
prices)191 (£)
Inflated unit
cost (2011–12
prices)192 (£) Notes
Acute ward Bed-day 319 329 MHIPA2 – adult: acute care
Assessment ward Bed-day 319 329 MHIPA2 – adult: acute care
Accident and emergency Bed-day 108 112 TA and EMSNA – accident and
emergency services: not leading to
admitted
Personality disorder Bed-day 553 571 SCU44 – high-dependency secure
provision: personality disorder
Mother and baby unit Bed-day 651 672 MHIPMB – mother and baby units
Medium secure Bed-day 483 499 SCU3 – medium-level secure
services
Intensive assessment Bed-day 627 647 MHIPA1 – adult: intensive care
Psychiatric intensive care Bed-day 627 647 MHIPA1 – adult: intensive care
Low secure Bed-day 427 441 SCU2 – low-level secure services
Adolescent inpatient Bed-day 602 622 MHIPC1 – children
Elderly Bed-day 329 340 MHIPE1 – elderly
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Data completeness
A total of 274 out of 293 participants (93.5%) had full data on resource use/costs for both the
12 months prior to and the 12 months following presentation for FEP, which were gathered from
electronic health records. However, fewer people had all relevant data on metabolic factors and
QALYs. This resulted in 100 participants with all relevant data for the examination of associations with
admission costs and 55 participants with all relevant data for the examination of associations with
QALYs. Table 2 shows that the two subgroups available for analyses were similar to the full sample in
terms of a range of baseline characteristics. However, both subgroups had lower admission costs at
baseline than the full sample. The potential implications of missing data are explored in Discussion.
Resource use and costs
Among the 293 participants, we were able to extract data for 278 on the number of inpatient days for
the year prior to FEP. Of these, 243 participants had no inpatient days prior to FEP. Of the 35 participants
who had had a mental health admission, this was mostly because of a few (1–5) days admitted for
symptoms during the prodromal period before a diagnosis of psychosis was assigned. Four participants
had total admission days ranging between 8 and 172 days and the most likely reason for this was an
evolving clinical picture before the diagnosis of psychosis became clear. The mean cost of admissions in
the year prior to FEP was £443 (SD £5814, range £0–95,957).
We were able to extract data on the number of inpatient days for the year following presentation for
FEP for all 279 participants. Twenty-eight participants had no admissions. The overall mean total was
63 days [SD 69 days, range 0–367 days (exceeds 365 as a result of accounting for movement between
wards)]. The associated mean cost was £25,376 (SD £34,411, range £0–236,945).
TABLE 2 Characteristics of full sample and subsamples with full data required for analyses
Variable Full sample (N= 293)
Subsample with full data
for admission cost analyses
(N= 100)
Subsample with full
data for utility analyses
(N= 54)
Gender, n (%)
Female 103 (35) 40 (40) 24 (44)
Male 190 (65) 60 (60) 31 (57)
Ethnicity, n (%)
White 136 (46) 42 (42) 23 (23)
Other 157 (54) 58 (58) 32 (32)
Living alone (n= 239), n (%)
No 217 (68) 70 (74) 40 (78)
Yes 76 (32) 25 (26) 11 (22)
Employment status (n = 234), n (%)
Employed/student 79 (34) 29 (31) 19 (37)
Unemployed 155 (66) 64 (69) 32 (63)
Age (years), mean (SD) 30.6 (10.5) 29.8 (9.8) 30.0 (10.1)
Baseline utility score (n = 178),
mean (SD)
0.79 (0.26) 0.82 (0.25) 0.83 (0.18)
Baseline admission costs (£)
(n = 274), mean (SD)
443 (5814) 77 (276) 83 (320)
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The proportion of participants who had at least one admission and the mean number of inpatient days
for the year prior to FEP were similar in the full sample and in the subsample who had all required
data for the analysis of admission costs (i.e. they also had full metabolic and sociodemographic data)
(Table 3). This was also true for the 1 year following presentation for FEP. However, the mean cost of
admissions in the year prior to FEP was lower for the subsample with full data than for the full sample
[£77 (SD £276) vs. £433 (SD £5814)].
Metabolic syndrome factors and admission costs
Univariate analyses suggested that being male, obese or of non-white ethnicity was associated with
higher admission costs during the 1-year follow-up (p < 0.1), whereas being older or having reduced
HDL cholesterol (< 1.03 mmol/l for men and < 1.29 mmol/l for women) was associated with lower
costs during the 1-year follow-up (p < 0.1) (Table 4). When these factors were carried through to a
multivariate analysis, all except ethnicity remained significantly associated with costs (Table 5).
Health state utility
Of the 293 participants in the full sample, 89 had full EQ-5D-3L data at both baseline and follow-up
to enable the calculation of QALY gains for the year following presentation for FEP. The mean QALY
gain for these 89 participants was 0.84 (SD 0.17). The subsample was further reduced to 55 when
accounting for availability of relevant metabolic and sociodemographic data; however, this subsample
appeared broadly representative of the full sample of participants, who had a comparable mean QALY
gain of 0.86 (SD 0.14).
Metabolic syndrome factors and quality-adjusted life-years
Both unadjusted and adjusted (for baseline utility value) univariate analyses suggested that, at baseline,
having a MetS, being obese, having reduced HDL cholesterol (binary variable), having higher HDL
cholesterol (continuous variable) and having more metabolic indicators were associated with lower
QALY gains (Table 6). Having raised fasting glucose or higher triglycerides (adjusted coefficient –0.03,
95% CI –0.07 to –0.00) was associated with lower QALY gains in adjusted analyses only.
When examining these seven variables in a multivariate analysis adjusted for baseline utility, only
HDL level (as a continuous variable) remained statistically associated with QALYs, with higher HDL
cholesterol associated with greater QALY gains (HDL 0.09, 95% CI 0.02 to 0.17; p = 0.013) (Table 7).
TABLE 3 Admissions data for the full sample and the subsample with full data required for analyses of admission costs
Full sample (N= 293)
Subsample with full data for
admission cost analyses (N= 100)
Baseline
Had at least one admission (%, n/valid n) 13 35/278 12 12/100
Mean number of days (mean, SD) 1 10 < 1 1
Mean cost (£) (SD) 433 5814 77 276
Follow-up
Had at least one admission (%, n/valid n) 90 251/279 89 89/100
Mean number of days (SD) 63 69 55 64
Mean cost (£) (SD) 25,376 34,411 20,922 25,510
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TABLE 4 Univariate associations between MetS factors and 1-year mental health admission costs
Variable Unadjusted coefficient Unadjusted 95% CI Adjusted coefficienta Adjusted 95% CIa
Gender
Female – – – –
Male 11,613 3092 to 20,133* 11,544 2861 to 20,226*
Ethnicity
White – – – –
Other 7990 –1439 to 17,420* 8437 –1179 to 18,054*
Age
–606 –1078 to –134* –631 –1119 to –143*
Binary MetS
No – – – –
Yes –4600 –13,945 to 4744 –4786 –14,192 to 4621
Binary obesity
No – – – –
Yes 15,350 –408 to 311.09* 15,378 –352 to 31,108*
Binary high triglycerides
No – – – –
Yes –1850 –12,742 to 9041 –2150 –13,106 to 8807
Binary high BP
No – – – –
Yes –4224 –13,452 to 5004 –4642 –14,114 to 4830
Binary raised fasting glucose
No – – – –
Yes –7197 –17,472 to 3078 –7266 –17,515 to 2983
Binary reduced HDL cholesterol
No – – – –
Yes –9452 –17,915 to –988* –9524 –18,069 to –979*
Triglycerides (continuous)
1693 –3600 to 6985 1564 –3762 to 6890
Systolic BP (continuous)
73 –127 to 273 69 –131 to 269
Diastolic BP (continuous)
–26 –486 to 434 –41 –510 to 427
Fasting glucose (continuous)
–6843 –16,718 to 3031 –7172 –17,302 to 2958
HDL cholesterol (continuous)
–2466 –12,471 to 7539 –1992 –12,467 to 8482
Number of metabolic factors (continuous)
–1189 –5322 to 2963 –1307 –5495 to 2880
*p < 0.1.
a Includes covariate for baseline admission costs.
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TABLE 5 Multivariate associations between MetS factors and 1-year mental health admission costs
Variable Adjusted coefficient SE 95% CIa
Constant 30,496 7854 15,102 to 45,890*
Gender
Female – – –
Male 12,227* 4226 3945 to 20,509*
Age
–557* 224 –995 to –119*
Binary obesity
No – – –
Yes 17,691* 7173 3632 to 31,750*
Binary reduced HDL cholesterol
No – – –
Yes –10,399* 4428 –19,077 to –1720*
*p < 0.1.
SE, standard error.
a Includes covariate for baseline admission costs.
Adjusted R2 = 0.1490.
TABLE 6 Univariate associations between metabolic factors and EQ-5D-3L-based QALYs
Variable Unadjusted coefficient Unadjusted 95% CI Adjusted coefficienta Adjusted 95% CIa
Gender
Female – – – –
Male –0.01 –0.08 to 0.07 –0.03 –0.08 to 0.02
Ethnicity
White – – – –
Other 0.00 –0.07 to 0.07 –0.02 –0.07 to 0.03
Age
0.00 –0.00 to 0.00 –0.00 –0.00 to 0.00
Binary MetS
No – – – –
Yes –0.12 –0.26 to 0.01* –0.13 –0.25 to –0.02*
Binary obesity
No – – – –
Yes –0.14 –0.25 to –0.02* –0.08 –0.17 to 0.00*
Binary high triglycerides
No – – – –
Yes –0.01 –0.09 to 0.06 –0.03 –0.10 to 0.03
Binary high BP
No – – – –
Yes 0.00 –0.08 to 0.09 –0.03 –0.09 to 0.04
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Discussion
The results suggest that obesity at baseline is associated with higher subsequent admission costs, that
low levels of HDL cholesterol at baseline is associated with lower subsequent admission costs and that
higher levels of HDL cholesterol at baseline is associated with a greater subsequent QALY gain.
TABLE 6 Univariate associations between metabolic factors and EQ-5D-3L-based QALYs (continued )
Variable Unadjusted coefficient Unadjusted 95% CI Adjusted coefficienta Adjusted 95% CIa
Binary raised fasting glucose
No – – – –
Yes –0.07 –0.22 to 0.07 –0.14 –0.31 to 0.02*
Binary reduced HDL cholesterol
No – – – –
Yes –0.11 –0.21 to –0.02* –0.08 –0.16 to –0.01*
Triglycerides (continuous)
–0.01 –0.06 to 0.04 –0.03 –0.07 to 0.00*
Systolic BP (continuous)
–0.00 –0.00 to 0.00 –0.00 –0.00 to 0.00
Diastolic BP (continuous)
–0.00 –0.01 to 0.00 –0.00 –0.01 to 0.00
Fasting glucose (continuous)
–0.01 –0.07 to 0.09 –0.05 –0.11 to 0.01
HDL cholesterol (continuous)
0.14 0.06 to 0.21* 0.09 0.02 to 0.17*
Number of metabolic factors (continuous)
–0.03 –0.06 to –0.00* –0.03 –0.06 to –0.01*
*p < 0.1.
a Includes covariate for baseline admission costs.
TABLE 7 Multivariate associations between metabolic factors and EQ-5D-3L-based QALYs
Variable Adjusted coefficient SE 95% CIa
Constant 0.320 0.066 0.190 to 0.450*
HDL cholesterol (continuous) 0.094 0.036 0.024 to 0.166*
*p < 0.1.
SE, standard error.
a Includes covariate for baseline admission costs.
Adjusted R2= 0.5429.
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Strengths and limitations
To our knowledge, this is the first study to examine the association between MetS indicators and
admission costs and QALYs in patients with a FEP. However, the findings should be seen as exploratory
and be interpreted with caution owing to several limitations. First, missing data resulted in small
sample sizes for the analyses. Although the subsamples analysed were broadly representative of the
full sample in terms of mean values for costs and QALYs, they may have differed on other factors and
the small sample size in general increases the risk of spurious results given the number of independent
factors that we sought to examine. Second, we examined only psychiatric admission costs and the impact
of MetS in this patient group is on broader health-care costs remains unclear. However, because
psychiatric inpatient costs are likely to be the main driver of total care costs in this patient group,226
the inclusion of other care costs is unlikely to substantially alter the findings.
Conclusion
Finally, this study examines cardiometabolic risk indicators that increase a person’s risk of heart
disease, stroke and other conditions affecting blood vessels in the long term.192 We have focused on
only short-term mental health admission costs because we were interested in any additional impacts
within the mental health care sector, but longer-term and broader data would be required to better
assess the full additional impact of these high levels of cardiometabolic risk.
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Appendix 2 Health promotion intervention
development (work package 2)
Definition of problem Need for a manual that addresses
physical health in SMI
Selection of experts
• Experts X
• Experts Y
• Experts Z
First round of Delphi Interview to develop initial list
Second round of Delphi
Participants score agreement or
disagreement with statements an a 
scale from 0 ‘total agreement’ to
10 ‘total disagreement’
Third round of Delphi
Participants rescore agreement or
disagreement in the light of the
group’s responses 
Results analysed for agreement
and degree of consensus
Report findings: test results
against real situation?
Repeat third round until consensus
reached or response too low
FIGURE 2 Model Delphi method adapted to our study, drawing on the method described by Jones and Hunter.173
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Substance use
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Post training
FIGURE 3 Mean self-rated knowledge and skills scores pre and post pilot training for the eight pilot-trained clinicians.
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Appendix 3 Care co-ordinator fidelity
to health promotion intervention
(work package 3: IMPaCT randomised
controlled trial)
Care co-ordinators recruited to the IMPaCT HPI trial were, importantly, randomly selected from withinroutine front-line NHS staff, and did not need to have prior therapy or research experience. Those
randomised to deliver the intervention attended a 4-day training programme. As part of the training
package, all care co-ordinators received their own copy of the IMPaCT HPI reference guide, manual and
Better Health Handbook (described in work package 2), which outlined the guiding ethos, core therapeutic
approaches and specific intervention adaptations for the different aspects of health behaviour, as well as
providing all session plans, example dialogues and a full set of resources to support delivery.
A number of possible approaches were considered to determine therapeutic competence and fidelity
to the HPI protocol. These included (1) the therapists’ own ratings of their perceived confidence and
competence in delivering the different aspects of the IMPaCT intervention immediately before
compared with immediately following the training delivery, thus providing both their final perceived
confidence and competence and their change during training; (2) an individual role play by each
therapist of a brief section of therapy delivery with a trained actor as the patient, to be conducted
during the final afternoon of training, and audio-recorded; and (3) a set of three audio-recorded sessions
to be obtained during an early, middle and late phase of therapy delivery from each care co-ordinator.
All audio-recordings would be transcribed, with the central 20 minutes rated by professionals trained
in the use of the Motivational Interviewing Treatment Integrity (MITI) scale (see Moyers et al.227).
This scale was selected as it has been well used as a research tool to determine fidelity to MI, which is
the main therapeutic approach of the IMPaCT HPI. The MITI scale provides five summary scores that
capture engagement with the spirit of MI, the process of MI (complex reflection, open questions, and
the ratio between these) and overall MI adherence. The final approach considered was (4) in the spirit
of the ‘learning to learn’ approach in MI, advocated by Miller and Moyers. Training alone has been
shown to be insufficient to produce a change in therapeutic competence. Regular, supervised practice
is also required to ensure that therapeutic competence is met and maintained (see Miller et al.228).
The IMPaCT therapy was designed to be supported, for each care co-ordinator, by a 1-hour session per
fortnight (see Greenwood et al.229).
On commencing the training with care co-ordinators, it was decided by consensus among the study
team that for this research and therapy-naive population of clinicians, an assessment of competence
through an audio-taped role play with an actor may be too threatening and may lead to therapist
disengagement from the trial. As a result, this assessment was excluded from the fidelity evaluation.
Of the 52 care co-ordinators who completed the IMPaCT HPI training, 16 completed the training
questionnaire both pre and post training. The questionnaire included ratings of knowledge across
domains of physical health, substance use, running groups and MI therapy approaches. All ratings
of knowledge and confidence post training were high (mean ratings of 73–80/100 for knowledge
compared with 42–52/100 pre training and 78–81/100 for confidence). Knowledge increased
significantly from pre training across all domains [physical health awareness t = –8.4 df(15), 95% CI
–37 to –22; p < 001; substance use awareness t = –8.1 df(14) 95% CI –36 to –21; p < 001; running
groups t = –4.4 df(15), 95% CI –42 to –15; p < 001; and MI t = –7.1 df(12), 95% CI –43 to –23;
p < 001]. These outcomes are consistent with care co-ordinators having obtained stage 1 of Miller and
Moyer’s eight stages of learning in MI, represented by their increased understanding and confidence
in the ethos of MI delivery. However, confidence does not necessarily relate to competence in clinical
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practice and therapy and, as a result, additional approaches were explored to investigate the
competence of the care co-ordinators to provide IMPaCT therapy.
Ten care co-ordinators each produced a single therapy audio-recording across sessions ranging from
early to late therapy delivery. Each tape was transcribed and the MITI scale applied to the typed
transcript by a trained professional and was independently validated by a second trained professional.
The independent raters achieved 86% concordance on thresholds for proficiency and competence, and,
in the case of different ratings, the higher rating was awarded. An analysis of the tapes revealed that
most care co-ordinators reached beginning proficiency in at least one of the five domains scored, but
only three (30%) reached this proficiency in more than two domains. These three had also obtained the
higher threshold of competency in at least three domains. Of rated care co-ordinators, 50% obtained
a rating that indicated adherence to a MI model. Table 8 summarises the level of care co-ordinator
proficiency and competence in therapy delivery.
The training questionnaires revealed that care co-ordinators rated themselves as having a high level
of knowledge and confidence in using the information about physical health and substance use, and
in offering motivational approaches and groups to address these health behaviours in their clinical
practice. This was a positive endorsement of the training from the care co-ordinator perspective and
reflected at least their self-reported achievement of level 1 (understanding and confidence) in the
stages of learning in MI.
Owing to concerns about acceptability, an assessment of initial competence using an audio-taped role
play with an actor in the final training session was dropped. This concern would appear to have been
borne out in the uptake of audio-taped therapy sessions, over which care the co-ordinators had
control. Despite continued encouragement to produce three audio-taped sessions of their therapy
from any of their clients over the course of therapy, only 10 care co-ordinators produced any audio
tape, and none produced more than one tape. The tapes that were provided are, therefore, likely to
derive from the smaller proportion of more enthusiastic and committed therapists in the IMPaCT trial.
It would be important to learn more about other factors that differentiate between those therapists
who adhered well to a MI model and those who were less able. Support for therapy delivery within the
local NHS environment, pre-existing therapist skills and commitment are just some of the candidate
factors that may mediate between therapy training and successful therapy delivery (Madson et al.230).
Although brief training sessions in MI have been shown to be effective in promoting MI therapy skills
(Madson et al.230), routine front-line clinical staff who work with people with psychosis, even when
willing to take part in a 4-day training programme and when offered fortnightly supervision, struggle to
consolidate training into meaningful adherence to MI therapy.
The MITI scale assesses the spirit and process of MI, which form the first five stages of learning in MI.
It does not assess the later stages of transition to behaviour change, commitment and integration
with other therapies such as CBT. However, based on the fidelity outcomes of these early MI phases
of therapy delivery it seems possible that therapists would also struggle with these later stages of
IMPaCT therapy.
TABLE 8 Summary of MITI scores for the 10 care co-ordinators who provided an audio-taped session
MITI summary score
Care co-ordinators achieving
beginning proficiency
Care co-ordinators achieving
competence
Global spirit of MI 4/10 4/10
Complex reflections (%) 8/10 7/10
Open questions (%) 4/10 1/10
Reflection-to-question ratio 3/10 1/10
MI adherence (%) 5/10 5/10
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Appendix 4 Economic evaluation of the
IMPaCT randomised controlled trial
(work package 3)
Analyses, missing data and sensitivity analyses
Data were analysed using Stata 11. Participants were analysed according to the group to which they
were randomised regardless of intervention compliance.
Costs and outcomes were compared at baseline and at 12 and 15 months and are presented as mean
values by arm with SDs. Mean differences and 95% CIs were obtained by non-parametric bootstrap
regressions (1000 repetitions) to account for the non-normal distribution commonly found in economic
data, with adjustment for clustering at the care co-ordinator level. To provide more relevant treatment-
effect estimates,189 regressions to calculate mean differences in costs included covariates for the
baseline value for the same cost category, baseline SF-36 MCS, baseline SF-36 PCS, baseline SF-36
utility and baseline EQ-5D-3L utility, plus baseline demographic variables expected to be associated
with costs (gender, ethnicity, borough). Similarly, comparisons of outcome data included baseline SF-36
MCS, SF-36 PCS, SF-36 utility and EQ-5D-3L utility as covariates, plus baseline demographic variables
that were expected to be associated with outcome (gender, age, ethnicity, place of birth and borough).
Individual item non-response for the CSRI was minimal. When this occurred, an item cost was imputed
using the mean cost for the same item for other users in the same trial arm and at the same assessment
point. When this was not possible, the overall cost component was imputed using the mean cost for
the same cost component in the same trial arm at the same assessment point. For medication data,
a series of assumptions and imputations were necessary depending on the nature of the missing
information, as follows, making use of available data components when possible. If medication name
was missing, we applied an average prescription cost [from DHSC prescription cost analyses (PCA)],
accounting for the reported number of days on that medication and assuming that the prescription
lasted for 1 month. If number of days on medication was missing, a PCA average item cost for that
medication was used, with the assumption that the patient was prescribed that medication just once in
that period. If dose was missing, a PCA average item cost was used, assuming that each prescription
lasted 1 month but accounting for the number of days on the medication. If the dose unit was missing,
a PCA average item cost was used assuming that each prescription lasted 1 month, with an account of
the number of days on medication. If dose frequency was missing, a PCA average item cost was used,
assuming that each prescription lasted 1 month, again accounting for number of days. Finally, if it was
unknown whether or not the medication was administered as a depot, a PCA average item cost was
used assuming that each prescription lasted 1 month, accounting for the number of days on medication.
The primary analysis was undertaken using cases with available relevant cost and/or outcome data
(i.e. excluding those lost to follow-up for the CSRI, EQ-5D-3L or SF-36 assessments, as relevant).
Cost-effectiveness and cost–utility analyses
Cost-effectiveness and cost–utility analyses were conducted at 15 months to focus on the more
pertinent question of whether or not any effect lasted beyond the end of the intervention, but
12-month cost and outcome data are also reported for information. The economic evaluation examined
eight possible cost–outcome combinations (accounting for the two cost perspectives and the four
outcomes). Incremental cost-effectiveness ratios (ICERs) were calculated for any combination showing
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both higher costs and better outcomes in either the intervention group or the control group (it was
unnecessary to calculate ICERs for any combinations where one group showed both lower costs and
better outcomes as this group was then considered to ‘dominate’ the other).
Uncertainty around cost-effectiveness/cost utility was explored using cost-effectiveness planes and
cost-effectiveness acceptability curves based on the net-benefit approach. These curves are an
alternative to CIs around ICERs and show the probability that one intervention is cost-effective
compared with the other for a range of values that a decision-maker would be willing to pay for an
additional unit of an outcome. Net benefits for each participant were calculated using the following formula,
where λ is the willingness to pay for one additional unit of outcome: net benefit = (λ × outcome) – cost.
A series of net benefits were calculated for each individual for a λ range that would include any policy-
making perspectives relevant at the time of analysis. After calculating net benefits for each participant
for each value of λ, coefficients of differences in net benefits between the trial arms were obtained
through a series of bootstrapped linear regressions (1000 repetitions) of group on net benefit that
included the covariates used for the comparisons of mean costs and outcomes (i.e. baseline value of
the same cost category, SF-36 MCS, SF-36 PCS, EQ-5D-3L utility score, SF-36 utility score, gender,
age, ethnicity, place of birth and borough) and an adjustment for clustering by care co-ordinator. The
resulting coefficients were then examined to calculate for each value of λ the proportion of times that
the intervention group had a greater net benefit than the control group. These proportions were then
plotted to generate cost-effectiveness acceptability curves for all eight cost–outcome combinations.
TABLE 9 Unit costs (IMPaCT) (2011/12 prices)
Item Unit Cost (£) Source Notes
Accommodation
Supported housing Day 100 Curtis192 Private-sector care home, excluding social
services and benefits
Sheltered housing Day 100 Curtis192 Private-sector care home, excluding social
services and benefits
Hostel/shelter Day 100 Curtis192 Private-sector care home, excluding social
services and benefits
Inpatient servicesa
Acute psychiatric ward Bed-day 329 NHS231 TMHIP (Mental Health Inpatients) tab,
MHIPA2 – adult: acute care
Psychiatric intensive care Bed-day 647 NHS231 TMHIP (Mental Health Inpatients) tab,
MHIPA1 – adult: intensive care
Medical ward Bed-day 440 NHS231 Using activity data to calculate a cost per
bed-day
Mother and baby unit Bed-day 672 NHS231 TMHIPSS (Mental Health Inpatients:
Specialist Services) tab, MHIPMB –
mother and baby units
Accident and emergency
department
Bed-day 112 NHS231 TA and EMSNA – Accident and
Emergency Services: Not Leading to
Admitted
Surgical ward Bed-day 440 NHS231 Medical ward cost
Medium secure Bed-day 499 NHS231 TMHSU (Mental Health Secure Units) tab,
SCU3 – medium level secure services
Low secure Bed-day 441 NHS231 TMHSU (Mental Health Secure Units) tab,
SCU2 – low level secure services
High Down prison Bed-day 69 Ministry of
Justice232
Based on £26,139 per prisoner per year
(deflated to 2011–12 costs)
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TABLE 9 Unit costs (IMPaCT) (2011/12 prices) (continued )
Item Unit Cost (£) Source Notes
Psychiatric rehabilitation Bed-day 289 NHS231 TMHIP (Mental Health Inpatients) tab,
MHIPA3 – adult: rehabilitation
Cardiology Bed-day 453 NHS231 Using activity data to calculate a cost per
bed-day for HRG chapter E items
(cardiology)
Ear, nose and throat Bed-day 440 NHS231 Medical ward cost
Older adults mental
health
Bed-day 340 NHS231 TMHIP (Mental Health Inpatients:
Specialist Services) tab, MHIPE1 – elderly
Stroke unit Bed-day 325 NHS231 TNEI_L (Non-Elective Inpatient (Long Stay)
HRG Data) tab, using activity data to
calculate a cost per bed day for HRG
items AA22A (Non-Transient Stroke or
Cerebrovascular Accident, Nervous
system infections or Encephalopathy
with CC) +AA22B (Non-Transient Stroke
or Cerebrovascular Accident, Nervous
system infections or Encephalopathy
without CC)
Acute medical ward Bed-day 440 NHS231 Medical ward cost
Respiratory ward Bed-day 326 NHS231 Using activity data to calculate a cost per
bed-day for HRG chapter D items
(respiratory system)
Emergency surgery Bed-day 440 NHS231 Medical ward cost
Respite care Bed-day 516 NHS231 TNEI_L (Non-Elective Inpatient (Long Stay)
HRG Data) tab, PA55Z – respite care
Spinal injury unit Bed-day 440 NHS231 Medical ward cost
Outpatient servicesb
Psychiatry Visit 171 NHS231 TMHCSOPFUAF tab (Mental Health
Consultant Services (Outpatient Setting) –
Follow-up Attendance Face to Face),
MHOPFUA2 – adult other services
Non-psychiatric/general/
medical
Visit 108 NHS231 Total – OPATT (Outpatient Attendances)
tab, Total – Outpatient Attendances
Diabetes clinic Visit 134 NHS231 Total – OPATT (Outpatient Attendances)
tab, 307 – diabetic medicine
Blood tests/phlebotomy Visit 3 NHS231 TDAPS (Direct Access: Pathology
Services) tab, DAP839 – Phlebotomy
Psychiatric day hospital Visit 103 NHS231 TMHDCFRAD tab (Mental Health Day
Care Facilities: Regular Attendances),
DCF41 – Mental Health Patients Adult
Non-psychiatric/general/
medical day hospital
Visit 686 NHS231 Index tab: TDC – Day Cases HRG Data
Day surgery centre Visit 686 NHS231 Index tab: TDC – Day Cases HRG Data
Accident and emergency Visit 117 NHS231 Index tab, average of all A&E tabs –
TAandEMSAD (Accident and Emergency
Services: Leading to Admitted),
TAandEMSNA (Accident and Emergency
Services: Not Leading to Admitted),
TAandEMinAD (Accident and Emergency
Services: Minor Injury Service: Leading to
Admitted), TAandEMinNA (Accident and
Emergency Services: Minor Injury Service:
Not Leading to Admitted), TAandEWiCAD
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TABLE 9 Unit costs (IMPaCT) (2011/12 prices) (continued )
Item Unit Cost (£) Source Notes
(Accident and Emergency Services: Walk
In Centres: Leading to Admitted),
TAandEWiCNA (Accident and Emergency
Services: Walk In Centres: Not Leading to
Admitted), TNon24HRDEPAD (Non 24 hr
AandE/Casualty Department: Leading to
Admitted), TNon24HRDEPNA (Non 24 hr
AandE/Casualty Department: Not Leading
to Admitted)
X-ray (X-ray only) Visit 30 NHS231 Total – OPATT (Outpatient Attendances)
Tab: DAPF – Direct Access Plain Film
Substance misuse clinic Visit 99 NHS231 TMHCSOPFUAF tab (Mental Health
Consultant Services (Outpatient Setting) –
Follow-up Attendance Face to Face),
MHOPFUA1 – adult drug and alcohol
services
Dietetics Visit 57 NHS231 Total – OPATT (Outpatient Attendances)
Tab, Service Code 654 A – Adult dietetics
Electrocardiogram Visit 58 NHS231 TDADS (Direct Access: Diagnostic Services)
tab, DA09 – 24-hour ECG/BP monitoring
Ambulance Visit 227 NHS231 Index tab, average of all paramedic
activity – TPARA (Paramedic Services:
Category A/Red), TPARB (Paramedic
Services: Category B/Amber, TPARC
(Paramedic Services: Category C/Green,
TPARETU (Paramedic Services: Emergency
Transfers/Urgents, TPARO (Paramedic
Services: Other, TPARA(Act) (Paramedic
Services: Category A/Red (Activity Data),
TPARB(Act) (Paramedic Services: Category B/
Amber (Activity Data), TPARC(Act)
(Paramedic Services: Category C/Green
(Activity Data), TPARETU(Act) (Paramedic
Services: Emergency Transfers/Urgents
(Activity Data), TPARO(Act) (Paramedic
Services: Other (Activity Data)
Angiogram Visit 125 NHS231 TDIAGIM_DA (Diagnostic Imaging: Direct
Access) tab, average of all the fluoroscopy –
RA16Z (Contrast Fluoroscopy Procedures
less than 20 minutes), RA17Z (Contrast
fluoroscopy Procedures 20–40 minutes),
RA18Z (Contrast fluoroscopy Procedures
more than 40 minutes), RA19Z (Mobile/
Intraoperative Contrast Fluoroscopy
Procedures less than 20 minutes),
RA20Z (Mobile/Intraoperative Contrast
Fluoroscopy Procedures 20–40 minutes),
RA21Z (Mobile/Intraoperative Contrast
Fluoroscopy Procedures more than
40 minutes)
Computerised tomography
scan
Visit 93 NHS231 TDIAGIM_DA (Direct Access: Diagnostic
Services) tab, average of all CT scans –
RA08Z (Computerised Tomography Scan,
one area, no contrast), RA09Z (Computerised
Tomography Scan, one area with post
contrast only), RA10Z (Computerised
Tomography Scan, one area, pre and
post contrast), RA11Z (Computerised
Tomography Scan, two areas without
contrast), RA12Z (Computerised
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TABLE 9 Unit costs (IMPaCT) (2011/12 prices) (continued )
Item Unit Cost (£) Source Notes
Tomography Scan, two areas with
contrast), RA13Z (Computerised
Tomography Scan, three areas with
contrast), RA14Z (Computerised
Tomography Scan, more than three areas),
RA50Z (Computerised Tomography Scan,
three areas without contrast)
Chiropodist Visit 44 NHS231 Total – OPATT (Outpatient Attendances)
tab, 653 – podiatry
Colonoscopy Visit 360 NHS231 TOPROC (Outpatient Procedures) tab –
mean of all colonoscopy procedures –
FZ51Z (Diagnostic Colonoscopy 19 years
and over), FZ52Z (Diagnostic Colonoscopy
with biopsy 19 years and over), FZ53Z
(Therapeutic Colonoscopy 19 years and
over)
Chronic obstructive
pulmonary disease clinic
Visit 153 NHS231 Total – OPATT (Outpatient Attendances)
tab, 340 – respiratory medicine
Computerised tomography
scan
Visit 93 NHS231 TDIAGIM_DA (Direct Access: Diagnostic
Services) tab, average of all CT scans –
RA08Z (Computerised Tomography
Scan, one area, no contrast), RA09Z
(Computerised Tomography Scan,
one area with post contrast only),
RA10Z (Computerised Tomography
Scan, one area, pre and post contrast),
RA11Z (Computerised Tomography Scan,
two areas without contrast), RA12Z
(Computerised Tomography Scan,
two areas with contrast), RA13Z
(Computerised Tomography Scan,
three areas with contrast), RA14Z
(Computerised Tomography Scan, more
than three areas), RA50Z (Computerised
Tomography Scan, three areas without
contrast)
Dental X-ray Visit 30 NHS231 Total – OPATT (Outpatient Attendances)
tab, DAPF – Direct Access Plain Film
Dentist Visit 81 NHS231 Total – Other Currencies tab, CN20 row –
community dental services
Diabetes eye test Visit 134 NHS231 Total – OPATT (Outpatient Attendances)
tab, 307 – diabetic medicine
Endocrinology/urology Visit 145 NHS231 Total – OPATT (Outpatient Attendances)
tab, 302 – endocrinology
Gynaecologist Visit 122 NHS231 Total – OPATT (Outpatient Attendances)
tab, 502 – gynaecology
Hearing aid clinic Visit 117 NHS231 Total – OPATT (Outpatient Attendances)
tab, 840 – audiology
Lung function clinic Visit 153 NHS231 Total – OPATT (Outpatient Attendances)
tab, 340 – respiratory medicine
Lupus clinic Visit 108 NHS231 Total – OPATT (Outpatient Attendances)
tab, OPATT tab: Total – Outpatient
Attendances
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TABLE 9 Unit costs (IMPaCT) (2011/12 prices) (continued )
Item Unit Cost (£) Source Notes
Magnetic resonance
imaging
Visit 180 NHS231 TDIAGIM_DA (Direct Access: Diagnostic
Services) tab, mean of all MRI scans –
RA01Z (Magnetic Resonance Imaging
Scan, one area, no contrast), RA02Z
(Magnetic Resonance Imaging Scan,
one area, post contrast only), RA03Z
(Magnetic Resonance Imaging Scan, one
area, pre and post contrast), RA04Z
(Magnetic Resonance Imaging Scan, two
or three areas, no contrast), RA05Z
(Magnetic Resonance Imaging Scan, two
or three areas, with contrast), RA06Z
(Magnetic Resonance Imaging Scan, more
than three areas), RA07Z (Magnetic
Resonance Imaging Scan, requiring
extensive patient repositioning and/or
more than one contrast agent)
Neurology assessment Visit 173 NHS231 Total – OPATT (Outpatient Attendances)
tab, 400 – neurology
Ophthalmologist Visit 86 NHS231 Total – OPATT (Outpatient Attendances)
tab, 130 – Ophthalmology
Physiotherapy Visit 39 NHS231 Total – OPATT (Outpatient Attendances)
tab, 650 A – Physiotherapy Total
Attendances – Adult (19 and Over)
Psychologist Visit 136 Curtis192 £136 per hour of client contact – assumes
1-hour appointment, excludes qualification
costs
Sexual health clinic Visit 67 NHS231 Total – OPATT (Outpatient Attendances)
tab, FPC – Sexual and Reproductive
Health Clinic (previously referred to as
Family Planning Clinic)
Thyroid clinic Visit 108 NHS231 Total – OPATT (Outpatient Attendances)
tab, OPATT tab: Total – Outpatient
Attendances
Turning Point Visit 35 Curtis192 Cost as care co-ordinator/key worker –
£67 per hour of face-to-face contact;
assumes 30-minute appointment, excludes
qualification costs
Ultrasound scan Visit 58 NHS231 TDIAGIM_DA (Direct Access: Diagnostic
Services) tab, average of ultrasound under
and over 20 minutes – RA23Z (Ultrasound
Scan less than 20 minutes), RA24Z
(Ultrasound Scan more than 20 minutes)
Community-based day services
Individual therapy CMHT,
etc.
Visit 68 NHS231 TCSCT (community therapy services) tab,
N6A1 – Community Occupational Therapy
Services: Adult – One-to-One
Individual therapy at
home
Visit 95 NHS231 TCSCT (community therapy services) tab,
N6A1 – Community Occupational Therapy
Services: Adult – One-to-One - plus the
proportion of district nurse home visit hour/
clinic hour proportion from Curtis 2010233
Group therapy,
all locations
Visit 73 NHS231 TCSCT (community therapy services) tab,
N6A2 – Community Occupational Therapy
Services: Adult – Group Services
Medication monitoring/
administration, all
locations
Visit 34 Curtis192 Cost as care co-ordinator
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TABLE 9 Unit costs (IMPaCT) (2011/12 prices) (continued )
Item Unit Cost (£) Source Notes
Music therapy,
all locations
Visit 40 Cancer Research
UK234
–
Art therapy, all locations Visit 30 Curtis192 Cost as occupational therapist
Community-based professionalsc
Care co-ordinator at
surgery
Occurrence 34 Curtis192 £67 per hour of face-to-face contact;
assumes 30-minute appointment, excludes
qualification costs
Care co-ordinator at home Occurrence 47 Curtis192 As above, plus proportion of district nurse
home visit hour/clinic hour proportion
from Curtis 2010233 (139%)
Care co-ordinator over
telephone
Occurrence 10 Curtis192 As above; assumes same proportion of
costs as a psychiatrist face to face vs.
non-face to face (30%)
Home treatment team at
surgery
Occurrence 188 NHS231 TMHSTSAF tab (Mental Health Specialist
Teams: Adult – Face to Face), MHST20
(Crisis resolution home treatment teams)
Home treatment team at
home
Occurrence 188 NHS231 As above
Home treatment team
over telephone
Occurrence 60 NHS231 TMHSTSANF tab (Mental Health
Specialist Teams: Adult – Non-Face to
Face), MHST20 (Crisis resolution home
treatment teams)
Crisis resolution team at
surgery
Occurrence 188 NHS231 TMHSTSAF tab (Mental Health Specialist
Teams: Adult – Face to Face), MHST20
(Crisis resolution home treatment teams)
Crisis resolution team at
home
Occurrence 188 NHS231 As above
Crisis resolution team
over telephone
Occurrence 60 NHS231 TMHSTSANF tab (Mental Health
Specialist Teams: Adult – Non-Face to
Face), MHST20 (Crisis resolution home
treatment teams)
Early intervention team at
surgery
Occurrence 177 NHS231 TMHSTSAF tab (mental health specialist
teams: adult – face to face), MHST22
(early intervention in psychosis studies)
Early intervention team at
home
Occurrence 177 NHS231 As above
Early intervention team
over telephone
Occurrence 57 NHS231 TMHSTSANF tab (Mental Health
Specialist Teams: Adult – Non-Face to
Face), MHST22 (Early intervention in
psychosis studies)
Community psychiatric
nurse at surgery
Occurrence 34 Curtis192 Care co-ordinator – above
Community psychiatric
nurse at home
Occurrence 47 Curtis192 Care co-ordinator – above
Community psychiatric
nurse over telephone
Occurrence 10 Curtis192 Care co-ordinator – above
Social worker at surgery Occurrence 78 Curtis192 £156 per hour of face-to-face contact,
assume 30-minute appointment, excludes
qualifications
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TABLE 9 Unit costs (IMPaCT) (2011/12 prices) (continued )
Item Unit Cost (£) Source Notes
Social worker at home Occurrence 108 Curtis192 As above, with proportion of district nurse
home visit hour/clinic hour proportion
from PSSRU 2010 (139%)
Social worker over
telephone
Occurrence 23 Curtis192 As above, assume same proportion of
costs as a psychiatrist face to face vs.
non-face to face (30%)
Psychiatrist at surgery Occurrence 171 NHS231 TMHCSOPFUAF tab (Mental Health
Consultant Services (Outpatient Setting) –
Follow-up Attendance Face to Face),
MHOPFUA2 (Adult other services)
Psychiatrist at home Occurrence 238 NHS231 As above, with the proportion of district
nurse home visit hour/clinic hour
proportion from PSSRU 2010 (139%)
Psychiatrist over
telephone
Occurrence 52 NHS231 TMHCSOPFUANF tab (Mental Health
Consultant Services (Outpatient Setting) –
Follow-up Attendance Non-Face to Face),
MHOPFUA2 (Adult other services)
Psychologist at surgery Occurrence 136 Curtis192 £136 per hour of client contact, assume
1-hour appointment, excludes qualification
costs
Psychologist at home Occurrence 189 Curtis192 As above, based on psychologist visit cost
above but use the proportion of district
nurse home visit hour/clinic hour
proportion from PSSRU 2010 (139%)
Psychologist over
telephone
Occurrence 41 Curtis192 As above, assume same proportion of
costs as a psychiatrist face to face vs. non
face to face (30%)
Psychotherapist at
surgery
Occurrence 136 Curtis192 Assume same as a psychologist
Psychotherapist at home Occurrence 189 Curtis192 Assume same as a psychologist
Psychotherapist over
telephone
Occurrence 41 Curtis192 Assume same as a psychologist
Counsellor at surgery Occurrence 59 Curtis192 £59 per consultation
GP at surgery Occurrence 36 Curtis192 £36 per patient contact lasting 11.7 minutes,
excludes qualification costs, including
direct care staff costs
GP at home Occurrence 92 Curtis192 £92 per patient out of surgery visit lasting
23.4 minutes, excludes qualification costs,
including direct care staff costs
GP over telephone Occurrence 22 Curtis192 £22 per telephone contact lasting
7.2 minutes, excludes qualification costs,
including direct care staff costs
Blood test at GP surgery Occurrence 12 Curtis192 Assume practice nurse
Blood test at home Occurrence 16 Curtis192 Assume practice nurse
Diabetes nurse at surgery Occurrence 12 Curtis192 Assume practice nurse
Diabetes nurse at home Occurrence 16 Curtis192 Assume practice nurse
Diabetes nurse over
telephone
Occurrence 7 Curtis192 Assume practice nurse
Practice nurse at surgery Occurrence 12 Curtis192 £45 per hour of face-to-face contact,
excluding qualifications assuming 15.5-
(specified on p180) minute appointment
Practice nurse at home Occurrence 16 Curtis192 As above, with the proportion of district
nurse home visit hour/clinic hour
proportion from Curtis 2010233 (139%)
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TABLE 9 Unit costs (IMPaCT) (2011/12 prices) (continued )
Item Unit Cost (£) Source Notes
Practice nurse over
telephone
Occurrence 7 Curtis192 As above, with same proportion of costs
as a GP telephone call (61%)
District nurse at surgery Occurrence 11 Curtis192 District nurse, with the proportion of
clinic hour/home visit hour proportion
from Curtis 2010233 (72%)
District nurse at home Occurrence 16 Curtis192 Community nurse including district, £61
per hour of home visiting including travel,
excluding qualifications; assumes
15.5-minute appointment
District nurse over
telephone
Occurrence 10 Curtis192 Assume same proportion of costs as a GP
telephone call (61%)
Occupational therapist at
surgery
Occurrence 30 Curtis192 NHS community occupational therapist –
£30 per hour, assumes 1-hour meeting
and excludes qualification costs
Occupational therapist at
home
Occurrence 55 Curtis192 As above, with proportions of client time
set down in PSSRU 2009–10 (183%)
excluding qualifications
Occupational therapist
over telephone
Occurrence 18 Curtis192 As above, with proportion of costs as a GP
telephone call (61%)
Dietitian at surgery Occurrence 72 NHS231 TOCS (Other Community Services) tab –
N800 Dietetics Services
Dietitian at home Occurrence 129 NHS231 As above, with proportions of client time
set down in PSSRU 2009–10 (179%),
excluding qualifications
Dietitian over telephone Occurrence 44 NHS231 As above, with proportion of costs as a GP
telephone call (61%)
Home help/care worker at
home
Occurrence 12 Curtis192 Home care worker per hour of face-to-face
contact, weighted average accounting for
different rates for day/evening/weekday/
weekends
Meals on wheels at home Occurrence 5 Curtis192 Average of £6 local authority meal and £4
independent sector cost per day
Pharmacist for advice at
surgery
Occurrence 4 Curtis192 £50, assuming 5-minute consultation;
excludes qualification costs
Pharmacist for advice
over telephone
Occurrence 4 Curtis192 As above
NHS Direct over
telephone
Occurrence 16 NHS Direct235 Inflated to 2011/12 prices
Samaritans over telephone Occurrence 4 National Register
of Personal
Trainers236
Inflated to 2011/12 prices
Other community-based professionals
Advocate at surgery Occurrence 76 Curtis192 Cost as an independent mental capacity
advocates assessment
Advocate at home Occurrence 106 Curtis192 As above, with the proportion of district
nurse home visit hour/clinic hour
proportion from Curtis 2010233 (139%)
Podiatrist at surgery Occurrence 15 Curtis192 Community chiropodist – £30 per hour;
assumes 30-minute appointment
Podiatrist at home Occurrence 42 Curtis192 As above, with proportion of district nurse
home visit hour/clinic hour proportion
from Curtis 2010233 (139%)
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TABLE 9 Unit costs (IMPaCT) (2011/12 prices) (continued )
Item Unit Cost (£) Source Notes
CMHT bloods at surgery Occurrence 12 Curtis192 Cost as GP surgery blood test
Emergency service over
telephone
Occurrence 16 NHS Direct235 Cost as NHS Direct
Depot at GP surgery Occurrence 12 Curtis192 Cost as practice nurse
Depot clinic surgery Occurrence 6 Curtis192 Cost as community psychiatric nurse for
5 minutes
Diabetes eye test at
surgery
Occurrence 134 NHS231 Total – OPATT (Outpatient Attendances)
tab, 307 – diabetic medicine
Employment support
worker at surgery
Occurrence 30 Curtis192 Cost as occupational therapist
Forensic team at surgery Occurrence 34 Curtis192 Cost as care co-ordinator
Forensic team at home Occurrence 47 Curtis192 Cost as care co-ordinator
Gym practitioner
(GP referral) at surgery
Occurrence 60 National Register
of Personal
Trainers236
Costs between £20 and £100; chose
mid-point – £60
Human immunodeficiency
virus clinic at surgery
Occurrence 110 NHS231 TCSCNSN (community and outreach
nursing services: specialist nursing) tab,
CN208AF – band 8 – human
immunodeficiency virus/acquired
immunodeficiency syndrome nursing
services: adult: face to face
Welfare benefits advisor
at home
Occurrence 78 Curtis192 Cost as social worker
Housing officer at home Occurrence 78 Curtis192 Cost as social worker
Lifestyle coach at surgery Occurrence 70 Life Coach
Directory237
Costs ranged between £40 and £100;
chose mid-point
Mental health helpline
over telephone
Occurrence 4 Samaritans238 Cost as Samaritans
Mind Advocates over
telephone
Occurrence 23 Curtis192 Cost as advocate, with proportion of costs
as a psychiatrist face to face vs. non-face
to face (30%)
Osteopath at surgery Occurrence 43 NHS Choices239 Costs ranged between £35 and £50 per
30- to 40-minute contact; chose mid-point
Probation officer at
surgery
Occurrence 78 Curtis192 Cost as social worker
Spirit Release Session at
surgery
Occurrence 38 Cancer Research
UK240
Costs ranged between £15–60 per
session; chose mid-point
Support worker at surgery Occurrence 11 Curtis192 Clinical support worker – assumes
30-minute appointment
Support worker at home Occurrence 15 Curtis192 As above, with proportion of district nurse
home visit hour/clinic hour proportion
from Curtis 2010233 (139%)
Benefits
Patient social security
benefits/tax credits
Week 53.45 Direct Gov241 Employment and support personal
allowance – assumes single < 25 years
Patient disability living allowance
Higher Week 73.60 Direct Gov241 Assumes the care component
Middle Week 49.30 Direct Gov241 –
Lower Week 19.55 Direct Gov241 –
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TABLE 9 Unit costs (IMPaCT) (2011/12 prices) (continued )
Item Unit Cost (£) Source Notes
Carer benefit
Higher Week 55.55 Direct Gov241 –
Middle Week 55.55 Direct Gov241 –
Lower Week 55.55 Direct Gov241 –
a All long stay, non-elective, non-excess: all costs in 2010–11 prices and inflated to 2011–12 prices using the Hospital
and Community Health Services index pay and prices index from Curtis.192
b All costs from NHS231 are inflated to 2011–12 prices using the Hospital and Community Health Services index pay
and prices index from Curtis.192
c All costs from NHS,231 NHS Direct235 and National Register of Personal Trainers236 are inflated to 2011–12 prices
using the Hospital and Community Health Services index pay and prices index from Curtis.192
Sources: NHS. NHS trust reference cost schedules 2010–11.191 Inflated up to 2011–12 prices using the retail price
inflation percentage from PSSRU 2012/13. URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/Publications
PolicyAndGuidance/DH_131140 (accessed 19 February 2013).
TABLE 10 Resources and costs associated with the interventions
Component
Control HPI
Resources Details
Unit
cost (£) Resources Details
Mean
cost (£)
Manual – – 0 Developmenta
Printingb
£35.68 per care
co-ordinator, divided
by a recommended
average of 20 patients
per care co-ordinator
1.78
Training
Trainer’s time Consultant
psychiatristc
(90 minutes)
£186 divided by
25 attendees,
divided by a
recommended
average of
20 patients per
care co-ordinator
0.37 Band 6 nursed
Band 8a nursee
Psychologist band 8df
Consultant
psychiatristg
(total 29 hours)
Cost of £2336 divided
by an average of five
care co-ordinators per
training course, divided
by a recommended
average of 20 patients
per care co-ordinator
23.36
Attendee’s time Band 6 nurseh
(90 minutes)
£63 per care
co-ordinator,
divided by a
recommended
average of
20 patients per
care co-ordinator
3.15 Band 6 nursei
(total 32 hours)
£1344 per care
co-ordinator divided
by a recommended
average of 20 patients
per care co-ordinator
67.20
Materials – None 0 One-off items:
BP machinej
Weighing scalesk
Tape measurel
Flip-chart standm
Memory stickn
£20.97 divided by
nine training courses,
divided by five care
co-ordinators per
course, divided by
a recommended
average of 20 patients
per care co-ordinator
£6.49 per care
co-ordinator, divided
by a recommended
0.02
0.32
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TABLE 10 Resources and costs associated with the interventions (continued )
Component
Control HPI
Resources Details
Unit
cost (£) Resources Details
Mean
cost (£)
Consumables:
Flip-chart papero
Flip-chart pensp
Paperq
Pensr
average of 20 patients
per care co-ordinator
Supervision – None 0 Training supervisor:
band 8 nurses
Care co-ordinator:
band 6 nurset
(90 minutes)
£150 per session,
per care co-ordinator,
divided by a
recommended
average of 20 patients
per care co-ordinator
41.41
Implementation – Implemented into
therapy as part of
continuing care
0 Band 6 nurseu
(individual times)
Individually calculated
for each participant
based on number and
type of sessions
attended
92.31
Mean total
cost (£)
3.52 per control participant 226.40 per intervention participant
a Sunk cost: £0.
b Based on actual printing cost: £35.68 for all three documents.
c Based on a consultant psychiatrist: £124 per contract hour, excluding qualifications, for 90 minutes of training.192
d Based on a community nurse: £42 per hour, excluding qualifications, for 150 minutes of training plus 10 minutes’
preparation time (160 minutes total).192
e Based on a band 8 nurse: £58 per hour (based on the same working time assumptions as applied to a band 6 nurse),
excluding qualifications, for 810 minutes of training plus 40 minutes’ preparation time (850 minutes in total).192
f Based on band 8d psychologist: £102 per hour (based on the same working time assumptions as applied to a band 8a
psychologist) excluding qualifications, for 270 minutes of training plus 20 minutes’ preparation time (290 minutes in total).192
g Based on a consultant psychiatrist: £124 per contract hour, excluding qualifications, for 420 minutes’ training plus
20 minutes’ preparation time (440 minutes in total).192
h Based on a community nurse: £42 per hour, excluding qualification costs, for 90 minutes of training.192
i Based on a community nurse: £42 per hour, excluding qualification costs, for 32 hours of training (9.00–17.00 for
4 days including break times).192
j £6.66 per machine, based on a purchase price of £30.60 deflated to correct year and annuitised by 4% assuming
5-year life. Source: www.boots.com/en/Boots-Pharmaceuticals-Basic-Blood-Pressure-Upper-Arm-Monitor_1014526/;
accessed 26 February 2014.
k £1.74 per scales, based on a purchase price of £7.99 deflated to correct year and annuitised by 4% assuming 5-year.
Source: www.amazon.co.uk/Jazooli-Digital-Bathroom-Electronic-Weighing/dp/B00H29ASC2/ref=sr_1_17?
s=drugstore&ie=UTF8&qid=1393413251&sr=1–17&keywords=digital+weighing+scales; accessed
26 February 2014.
l £0.22 per tape measure, based on a purchase price of £1.00 deflated to correct year and annuitised by 4% assuming
5-year life. Source: www.amazon.co.uk/150cm-Plastic-Tailor-Sewing-Measure/dp/B0081OW708/ref=sr_1_10?
ie=UTF8&qid=1393413801&sr=8–10&keywords=tape+measure+body; accessed 26 February 2014.
m £11.23 per stand, based on a purchase price of £51.59 deflated to correct year and annuitised by 4% assuming
5-year life. Source: www.viking-direct.co.uk/a/pb/niceday-Classic-Easel-900H-x-600Wmm/pr=Q22&id=5341293/;
accessed 26 February 2014.
n £1.12 per stick, based on a purchase price of £5.15 deflated to correct year and annuitised by 4% assuming 5-year
life. Source: www.viking-direct.co.uk/a/pb/Ativa-4GB-USB-Flash-Drive/pr=Q22&id=978944/; accessed
26 February 2014.
o £0.93 per care co-ordinator, based on £23.99 per pack of five, using one pad per training course, deflated to
correct year and divided by an average of five care co-ordinators per training course. Source: www.viking-direct.co.uk/
a/pb/Niceday-A1-Flipchart-Pads-Pack-of-5/pr=Q22&id=2650338/; accessed 26 February 2014.
p £1.58 per care co-ordinator, based on £8.15 per pack, deflated to correct year and divided by an average of five
care co-ordinators per training course. Source: www.viking-direct.co.uk/a/pb/niceday-Bullet-Tip-Assorted-1-x-Black-
Blue-Red-Green-Orange-Purple-Flipchart-Markers-6pk/pr=Q22&id=1644422/; accessed 26 February 2014.
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Sensitivity analyses
We conducted four sensitivity analyses to check the robustness of the base-case analyses defined
above. First, we explored the potential impact of excluding those lost to follow-up. We examined key
sociodemographic and clinical characteristics for those included and those excluded from the analyses
and conducted an intention-to-treat analysis, which included those lost to follow-up by imputing
missing total costs and outcomes using imputation in Stata 13. Imputations of costs and outcomes
were based on variables that were expected to predict costs and outcomes. For cost imputations, these
variables were baseline and 12-month values for the equivalent cost category, the SF-36 MCS, SF-36 PCS,
EQ-5D-3L utility score, SF-36 utility score, plus gender, ethnicity, borough, age, place of birth and care
co-ordinator. Imputation of outcomes was based on baseline and 12-month values of the SF-36 MCS,
SF-36 PCS, EQ-5D-3L utility score, SF-36 utility score, plus gender, age, ethnicity, place of birth and
borough, and care co-ordinator.
Second, to explore the potential impact of having follow-up interviews conducted more than 30 days
before or after the follow-up date, we conducted a ‘correct time window’ analysis including only those
trial participants whose data were collected within the correct window (within 30 days either side of
the planned assessment date).
Third, to explore the potential impact of insufficient implementation of the HPI, we conducted a
per-protocol analysis that included only those intervention arm trial participants who received the
predefined minimum of six intervention sessions of at least 30 minutes each.
Finally, to explore the potential impact of care co-ordinator dropout, we conducted analyses that included
only those trial participants whose care co-ordinator remained the same throughout the study.
For each of these sensitivity analyses, we examined whether or not the conclusions concerning the
mean difference in costs or outcomes between the two trial arms differed from those drawn from the
base-case analyses.
Economic evaluation results
In line with the analysis of the primary outcome measure and other clinical outcomes, the economic
evaluation was based on all 406 participants who were randomised. We summarise the response rates
in Tables 12–14.
Table 15 summarises the joint availability of both cost and outcome data at 15 months (a requirement
for the constructions of CEACs), by outcome measure. Equivalent data are also provided for the
12-month follow-up for information.
Tables 16 and 17 suggest that there were no notable differences in the baseline characteristics of the
subsamples included in the base-case analyses of those with available data against the full sample.
q £2.52 per care co-ordinator, based on £7.79 per pack of three (one per care co-ordinator) and deflated to correct year.
Source: www.viking-direct.co.uk/a/pb/Pukka-Reporters-160-Page-White-Pad-205-x-140mm-3pk/pr=Q22&
id=1087752/; accessed 26 February 2014.
r £0.35 per care co-ordinator, based on £3.59 per pack of 10 (one per care co-ordinator) and deflated to correct year.
Source: www.viking-direct.co.uk/a/pb/Bic-Cristal-Medium-10mm-Ballpoint-Pen-Black-Pack-of-10/pr=Q22&id=103-BK/;
accessed 26 February 2014.
s Based on a band 8 nurse: £58 per hour (based on the same working time assumptions as applied to a band 6 nurse)
excluding qualifications, 90-minute supervisions multiplied by number of supervisions.192
t Based on £42 per hour, excluding qualifications, 90-minute supervisions multiplied by number of supervisions.192
u Based on a community nurse: £42 per hour (£58.38 for contacts not at the care co-ordinator’s base) based on the
same travel time assumptions as applied to a band 6 nurse,233 excluding qualifications.192
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TABLE 11 Staff resourcing for the HPI training programme
Trainer staff type Number of sessions delivered Total training time (minutes)
Total preparation time
(minutes)
Nurse band 6 1 150 10
Nurse band 8a 4 810 40
Psychologist band 8d 2 270 20
Consultant psychiatrist 2 420 20
TABLE 12 Client Service Receipt Inventory response rates
Trial group
Time point, n (%)
All time points, n (%)Baseline 12 months 15 months
Intervention (N = 213) 212 (100) 160 (75) 152 (71) 138 (65)
Control (N= 193) 193 (100) 159 (82) 149 (77) 143 (74)
Total (N= 406) 405 (98) 319 (79) 301 (74) 281 (69)
Percentages are rounded to nearest whole number.
TABLE 13 The SF-36 and EQ-5D-3L response rates
Outcome Trial group
Time point, n (%)
All time points,
n (%)Baseline 12 months 15 months
SF-36 Intervention (N = 213) 210 (99) 158 (74) 149 (70) 132 (62)
Control (N= 193) 192 (100) 155 (80) 148 (77) 138 (72)
Total (N= 406) 402 (99) 313 (77) 297 (73) 270 (67)
EQ-5D-3L Intervention (N = 213) 211 (99) 159 (75) 152 (71) 136 (64)
Control (N= 193) 193 (100) 156 (81) 149 (77) 140 (73)
Total (N= 406) 404 (100) 315 (78) 301 (74) 276 (68)
Percentages are rounded to nearest whole number.
TABLE 14 Availability of intervention data
Trial group n (%)
Intervention (n = 213) 213 (100)
Control (n= 193) 193 (100)
Total (n= 406) 406 (100)
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TABLE 15 Availability of both cost and outcome data, by outcome measure
Outcome Trial group
Time point, n (%)
12 months 15 months Both 12 and 15 months
SF-36 Intervention (n= 213) 157 (74) 149 (70) 131 (62)
Control (n = 193) 154 (80) 147 (76) 137 (71)
Total (n = 406) 311 (77) 296 (73) 268 (66)
EQ-5D-3L Intervention (n= 213) 158 (74) 152 (71) 135 (63)
Control (n = 193) 155 (80) 148 (77) 139 (72)
Total (n = 406) 313 (77) 300 (74) 274 (68)
Percentages are rounded to nearest whole number.
TABLE 16 Baseline characteristics of full sample and subsample with cost and SF-36 data
Characteristic Full sample (N= 406)
Subsample
With 12-month costs and
SF-36 data (N= 311)
With 15-month costs and
SF-36 data (N= 296)
Gender, n (%)
Male 234 (58) 183 (59) 172 (58)
Female 172 (42) 128 (41) 124 (42)
Ethnicity, n (%)
White 222 (55) 174 (56) 170 (58)
Black 137 (34) 102 (33) 97 (33)
Asian 15 (4) 11 (4) 11 (4)
Mixed or other 29 (7) 23 (7) 17 (6)
Place of birth, n (%)
UK 318 (78) 251 (81) 237 (80)
Other 88 (22) 60 (19) 59 (20)
Borough, n (%)
Croydon 58 (14) 51 (16) 48 (16)
Lambeth 44 (11) 31 (10) 31 (11)
Lewisham 84 (21) 62 (20) 54 (18)
Southwark 83 (20) 66 (21) 66 (22)
Greenwich 30 (7) 26 (8) 26 (9)
Bromley 34 (8) 24 (8) 25 (9)
Bexley 23 (6) 18 (6) 18 (6)
East Sussex 23 (6) 20 (6) 20 (7)
Somerset 17 (4) 5 (2) 8 (3)
South Staffordshire 10 (3) 8 (3) 0 (0)
Age (years), mean (SD) 44 (10) 45 (10) 45 (10)
SF-36 MCS, mean score (SD) 43 (13) 43 (13) 43 (13)
SF-36 PCS, mean score (SD) 48 (11) 48 (11) 48 (11)
Percentages and SDs are rounded to nearest whole number.
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Resource use
Resource use pattern data suggest that both arms were broadly balanced in their use of core services
both before and during the study. These data are available for reference in Tables 18–20. As would be
expected for this group of patients, service use is very broad in both nature and sector, illustrating the
complexity of their care provision. These data were not compared statistically because the economic
evaluation was focused on costs and cost-effectiveness/utility, and to avoid problems associated with
multiple testing.
Costs
There were 52 care co-ordinators in the intervention group and a total of 213 patient participants with
whom they implemented the HPI. The mean number of trial participants per care co-ordinator was four
(range 1–10 participants). The total average cost per case in the intervention arm was £226.40, compared
with £3.52 in the control arm.
TABLE 17 Baseline characteristics of full sample and subsample with cost and EQ-5D-3L data
Characteristic Full sample (N = 406)
Subsample
With 12-month costs and
EQ-5D-3L data (N = 313)
With 15-month costs and
EQ-5D-3L data (N = 300)
Gender, n (%)
Male 234 (58) 183 (49) 174 (58)
Female 172 (42) 130 (42) 126 (42)
Ethnicity, n (%)
White 222 (55) 175 (56) 172 (58)
Black 137 (34) 102 (33) 98 (33)
Asian 15 (4) 12 (4) 11 (4)
Mixed or other 29 (7) 23 (7) 18 (60
Place of birth, n (%)
UK 318 (78) 253 (81) 241 (80)
Other 88 (22) 60 (19) 59 (20)
Borough, n (%)
Croydon 58 (14) 51 (16) 48 (16)
Lambeth 44 (11) 31 (10) 31 (10)
Lewisham 84 (21) 63 (20) 55 (18)
Southwark 83 (20) 66 (21) 66 (22)
Greenwich 30 (7) 26 (8) 27 (9)
Bromley 34 (8) 25 (8) 25 (8)
Bexley 23 (6) 18 (6) 18 (6)
East Sussex 23 (6) 20 (3) 20 (7)
Somerset 17 (4) 5 (2) 10 (3)
South Staffordshire 10 (3) 8 (3) 0 (0)
Age (years), mean (SD) 44 (10) 45 (10) 43 (11)
SF-36 MCS, mean score (SD) 43 (13) 43 (13) 43 (13)
SF-36 PCS, mean score (SD) 48 (11) 48 (11) 48 (11)
Percentages and SDs are rounded to nearest whole number.
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TABLE 18 Resource use at baseline (for the previous 6 months)
Resource Unit
Trial group
Intervention (N= 212) Control (N= 193)
Users (n) Meana SD Users (n) Meana SD
Specialist accommodation
Supported housing/assisted living Bed-day 51 157 50 42 166 44
Sheltered housing Bed-day 3 154 48 6 170 29
Hostel/shelter Bed-day 7 120 83 6 182 0
Hospital inpatient
Inpatient Bed-day 60 155 54 54 168 40
Hospital outpatient
Psychiatric outpatient Visit 35 4 5 49 3 4
Non-psychiatric/general/medical outpatient Visit 29 3 4 22 2 1
Diabetes clinic Visit 15 2 2 13 2 1
Blood tests Visit 95 5 4 84 4 3
Psychiatric day hospital Visit 12 18 33 3 58 9
Non-psychiatric/general/medical day hospital Visit 3 1 0 3 1 1
Day surgery centre Visit 7 2 2 7 2 2
Accident and emergency department Visit 32 2 2 23 1 1
X-ray Visit 24 1 1 27 1 1
Substance misuse clinic Visit 13 9 8 7 7 9
Dietetics Visit 7 3 2 9 3 2
Community-based day services
Community-based services Visit 72 34 32 73 29 31
Community-based professionals
Care co-ordinator Surgery visit 129 10 8 132 9 6
Care co-ordinator Home visit 107 10 9 83 8 7
Care co-ordinator Telephone call 39 10 19 28 7 8
Home treatment team Surgery visit 3 2 1 4 3 2
Home treatment team Home visit 10 9 12 14 11 12
Home treatment team Telephone call 1 1 – 2 3 1
Crisis resolution team Surgery visit 0 – – 0 – –
Crisis resolution team Home visit 8 7 7 3 3 1
Crisis resolution team Telephone call 1 1 – 1 1 –
Early intervention team Surgery visit 0 – – 0 – –
Early intervention team Home visit 2 10 6 0 – –
Early intervention team Telephone call 0 – – 0 – –
Community psychiatric nurse Surgery visit 13 7 7 6 5 4
Community psychiatric nurse Home visit 5 5 3 1 4 –
Community psychiatric nurse Telephone call 3 4 4 3 3 1
Social worker Surgery visit 18 1 1 22 2 2
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TABLE 18 Resource use at baseline (for the previous 6 months) (continued )
Resource Unit
Trial group
Intervention (N= 212) Control (N= 193)
Users (n) Meana SD Users (n) Meana SD
Social worker Home visit 1 12 – 3 3 3
Social worker Telephone call 2 4 4 1 1 –
Psychiatrist Surgery visit 85 3 5 75 3 4
Psychiatrist Home visit 6 5 9 9 2 1
Psychiatrist Telephone call 0 – – 0 – –
Psychologist Surgery visit 19 8 9 20 9 8
Psychologist Home visit 3 11 2 2 12 0
Psychologist Telephone call 0 – – 0 – –
Psychotherapist Surgery visit 1 5 – 3 12 11
Psychotherapist Home visit 1 12 – 1 6 –
Psychotherapist Telephone call 0 – – 0 – –
Counsellor Surgery visit 26 3 5 19 3 5
Counsellor Home visit 0 – – 1 1 –
Counsellor Telephone call 0 – – 0 – –
GP Surgery visit 119 4 7 108 3 3
GP Home visit 3 2 1 2 2 1
GP Telephone call 1 2 – 1 1 –
Blood test at GP Surgery visit 47 2 2 47 2 1
Diabetes nurse Surgery visit 11 2 1 10 1 < 1
Diabetes nurse Home visit 0 – – 0 – –
Diabetes nurse Telephone call 0 – – 2 1 0
Practice nurse Surgery visit 27 3 5 31 2 2
Practice nurse Home visit 0 – – 0 – –
Practice nurse Telephone call 1 1 – 0 – –
District nurse Surgery visit 1 120 – 1 1 –
District nurse Home visit 0 – – 2 2 107
District nurse Telephone call 0 – – 0 – –
Occupational therapist Surgery visit 8 7 8 8 9 10
Occupational therapist Home visit 0 – – 2 5 4
Occupational therapist Telephone call 0 – – 0 – –
Dietitian Surgery visit 7 2 2 12 2 2
Dietitian Home visit 0 – – 1 1 –
Dietitian Telephone call 0 – – 0 – –
Home help Home visit 11 57 72 6 32 37
Meals on wheels Home visit 0 – – 2 2 1
Pharmacist for advice Surgery visit 21 2 2 20 2 2
Pharmacist for advice Home visit 1 2 – 0 – –
Pharmacist for advice Telephone call 0 – – 1 2 –
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TABLE 18 Resource use at baseline (for the previous 6 months) (continued )
Resource Unit
Trial group
Intervention (N= 212) Control (N= 193)
Users (n) Meana SD Users (n) Meana SD
NHS Direct Telephone call 3 1 1 6 2 1
Samaritans Telephone call 3 5 5 2 52 62
Medication 208 – – 191 – –
a Mean for users only.
All quantities are rounded to nearest whole number.
TABLE 19 Resource use at the 12-month follow-up (for the previous 6 months)
Resource Unit
Trial group
Intervention (N= 160) Control (N= 159)
Users (n) Meana SD Users (n) Meana SD
Specialist accommodation
Supported housing/assisted living Bed-day 37 182 1 30 179 12
Sheltered housing Bed-day 1 182 – 6 158 60
Hostel/shelter Bed-day 4 182 0 5 152 68
Hospital inpatient
Inpatient Bed-day 42 182 1 41 173 34
Hospital outpatient
Psychiatric outpatient Visit 13 4 2 6 2 1
Non-psychiatric/general/medical outpatient Visit 14 3 2 16 2 2
Diabetes clinic Visit 11 3 3 9 1 1
Blood tests Visit 79 5 4 69 4 3
Psychiatric day hospital Visit 2 2 1 1 6 -
Non-psychiatric/general/medical day hospital Visit 2 1 0 2 4 4
Day surgery centre Visit 4 2 1 6 1 0
Accident and emergency department Visit 22 2 4 19 2 1
X-ray Visit 23 1 1 14 1 < 1
Substance misuse clinic Visit 3 10 12 3 7 4
Dietetics Visit 4 2 3 1 1 –
Community-based day services
Community-based services Visit 70 44 40 63 40 36
Community-based professionals
Care co-ordinator Surgery visit 95 9 7 98 7 7
Care co-ordinator Home visit 67 9 8 64 8 8
Care co-ordinator Telephone call 32 8 10 29 6 7
Home treatment team Surgery visit 1 1 – 1 1 –
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TABLE 19 Resource use at the 12-month follow-up (for the previous 6 months) (continued )
Resource Unit
Trial group
Intervention (N= 160) Control (N= 159)
Users (n) Meana SD Users (n) Meana SD
Home treatment team Home visit 10 17 11 3 13 7
Home treatment team Telephone call 1 2 – 0 – –
Crisis resolution team Surgery visit 1 3 – 0 – –
Crisis resolution team Home visit 1 2 – 0 – –
Crisis resolution team Telephone call 1 2 – 0 – –
Early intervention team Surgery visit 0 – – 0 – –
Early intervention team Home visit 0 – – 0 – –
Early intervention team Telephone call 0 – – 0 – –
Community psychiatric nurse Surgery visit 1 6 – 2 4 4
Community psychiatric nurse Home visit 2 5 2 3 3 3
Community psychiatric nurse Telephone call 0 – – 0 – –
Social worker Surgery visit 4 3 3 5 2 1
Social worker Home visit 2 9 4 2 3 2
Social worker Telephone call 0 – – 0 – –
Psychiatrist Surgery visit 85 2 2 86 2 4
Psychiatrist Home visit 7 5 9 8 6 8
Psychiatrist Telephone call 0 – – 0 – –
Psychologist Surgery visit 10 11 10 15 11 13
Psychologist Home visit 1 14 – 1 24 –
Psychologist Telephone call 0 – – 1 1 –
Psychotherapist Surgery visit 1 4 – 1 3 –
Psychotherapist Home visit 0 – – 0 – –
Psychotherapist Telephone call 0 – – 0 – –
Counsellor Surgery visit 9 4 5 5 4 2
Counsellor Home visit 0 – – 0 – –
Counsellor Telephone call 0 – – 0 – –
GP Surgery visit 110 3 3 104 3 4
GP Home visit 1 3 – 2 3 2
GP Telephone call 1 1 – 1 1 –
Blood test at GP Surgery visit 38 2 1 44 2 2
Diabetes nurse Surgery visit 9 2 4 6 2 1
Diabetes nurse Home visit 0 – – 0 – –
Diabetes nurse Telephone call 0 – – 3 1 0
Practice nurse Surgery visit 33 3 3 21 11 39
Practice nurse Home visit 0 – – 1 6 –
Practice nurse Telephone call 1 2 – 0 – –
District nurse Surgery visit 2 6 6 0 – –
District nurse Home visit 0 – – 0 – –
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TABLE 19 Resource use at the 12-month follow-up (for the previous 6 months) (continued )
Resource Unit
Trial group
Intervention (N= 160) Control (N= 159)
Users (n) Meana SD Users (n) Meana SD
District nurse Telephone call 0 – – 0 – –
Occupational therapist Surgery visit 4 6 7 2 6 4
Occupational therapist Home visit 4 22 34 2 3 0
Occupational therapist Telephone call 1 2 – 1 2 –
Dietitian Surgery visit 3 1 0 6 3 3
Dietitian Home visit 0 – – 0 – –
Dietitian Telephone call 0 – – 0 – –
Home help Home visit 11 53 52 7 61 59
Meals on wheels Home visit 2 13 16 0 – –
Pharmacist for advice Surgery visit 16 2 2 14 3 2
Pharmacist for advice Home visit 0 – – 0 – –
Pharmacist for advice Telephone call 2 1 0 0 – –
NHS Direct Telephone call 0 – – 2 2 1
Samaritans Telephone call 5 79 90 4 24 45
Medication 159 – – 158 – –
a Mean for users only.
All quantities are rounded to nearest whole number.
TABLE 20 Resource use at the 15-month follow-up (for the previous 3 months)
Resource Unit
Trial group
Intervention (N= 152) Control (N= 149)
Users (n) Meana SD Users (n) Meana SD
Specialist accommodation
Supported housing/assisted living Bed-day 36 90 3 30 90 3
Sheltered housing Bed-day 2 70 30 6 91 0
Hostel/shelter Bed-day 1 81 – 5 91 0
Hospital inpatient
Inpatient Bed-day 39 90 8 41 90 2
Hospital outpatient
Psychiatric outpatient Visit 8 2 1 1 1 –
Non-psychiatric/general/medical outpatient Visit 7 1 < 1 10 2 2
Diabetes clinic Visit 4 1 0 6 1 0
Blood tests Visit 63 2 2 56 3 1
Psychiatric day hospital Visit 2 5 1 0 – –
Non-psychiatric/general/medical day hospital Visit 1 2 – 3 1 0
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TABLE 20 Resource use at the 15-month follow-up (for the previous 3 months) (continued )
Resource Unit
Trial group
Intervention (N= 152) Control (N= 149)
Users (n) Meana SD Users (n) Meana SD
Day surgery centre Visit 3 1 0 2 1 0
Accident and emergency department Visit 15 1 1 15 1 1
X-ray Visit 10 1 0 12 1 1
Substance misuse clinic Visit 2 24 17 1 1 –
Dietetics Visit 2 1 0 2 1 0
Community-based day services
Community-based services Visit 57 20 19 50 26 25
Community-based professionals
Care co-ordinator Surgery visit 78 5 6 70 4 4
Care co-ordinator Home visit 59 5 3 52 4 3
Care co-ordinator Telephone call 28 5 6 26 5 5
Home treatment team Surgery visit 2 2 1 1 8 –
Home treatment team Home visit 7 9 8 4 12 13
Home treatment team Telephone call 0 – – 0 – –
Crisis resolution team Surgery visit 1 1 – 0 – –
Crisis resolution team Home visit 1 1 – 1 1 –
Crisis resolution team Telephone call 0 – – 0 – –
Early intervention team Surgery visit 1 36 – 0 – –
Early intervention team Home visit 0 – – 0 – –
Early intervention team Telephone call 0 – – 0 – –
Community psychiatric nurse Surgery visit 6 6 4 13 4 2
Community psychiatric nurse Home visit 2 4 1 3 1 1
Community psychiatric nurse Telephone call 3 8 10 4 5 5
Social worker Surgery visit 2 8 6 4 5 5
Social worker Home visit 0 – – 2 7 7
Social worker Telephone call 0 – – 1 5 –
Psychiatrist Surgery visit 65 1 1 60 1 1
Psychiatrist Home visit 3 5 6 5 4 5
Psychiatrist Telephone call 0 – – 0 – –
Psychologist Surgery visit 14 6 5 8 5 5
Psychologist Home visit 1 10 – 0 – –
Psychologist Telephone call 0 – – 0 – –
Psychotherapist Surgery visit 2 10 3 0 – –
Psychotherapist Home visit 0 – – 1 1 –
Psychotherapist Telephone call 0 – – 0 – –
Counsellor Surgery visit 3 2 2 1 2 –
Counsellor Home visit 0 – – 0 – –
Counsellor Telephone call 0 – – 0 – –
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Health and social care and lost productivity formed the largest components of total societal costs.
Costs at baseline, 12 months and 15 months are summarised for reference in Table 21. The mean costs
of all summary components were similar between trial arms at all assessment points, except the cost
of the intervention, which was naturally higher in the intervention group given the additional inputs
required compared with the control group (adjusted mean difference £311, 95% CI £267 to £355),
and costs borne by charities, which were higher in the intervention group at 12 months (adjusted mean
difference £80, 95% CI £9 to £151).
TABLE 20 Resource use at the 15-month follow-up (for the previous 3 months) (continued )
Resource Unit
Trial group
Intervention (N= 152) Control (N= 149)
Users (n) Meana SD Users (n) Meana SD
GP Surgery visit 81 3 2 83 2 1
GP Home visit 1 1 – 0 – –
GP Telephone call 1 2 – 1 4 –
Blood test at GP Surgery visit 26 2 5 27 1 1
Diabetes nurse Surgery visit 4 2 2 3 1 1
Diabetes nurse Home visit 1 1 – 0 – –
Diabetes nurse Telephone call 0 – – 0 – –
Practice nurse Surgery visit 16 2 2 21 2 1
Practice nurse Home visit 0 – – 0 – –
Practice nurse Telephone call 1 1 – 0 – –
District nurse Surgery visit 3 21 34 2 46 62
District nurse Home visit 1 24 – 0 – –
District nurse Telephone call 0 – – 0 – –
Occupational therapist Surgery visit 4 12 9 5 5 4
Occupational therapist Home visit 2 13 16 3 12 0
Occupational therapist Telephone call 1 3 – 0 – –
Dietitian Surgery visit 1 1 – 6 2 1
Dietitian Home visit 0 – – 1 12 –
Dietitian Telephone call 0 – – 0 – –
Home help Home visit 12 38 52 4 39 37
Meals on wheels Home visit 4 47 33 1 15 –
Pharmacist for advice Surgery visit 6 3 2 8 3 4
Pharmacist for advice Home visit 0 – – 0 – –
Pharmacist for advice Telephone call 2 2 1 1 1 –
NHS Direct Telephone call 2 7 8 5 3 5
Samaritans Telephone call 4 36 39 4 15 21
Medication 149 145
a Mean for users only.
All quantities are rounded to nearest whole number.
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TABLE 21 Costs at baseline and at 12 and 15 months (2011/12 prices; all 15-month costs, except the intervention costs, are discounted)
Costs Valid (n)
Intervention costs (£)
(N= 213)
Valid (n)
Control costs (£)
(N= 193) Unadjusted mean
95% CIa
Adjusted mean
95% CIbMean SD Mean SD Differencea Differenceb
Costs at baseline
Health and social care excluding
interventionc
212 10,242 13,374 193 9714 13,767 528 –2953 to 4010 967 –2442 to 4435
Charityc 212 83 611 193 80 435 3 –109 to 115 –22 –137 to 94
Lost productivityc 212 8755 5964 193 7472 6311 1283 –354 to 2920 456 –894 to 1806
Patientc 212 72 433 193 188 188 35 –31 to 102 33 –37 to 104
Benefitsc 212 2211 1006 193 2009 940 202d 13 to 391d 127 –70 to 324
Costs at 12 months
Health and social care excluding
interventionc
160 10,220 12,341 159 10,196 16,987 24 –4219 to 4267 –1596 –5145 to 1954
Charityc 160 120 369 159 61 256 60 –6 to 125 80d 9 to 151d
Lost productivityc 160 8882 5998 159 7707 6333 1174 –317 to 2665 1038 –367 to 2443
Patientc 160 84 369 159 53 300 31 –38 to 100 25 –46 to 96
Benefitc 160 2328 931 159 2129 957 200 –14 to 413 87 –105 to 279
Costs at 15 months
Health and social care excluding
interventione
152 4874 6317 149 4708 6383 166 –1577 to 1910 –231 –1734 to 1272
Charitye 152 63 215 149 49 230 14 –39 to 67 24 –37 to 84
Lost productivitye 152 4731 2674 149 3880 3027 850d 127 to 1573d 608 –25 to 1240
Patiente 152 24 141 149 30 162 –6 –38 to 27 –6 –37 to 25
Benefitse 152 1089 439 149 1049 441 40 –70 to 150 –24 –125 to 76
Intervention 213 316 173 193 4 0 312d 267 to 357d 3142d 268 to 359d
a Controlling for clustering of care co-ordinator only.
b Includes covariates for baseline: equivalent cost, SF-36 MCS, SF-36 PCS, EQ-5D-3L utility, SF-36 utility, gender, ethnicity and borough, plus clustering for care co-ordinator.
c Costs for a 6-month retrospective period.
d CI excludes zero.
e Costs for a 3-month retrospective period.
All figures are rounded to the nearest whole number.
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Comparisons of the total costs from both health and social care and societal perspectives at 15 months
suggested no difference between the trial arms, although the 95% CIs suggested a tendency for societal
costs to be higher in the intervention arm (Table 22). Imputing the missing total costs at 15 months for
the sensitivity analyses confirmed this (Table 23).
Outcomes
There were no differences in any outcome at any time point (Table 24). As with cost data, imputing
missing outcome data for those lost to follow-up (Table 25) did not alter the conclusions drawn from
the base-case analyses of only those with available data.
Cost-effectiveness and cost–utility analyses
The two trial arms showed the same costs and same outcomes for all prespecified 15-month
cost–outcome combinations using the base-case approach (Table 26); therefore, it was not necessary
to compute any ICERs. Furthermore, none of the four sensitivity analyses altered the conclusions
about between-group differences in total costs or outcomes.
The cost-effectiveness planes from health/social care and societal perspectives for all four outcomes
are in Figures 4–11, showing no difference between the groups in costs or outcomes. Although
cost-effectiveness planes for EQ-5D-3L-based QALYs from the health and social perspective indicate
a tendency for estimates to predominate in the north-east or south-east quadrants (indicating higher
or lower costs and better outcomes), those for the SF-36 MCS and SF-36 PCS show more estimates
falling into the north-west or south-west quadrants (indicating higher or lower costs and worse
outcomes). Cost-effectiveness planes from the societal perspective (see Figures 8–11) all suggest that
mean costs in the intervention arm are likely to be higher than in the control arm, as was suggested by
the 95% CIs for estimates of mean cost differences (see Tables 22 and 23).
From a health and social care perspective, the probability that the HPI is cost-effective does not
exceed 0.4 for any of the examined willingness-to-pay thresholds for QALY gains (based on either the
SF-36 or the EQ-5D-3L). When considering willingness to pay for point improvements in the PCS
and MCS of the SF-36, the probability of the intervention being cost-effective starts at 0.34 at a
willingness to pay of £0 but reduces to around 0.2 for willingness-to-pay values between £5000 and
£50,000 (Figures 12–15).
Conclusions are similar from a societal perspective: the probability that the HPI is cost-effective does
not exceed 0.12 for any of the willingness-to-pay thresholds examined for QALY gains (calculated from
either the SF-36 or the EQ-5D-3L), or 0.21 for the thresholds examined for the point improvements in
the two SF-36 component scores.
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TABLE 22 Total costs at 15 months
Costs Valid (n)
Intervention costs (£)
(N= 213)
Valid (n)
Control costs (£)
(N= 193)
Unadjusted mean
differencea 95% CIa
Adjusted mean
differenceb 95% CIbMean SD Mean SD
Health and social care including
interventionc
152 5209 6326 149 4711 6383 498 –1248 to 2244 95 –1410 to 1599
Societal perspective including
interventionc
152 11,116 7271 149 9720 7707 1396 –684 to 3476 675 –1039 to 2388
a Controlling for clustering of care co-ordinator only.
b Includes covariates for baseline: equivalent cost, SF-36 MCS, SF-36 PCS, EQ-5D-3L utility, SF-36 utility, gender, ethnicity and borough, plus clustering for care co-ordinator.
c Fifteen-month costs discounted.
All figures are rounded to the nearest whole number.
TABLE 23 Total costs at 15 months based on imputed missing data
Costs Valid (n)
Intervention costs (£)
(N= 213)
Valid (n)
Control costs (£)
(N= 193)
Unadjusted mean
differencea 95% CIa
Adjusted mean
differenceb 95% CIbMean SD Mean SD
Health and social care including
interventionc
213 5077 5652 193 4705 5848 372 –1047 to 1791 51 –1091 to 1192
Societal perspective including
interventionc
213 10,830 6595 193 9683 7129 1147 –551 to 2845 537 –776 to 1850
a Controlling for clustering of care co-ordinator only.
b Includes covariates for baseline: equivalent cost, SF-36 MCS, SF-36 PCS, EQ-5D-3L utility, SF-36 utility, gender, ethnicity and borough, plus clustering for care co-ordinator.
c Fifteen-month costs discounted. Missing data at 15 months imputed from baseline and 12 months: equivalent cost, SF-36 MCS, SF-36 PCS, EQ-5D-3L utility, SF-36 utility,
plus baseline gender, ethnicity, age, place of birth, borough and care co-ordinator.
All figures are rounded to the nearest whole number.
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TABLE 24 Outcomes at baseline and at 12 and 15 months (with all 15-month outcomes discounted)
Time point
Intervention (N= 213) Control (N= 193)
Unadjusted mean
differencea 95% CIa
Adjusted mean
differenceb 95% CIbValid (n) Mean SD Valid (n) Mean SD
Baseline
SF-36 MCS 213 41.37 13.26 193 42.25 11.81 –0.88 –3.44 to 1.68 –0.26 –1.55 to 1.02
SF-36 PCS 213 45.83 10.94 193 47.04 9.26 –1.20 –3.31 to 0.91 –0.60 –1.72 to 0.52
SF-36 utility 210 0.69 0.16 192 0.71 0.14 –0.02 –0.05 to 0.02 0.00 –0.01 to 0.01
EQ-5D-3L utility 211 0.76 0.31 193 0.79 0.28 –0.02 –0.08 to 0.04 0.01 –0.04 to 0.06
12 months
SF-36 MCS 160 43.18 13.31 158 44.09 13.47 –0.91 –3.94 to 2.11 –0.05 –2.64 to 2.55
SF-36 PCS 160 46.76 11.23 158 49.02 10.55 –2.27 –4.74 to 0.21 –1.45 –3.56 to 0.66
SF-36 utility 158 0.70 0.16 155 0.71 0.15 –0.02 –0.05 to 0.02 –0.00 –0.03 to 0.02
EQ-5D-3L utility 159 0.80 0.25 156 0.80 0.28 0.00 –0.06 to 0.06 0.03 –0.03 to 0.08
15 months
SF-36 MCS 152 42.47 13.58 149 45.01 13.65 –2.54 –6.00 to 0.92 –0.80 –3.66 to 2.06
SF-36 PCS 152 47.25 11.62 149 48.54 9.88 –1.29 –4.02 to 1.44 –0.68 –3.01 to 1.65
SF-36 utility 149 0.66 0.14 148 0.70 0.15 –0.03c –0.07 to –0.00c –0.02 –0.05 to 0.01
SF-36-based QALY gain 134 0.17 0.03 139 0.17 0.09 –0.01 –0.01 to 0.00 –0.00 –0.01 to 0.00
EQ-5D-3L utility 152 0.77 0.24 149 0.80 0.25 –0.02 –0.09 to 0.04 0.00 –0.06 to 0.06
EQ-5D-3L-based QALY gain 137 0.19 0.05 140 0.20 0.06 –0.00 –0.02 to 0.01 0.00 –0.01 to 0.02
a Controlling for clustering of care co-ordinator.
b Includes covariates for baseline: SF-36 MCS, SF-36 PCS, EQ-5D-3L utility, SF-36 utility, gender, age, ethnicity, place of birth and borough, plus clustering for care co-ordinator.
c CI excludes zero.
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TABLE 25 Outcomes at 15 months based on imputed missing data (with all 15-month outcomes discounted)
Outcome
Intervention (N= 213) Control (N= 193)
Unadjusted mean
differencea 95% CI
Adjusted mean
differenceb 95% CIaValid (n) Mean SD Valid (n) Mean SD
SF-36 MCS 213 42.95 12.59 193 44.84 12.52 –1.88 –4.75 to 0.98 –0.64 –2.77 to 1.49
SF-36 PCS 213 47.72 10.58 193 48.97 9.18 –1.25 –3.23 to 0.73 –0.47 –2.09 to 1.14
SF-36-based QALY 213 0.17 0.03 193 0.17 0.03 –0.01 –0.01 to 0.00 –0.00 –0.00 to 0.00
EQ-5D-3L-based QALY 213 0.19 0.05 193 0.20 0.05 –0.00 –0.01 to 0.01 0.00 –0.01 to 0.01
a Controlling for clustering of care co-ordinator.
b Includes covariates for baseline: SF-36 MCS, SF-36 PCS, EQ-5D-3L utility, SF-36 utility, gender, age, ethnicity, place of birth and borough, plus clustering for care co-ordinator.
Missing data at 15 months imputed from baseline and 12 months: equivalent cost, SF-36 MCS, SF-36 PCS, EQ-5D-3L utility, SF-36 utility, plus baseline gender, ethnicity, age, place of
birth, borough and care co-ordinator.
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FIGURE 4 Cost-effectiveness plane of mean differences in EQ-5D-3L-based QALYs and health and social care costs.
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FIGURE 5 Cost-effectiveness plane of mean differences in SF-36-based QALYs and health and social care costs.
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FIGURE 6 Cost-effectiveness plane of mean differences in SF-36 MCS and health and social care costs.
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FIGURE 7 Cost-effectiveness plane of mean differences in SF-36 PCS and health and social care costs.
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FIGURE 8 Cost-effectiveness plane of mean differences in EQ-5D-3L-based QALYs and societal costs.
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FIGURE 9 Cost-effectiveness plane of mean differences in SF-36-based QALYs and societal costs.
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FIGURE 10 Cost-effectiveness plane of mean differences in SF-36 MCS and societal costs.
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FIGURE 11 Cost-effectiveness plane of mean differences in SF-36 PCS and societal costs.
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perspective.
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TABLE 26 Cost-effectiveness and cost–utility summary at 15 months
Costs
Cost per additional
point improvement
on the SF-36 PCS
Cost per additional
point improvement
on the SF-36 MCS
Cost per
additional QALY
(SF-36 based)
Cost per
additional QALY
(EQ-5D-3L based)
Control vs.
intervention
Control vs.
intervention
Control vs.
intervention
Control vs.
intervention
Health and social
costs including
intervention costs
Same cost, same
outcome
Same cost, same
outcome
Same cost, same
outcome
Same cost, same
outcome
Societal perspective
costs including
intervention costs
Same cost, same
outcome
Same cost, same
outcome
Same cost, same
outcome
Same cost, same
outcome
Incremental cost-effectiveness ratios are unnecessary because costs and outcomes are equivalent in both trial arms.
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Appendix 5 Primary outcome analyses
Appendix 4 shows that sensitivity analyses did not alter the conclusion that there was no treatmenteffect at any time point for the two main outcomes, PHC and MHC score. Furthermore, no changes
over time could be detected. Tables 27 and 28 show the results of the main analyses presented in
Gaughran et al.176
TABLE 27 All data: PHC
Variable Coefficient SE z p-value 95% CI
Arm (HPI = 1) –1.7 0.98 –1.73 0.083 –3.63 to 0.23
Time (15 months= 1) –0.23 0.72 –0.32 0.746 –1.64 to 1.17
Arm × time 1.1 1.02 1.08 0.282 –0.9 to 3.1
Borough χ2(9) = 3.71; p = 0.93
Croydon 0
Lambeth 1.72 1.66 1.04 0.3 –1.53 to 4.97
Lewisham 0.93 1.39 0.67 0.503 –1.8 to 3.66
Southwark 2.02 1.36 1.49 0.136 –0.64 to 4.68
Greenwich 2.09 1.74 1.2 0.229 –1.32 to 5.51
Bromley 1.75 1.77 0.99 0.323 –1.72 to 5.23
Bexley 1.24 2 0.62 0.536 –2.68 to 5.15
East Sussex 1.69 1.9 0.89 0.375 –2.04 to 5.41
Somerset 2.8 2.56 1.09 0.274 –2.22 to 7.82
South Staffordshire 3.23 3.26 0.99 0.322 –3.16 to 9.61
PHC baseline 0.61 0.04 15.77 0 0.53 to 0.69
Constant 18 2.22 8.12 0 13.66 to 22.35
Pairwise comparison Coefficient SE z p-value 95% CI
12 months: TAU vs. HPI –1.7 0.98 –1.73 0.083 –3.63 to 0.23
15 months: TAU vs. HPI –0.6 0.99 –0.61 0.541 –2.54 to 1.33
Group HPI: 15 months vs. 12 months –0.23 0.72 –0.32 0.746 –1.64 to 1.17
Group TAU: 15 months vs. 12 months 0.87 0.72 1.19 0.232 –0.55 to 2.29
Random-effects parameters Estimate SE 95% CI
Care co-ordinator (SD) 0 0
Residual
SD (12 months) 8.58 0.34 7.94 to 9.27
SD (15 months) 8.54 0.35 7.89 to 9.25
Correlation (12 months, 15 months) 0.48 0.04 0.39 to 0.56
SE, standard error.
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TABLE 28 All data: MHC
Variable Coefficient SE z p-value 95% CI
Arm (HPI = 1) –0.41 1.29 –0.32 0.751 –2.95 to 2.13
Time (15 months= 1) 1 0.87 1.16 0.248 –0.7 to 2.71
Arm × time –0.71 1.36 –0.53 0.598 –3.37 to 1.94
Borough χ2(9) = 14.69; p = 0.10
Croydon 0
Lambeth –1.91 2.17 –0.88 0.378 –6.16 to 2.34
Lewisham –1.97 1.85 –1.06 0.288 –5.6 to 1.66
Southwark –5.33 1.8 –2.96 0.003 –8.85 to –1.8
Greenwich –5.23 2.35 –2.23 0.026 –9.83 to –0.63
Bromley –3.7 2.34 –1.58 0.113 –8.28 to 0.88
Bexley –0.99 2.65 –0.37 0.709 –6.18 to 4.2
East Sussex –4.95 2.5 –1.98 0.047 –9.84 to –0.06
Somerset –6.91 3.37 –2.05 0.04 –13.53 to –0.3
South Staffordshire –2.09 4.44 –0.47 0.637 –10.79 to 6.6
PHC baseline 0.58 0.04 14.23 0 0.5 to 0.67
Constant 21.25 2.32 9.15 0 16.7 to 25.79
Pairwise comparison Coefficient SE z p-value 95% CI
12 months: B vs. A –0.41 1.29 –0.32 0.751 –2.95 to 2.13
15 months: B vs. A –1.13 1.31 –0.86 0.389 –3.69 to 1.44
Group TAU: 15 months vs. 12 months 1 0.87 1.16 0.248 –0.7 to 2.71
Group HPI: 15 months vs. 12 months 0.29 1.04 0.28 0.78 –1.75 to 2.33
Random-effects parameters Estimate SE 95% CI
Care co-ordinator (SD) 1.68 1.3 0.37 to 7.65
Residual
Group TAU
SD (12 months, 15 months) 10.42 0.51 9.46 to 11.47
Correlation (12 months, 15 months) 0.49 0.07 0.34 to 0.61
Group HPI
SD (12 months, 15 months) 11.22 0.52 10.24 to 12.3
Correlation (12 months, 15 months) 0.37 0.08 0.21 to 0.51
SE, standard error.
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TABLE 29 Within time window with age as a predictor of missingness: PHC
Variable Coefficient SE z p-value 95% CI
Arm (HPI = 1) –1.86 1.07 –1.74 0.082 –3.95 to 0.24
Time (15 months= 1) –0.09 0.81 –0.12 0.907 –1.68 to 1.49
Arm × time 0.69 1.15 0.6 0.551 –1.57 to 2.95
Borough χ2(9) = 8.46; p = 0.49
Croydon
Lambeth 1.3 1.76 0.74 0.461 –2.15 to 4.74
Lewisham 1.48 1.5 0.99 0.324 –1.46 to 4.41
Southwark 2.27 1.46 1.56 0.119 –0.59 to 5.12
Greenwich 4.77 1.92 2.48 0.013 1.01 to 8.53
Bromley 1.2 1.96 0.61 0.539 –2.63 to 5.04
Bexley 2.35 2.21 1.06 0.288 –1.99 to 6.69
East Sussex 2.17 2.01 1.08 0.279 –1.76 to 6.11
Somerset 3.58 2.77 1.29 0.197 –1.85 to 9.01
South Staffordshire 5.49 3.7 1.48 0.138 –1.76 to 12.75
PHC baseline 0.59 0.04 13.91 0 0.5 to 0.67
Age at baseline –0.11 0.05 –2.4 0.016 –0.2 to –0.02
Constant 23.85 3.51 6.8 0 16.97 to 30.72
Pairwise comparison Coefficient SE z p-value 95% CI
12 months: TAU vs. HPI –1.86 1.07 –1.74 0.082 –3.95 to 0.24
15 months: TAU vs. HPI –1.17 1.08 –1.08 0.28 –3.29 to 0.95
Group HPI: 15 months vs. 12 months –0.09 0.81 –0.12 0.907 –1.68 to 1.49
Group TAU: 15 months vs. 12 months 0.59 0.83 0.72 0.474 –1.03 to 2.21
Random-effects parameters Estimate SE 95% CI
Care co-ordinator (SD) 0.9 1.65 0.02 to 33.04
Residual
SD (12 months) 8.32 0.39 7.58 to 9.13
SD (15 months) 8.13 0.43 7.34 to 9.01
Correlation (12 months, 15 months) 0.48 0.06 0.36 to 0.59
SE, standard error.
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TABLE 30 Within time window with age as a predictor of missingness: MHC
Variable Coefficient SE z p-value 95% CI
Arm (HPI = 1) 0.38 1.42 0.27 0.789 –2.4 to 3.15
Time (15 months= 1) 0.19 1 0.19 0.851 –1.78 to 2.16
Arm × time –1 1.58 –0.63 0.526 –4.09 to 2.09
Borough χ2(9) = 8.79; p = 0.46
Croydon 0
Lambeth –1.68 2.32 –0.73 0.468 –6.23 to 2.86
Lewisham –2.17 2.03 –1.07 0.286 –6.15 to 1.81
Southwark –4.3 1.96 –2.2 0.028 –8.13 to –0.46
Greenwich –3.63 2.6 –1.4 0.163 –8.73 to 1.47
Bromley –4.22 2.62 –1.61 0.107 –9.35 to 0.91
Bexley –0.68 2.95 –0.23 0.819 –6.45 to 5.1
East Sussex –4.9 2.67 –1.83 0.067 –10.13 to 0.34
Somerset –6.15 3.69 –1.67 0.095 –13.38 to 1.08
South Staffordshire –3.34 5.01 –0.67 0.505 –13.16 to 6.47
PHC baseline 0.58 0.04 12.96 0 0.49 to 0.67
Age at baseline 0.06 0.06 1 0.316 –0.05 to 0.17
Constant 18.59 3.54 5.26 0 11.66 to 25.52
Pairwise comparison Coefficient SE z p-value 95% CI
12 months: B vs. A 0.38 1.42 0.27 0.789 –2.4 to 3.15
15 months: B vs. A –0.62 1.47 –0.42 0.671 –3.49 to 2.25
Group TAU: 15 months vs. 12 months 0.19 1 0.19 0.851 –1.78 to 2.16
Group HPI: 15 months vs. 12 months –0.81 1.22 –0.67 0.506 –3.2 to 1.58
Random-effects parameters Estimate SE 95% CI
Care co-ordinator (SD) 2.14 1.24 0.69 to 6.65
Residual
Group TAU
SD (12 months, 15 months) 10.23 0.56 9.19 to 11.38
Correlation (12 months, 15 months) 0.49 0.09 0.3 to 0.64
Group HPI
SD (12 months, 15 months) 10.79 0.58 9.72 to 11.98
Correlation (12 months, 15 months) 0.32 0.1 0.12 to 0.5
SE, standard error.
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TABLE 31 All data with age as a predictor for missingness: PHC
Variable Coefficient SE z p-value 95% CI
Arm (HPI = 1) –1.81 0.98 –1.85 0.065 –3.73 to 0.11
Time (15 months= 1) –0.22 0.72 –0.31 0.756 –1.63 to 1.18
Arm × time 1.07 1.02 1.05 0.294 –0.93 to 3.07
Borough χ2(9) = 4.04; p = 0.91
Croydon 0
Lambeth 0.76 1.68 0.45 0.652 –2.53 to 4.05
Lewisham 0.59 1.39 0.43 0.668 –2.12 to 3.31
Southwark 1.89 1.34 1.4 0.161 –0.75 to 4.52
Greenwich 2.07 1.72 1.2 0.229 –1.31 to 5.45
Bromley 1.96 1.76 1.11 0.266 –1.49 to 5.4
Bexley 1.33 1.98 0.67 0.503 –2.55 to 5.2
East Sussex 1.31 1.89 0.7 0.486 –2.38 to 5.01
Somerset 2.06 2.55 0.81 0.42 –2.95 to 7.06
South Staffordshire 3.81 3.25 1.17 0.241 –2.56 to 10.17
PHC baseline 0.59 0.04 14.94 0 0.51 to 0.66
Age at baseline –0.12 0.04 –2.64 0.008 –0.2 to –0.03
Constant 24.57 3.32 7.41 0 18.07 to 31.07
Pairwise comparison Coefficient SE z p-value 95% CI
12 months: TAU vs. HPI –1.81 0.98 –1.85 0.065 –3.73 to 0.11
15 months: TAU vs. HPI –0.74 0.98 –0.76 0.45 –2.66 to 1.18
Group HPI: 15 months vs. 12 months –0.22 0.72 –0.31 0.756 –1.63 to 1.18
Group TAU: 15 months vs. 12 months 0.85 0.72 1.17 0.242 –0.57 to 2.27
Random-effects parameters Estimate SE 95% CI
Care co-ordinator (SD) 0 0
Residual
SD (12 months) 8.54 0.34 7.9 to 9.23
SD (15 months) 8.45 0.34 7.8 to 9.15
Correlation (12 months, 15 months) 0.47 0.04 0.38 to 0.56
SE, standard error.
DOI: 10.3310/pgfar08010 Programme Grants for Applied Research 2020 Vol. 8 No. 1
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Gaughran et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
119
Multiple imputation
The following variables were used for the imputation model: relationship with two levels (yes or no,
categorical), education as an ordinal variable, age at baseline, waist, BMI, systolic and diastolic BP, levels
of HbA1c, GAF score, number of children, fasting glucose, PANNS total score, Montgomery–Åsberg
Depression Rating Scales (MADRS), gender (categorical variable), attended 12 months within/outside
follow-up (nominal variable), attended the 15-month follow-up within/outside time limits (nominal variable),
MHC at baseline and at 12 and 24 months’ follow-up (log-transformed), PHC at baseline and at 12 and
24 months’ follow-up (log-transformed). Estimation was performed for each treatment arm ( = interaction
between group TAU and all variables). Fifty data sets were imputed. MHC and PHC were log-transformed
to be more nearly normal during the imputation process to avoid prediction outside the possible range.
TABLE 32 All data with age as a predictor for missingness: MHC
Variable Coefficient SE z p-value 95% CI
Arm (HPI = 1) –0.38 1.29 –0.3 0.766 –2.92 to 2.15
Time (15 months= 1) 1 0.87 1.15 0.251 –0.7 to 2.7
Arm × time –0.7 1.36 –0.52 0.603 –3.36 to 1.95
Borough χ2(9) = 14.65; p = 0.10
Croydon 0
Lambeth –1.5 2.21 –0.68 0.498 –5.82 to 2.83
Lewisham –1.8 1.86 –0.97 0.334 –5.44 to 1.85
Southwark –5.25 1.8 –2.92 0.003 –8.77 to –1.73
Greenwich –5.19 2.34 –2.22 0.027 –9.79 to –0.6
Bromley –3.83 2.34 –1.64 0.101 –8.41 to 0.75
Bexley –1.06 2.64 –0.4 0.689 –6.24 to 4.12
East Sussex –4.83 2.5 –1.93 0.053 –9.72 to 0.06
Somerset –6.54 3.39 –1.93 0.054 –13.18 to 0.1
South Staffordshire –2.36 4.44 –0.53 0.596 –11.05 to 6.34
PHC baseline 0.58 0.04 14.09 0 0.5 to 0.66
Age at baseline 0.05 0.05 0.98 0.329 –0.05 to 0.16
Constant 18.91 3.33 5.68 0 12.39 to 25.44
Pairwise comparison Coefficient SE z p-value 95% CI
12 months: B vs. A –0.38 1.29 –0.3 0.766 –2.92 to 2.15
15 months: B vs. A –1.09 1.31 –0.83 0.404 –3.65 to 1.47
Group TAU: 15 months vs. 12 months 1 0.87 1.15 0.251 –0.7 to 2.7
Group HPI: 15 months vs. 12 months 0.29 1.04 0.28 0.778 –1.75 to 2.33
Random-effects parameters Estimate SE 95% CI
Care co-ordinator (SD) 1.68 1.3 0.37 to 7.67
Residual
Group TAU
SD (12 months, 15 months) 10.42 0.51 9.46 to 11.48
Correlation (12 months, 15 months) 0.49 0.07 0.34 to 0.61
Group HPI
SD (12 months, 15 months) 11.2 0.52 10.22 to 12.28
Correlation (12 months, 15 months) 0.37 0.08 0.21 to 0.51
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After imputation, the variables were back-transformed to the original scale. This procedure generally
reduces bias and improves statistical properties.242 The data were then analysed using the same model as
in the main analyses.
TABLE 33 Multiple imputation: PHC
Variable Coefficient SE z p-value 95% CI
Arm (HPI = 1) –0.98 1.73 –0.56 0.58 –4.41 to 2.46
Time (15 months= 1) 0.36 1.47 0.24 0.81 –2.55 to 3.26
Arm × time 0.45 2.01 0.23 0.82 –3.52 to 4.42
Borough
Croydon 0.00
Lambeth 1.08 2.26 0.48 0.63 –3.37 to 5.52
Lewisham 0.72 1.91 0.38 0.71 –3.04 to 4.48
Southwark 1.56 1.86 0.84 0.40 –2.10 to 5.21
Greenwich 2.11 2.43 0.87 0.39 –2.66 to 6.87
Bromley 0.20 2.55 0.08 0.94 –4.81 to 5.20
Bexley 1.50 2.74 0.55 0.59 –3.89 to 6.89
East Sussex 2.08 2.60 0.80 0.43 –3.02 to 7.17
Somerset 0.32 3.75 0.08 0.93 –7.09 to 7.72
South Staffordshire 2.12 4.24 0.50 0.62 –6.24 to 10.48
PHC baseline 0.61 0.06 10.34 0.00 0.49 to 0.72
Constant 17.44 3.36 5.20 0.00 10.83 to 24.06
Random-effects parameters Estimate SE 95% CI
Care co-ordinator (SD) –5.70 333.69 –659.73 to 648.33
Residual
SD (12 months) 2.32 0.09 2.14 to 2.50
SD (15 months) 0.34 0.11 0.12 to 0.56
Correlation (12 months, 15 months) 0.19 0.18 –0.17 to 0.55
SE, standard error.
TABLE 34 Multiple imputation: MHC
Variable Coefficient SE z p-value 95% CI
Arm (HPI = 1) 0.57 2.10 0.27 0.79 –3.55 to 4.69
Time (15 months= 1) –0.96 2.28 –0.42 0.67 –5.48 to 3.55
Arm × time –0.60 3.70 –0.16 0.87 –7.94 to 6.74
Borough
Croydon 0.00
Lambeth –1.71 3.23 –0.53 0.60 –8.06 to 4.64
Lewisham –3.06 2.73 –1.12 0.26 –8.44 to 2.32
Southwark –3.20 2.77 –1.16 0.25 –8.66 to 2.25
Greenwich –2.63 3.28 –0.80 0.42 –9.06 to 3.80
Bromley –3.06 3.52 –0.87 0.38 –9.99 to 3.86
continued
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Multiple imputation 2: sensitivity analysis for not missing at random pattern
Some large positive and large negative values were added to the multiple imputed missing values
(values correspond to approximately ± 2 SDs and ± 1 SD of baseline measure of physical and mental
health scores, respectively).
(Fifty imputed data sets; same imputation data sets used in multiple imputation analyses above were used.)
Only parameter estimates for arm (HPI = 1), time (15 months = 1) and arm × time interaction are shown.
TABLE 34 Multiple imputation: MHC (continued )
Variable Coefficient SE z p-value 95% CI
Bexley –1.41 3.87 –0.36 0.72 –9.02 to 6.21
East Sussex –3.82 4.01 –0.95 0.34 –11.70 to 4.07
Somerset –6.72 4.99 –1.35 0.18 –16.58 to 3.13
South Staffordshire –0.19 6.44 –0.03 0.98 –12.89 to 12.52
PHC baseline 0.65 0.07 9.25 0.00 0.51 to 0.78
Constant 17.19 3.79 4.54 0.00 9.73 to 24.65
Random-effects parameters Estimate SE 95% CI
Care co-ordinator (SD)
Residual –5.10 195.33 –387.94 to 377.75
Group TAU
ln [SD (12 months, 15 months)] 2.76 0.17 2.43 to 3.09
Correlation (12 months, 15 months) 0.33 0.17 0.00 to 0.67
Group HPI
ln [SD (12 months, 15 months)] –0.01 0.25 –0.52 to 0.50
Correlation (12 months, 15 months) 0.18 0.12 –0.05 to 0.42
SE, standard error.
TABLE 35 Not missing at random: PHC – values added to imputed missing value were –20, –10, 0, 10 and 20, respectively
(correspond to approximately ± 2 SDs, ± 1 SD and 0 SDs of baseline measure)
Value added to imputed
missing values Variable Coefficient SE z p-value 95% CI
–20 for missing
Arm (HPI= 1) –2.48 2.03 –1.22 0.22 –6.49 to 1.53
Time (15 months = 1) –1.51 1.68 –0.90 0.37 –4.82 to 1.80
Arm × time 1.38 2.31 0.60 0.55 –3.16 to 5.92
–10 for missing
Arm (HPI= 1) –1.74 1.83 –0.95 0.34 –5.36 to 1.87
Time (15 months = 1) –0.58 1.53 –0.38 0.71 –3.59 to 2.44
Arm × time 0.92 2.09 0.44 0.66 –3.21 to 5.04
0 for missing
Arm (HPI= 1) –0.98 1.73 –0.56 0.58 –4.41 to 2.46
Time (15 months = 1) 0.36 1.47 0.24 0.81 –2.55 to 3.26
Arm × time 0.45 2.01 0.23 0.82 –3.52 to 4.42
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TABLE 35 Not missing at random: PHC – values added to imputed missing value were –20, –10, 0, 10 and 20, respectively
(correspond to approximately ± 2 SDs, ± 1 SD and 0 SDs of baseline measure) (continued )
Value added to imputed
missing values Variable Coefficient SE z p-value 95% CI
+10 for missing
Arm (HPI= 1) –0.19 1.77 –0.11 0.92 –3.69 to 3.31
Time (15 months = 1) 1.29 1.52 0.85 0.40 –1.71 to 4.29
Arm × time –0.01 2.08 –0.01 1.00 –4.12 to 4.10
+20 for missing
Arm (HPI= 1) 0.59 1.93 0.30 0.76 –3.23 to 4.40
Time (15 months = 1) 2.22 1.67 1.33 0.19 –1.07 to 5.52
Arm × time –0.47 2.29 –0.21 0.84 –4.99 to 4.04
SE, standard error.
TABLE 36 Not missing at random: MHC – values added to imputed missing value were –25, –12, 0, 12 and 25, respectively
(correspond to approximately ± 2 SDs, ± 1 SD and 0 SDs of baseline measure)
Value added to imputed
missing values Variable Coefficient SE z p-value 95% CI
–20 for missing
Arm (HPI= 1) –1.28 2.38 –0.54 0.59 –5.96 to 3.40
Time (15 months = 1) –3.30 2.53 –1.30 0.20 –8.29 to 1.70
Arm × time 0.56 3.95 0.14 0.89 –7.27 to 8.39
–10 for missing
Arm (HPI= 1) –0.34 2.09 –0.16 0.87 –4.45 to 3.77
Time (15 months = 1) –2.08 2.37 –0.88 0.38 –6.77 to 2.61
Arm × time –0.04 3.76 –0.01 0.99 –7.50 to 7.42
0 for missing
Arm (HPI= 1) 0.57 2.10 0.27 0.79 –3.55 to 4.69
Time (15 months = 1) –0.96 2.28 –0.42 0.67 –5.48 to 3.55
Arm × time –0.60 3.70 –0.16 0.87 –7.94 to 6.74
+10 for missing
Arm (HPI= 1) 1.44 2.00 0.72 0.47 –2.51 to 5.39
Time (15 months = 1) 0.15 2.37 0.07 0.95 –4.54 to 4.85
Arm × time –1.15 3.76 –0.31 0.76 –8.62 to 6.31
+20 for missing
Arm (HPI= 1) 2.38 2.23 1.07 0.29 –1.99 to 6.76
Time (15 months = 1) 1.37 2.53 0.54 0.59 –3.63 to 6.37
Arm × time –1.76 3.95 –0.44 0.66 –9.59 to 6.08
SE, standard error.
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